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Thesis Summary 
Efflux transporters such as ABCB1 (P-gp) and ABCC2 (MRP-2) expressed on the apical 
membranes of epithelial cells of the intestine represent a formidable barrier for the effective 
delivery of a plethora of pharmaceutically relevant compounds. Excipients have attracted 
significant interest in their role as efflux protein inhibitors. To this end, the aim of this 
study was to examine the biological effects of commonly used excipients, and utilise this 
information in the design and manufacture of orally disintegrating tablets (ODT) using a 
design of experiments (DoE) approach. 
The ‘gold standard’ model of assessing intestinal efflux modulation remains the Caco-2 
Transwell® model. As this method is time and resource consuming, a novel high-
throughput screening assay was developed to screen excipients for activity against the 
ABCB1 and ABCC2 transporters using the specific fluorescent probes rhodamine 123 (R-
123) and 5(6)-carboxy-2′,7′-dichlorofluorescein (CDF) respectively. Of all the excipients 
screened, surfactants showed the highest efficacy against ABCB1 with some materials 
showing lower IC50 values than the established inhibitors verapamil (VER) and ciclosporin 
(CsA).  
One of the lead candidate excipients, poloxamer 407, was incorporated into a high-dose 
(795 mg) and a low-dose (295 mg) paracetamol (acetaminophen, APAP) formulation at 2 % 
(w/w). Whilst the development of the high-dose tablets was terminated with a 
disintegration time of 37 s, conforming to European Pharmacopeia specifications, the low-
dose tablets were selected for manufacture using a rotary tablet press. These final 
formulations had disintegration times of 9-43 s over a range of compressions (6-23 kN), 
providing tablets that conform to both the European Pharmacopeia and United States 
Pharmacopeia. Taken with a 250 mL glass of water, these tablets are capable of delivering 5.9 
mg of poloxamer 407 to give a final concentration of 2.36 x 10 -3 % (w/v), 2.7 times higher 
than the determined IC50 value for this excipient. To investigate an additional method of 
incorporating surfactants into ODTs, granules containing ibuprofen were coated in a 
Kollicoat IR solution containing 2 % (w/v) PEG 2000, poloxamer 407 or Cremophor EL. The 
ODTs made from these granules by direct compression produced tablets with 
disintegration times below 30 seconds, showing the viability of this complementary 
method of propagating the surfactant content of oral dosage formulations. 
Key words: Oral drug delivery, excipients, efflux transporters, kinetics, orally 
disintegrating tablets 
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 1. Introduction 
  The Advantages and Disadvantages of the Oral Route of Drug Administration 1.1.
The ease of administration and increased patient compliance rank highly among the 
multitude of reasons why oral delivery is still the preferred route of administration for 
many pharmaceutical products today, despite advances in transmucosal, transdermal and 
even pulmonary delivery systems, amongst others. Oral drug formulations have been 
estimated to account for 90 % of all medicines, with further growth expected as the market 
develops (Gabor et al., 2010).  
As such, absorption following oral administration has been subject to intense study in 
order to optimise the amount of material that is able to reach the systemic circulation. 
Unlike a drug delivered directly into the circulatory system via the intravenous route, which 
will reach 100 % bioavailability, pharmaceutical compounds taken via the oral route must 
pass a series of barriers in order to reach the systemic circulation. The intestinal wall, 
particularly the jejunum, represents the final obstacle before the compound is able to enter 
the body, coinciding with the greatest concentration in expression of the major ABC-
binding cassette transporters such as P-glycoprotein (P-gp, ABCB1) and the multidrug 
resistance protein (MRP2, ABCC2) (Taipalensuu et al., 2001). These transporters are 
expressed on the apical membranes of cells of the intestinal epithelium and act to expel 
drugs back into the intestinal lumen. The substrate promiscuity of P-gp is well known, and 
collectively efflux transporters pose a challenge to efficient drug delivery via the oral route 
of administration. Beyond the role of limiting bioavailability of drugs taken via the oral 
route, up-regulation of efflux transporters is one mechanism by which neoplastic cells 
become refractory to treatments (Ling, 1987). 
Whilst inhibitors of efflux proteins exist, they are limited by the high concentrations 
required, which often impart their own toxic effects. Recent advances in the field of 
excipient-drug interactions have revealed a diverse range of materials which are able to 
overcome efflux, either by increasing the uptake of test substrates across intestinal barriers 
in vitro or in vivo, or by sensitising refractory tumours to treatments. Such excipients 
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already have FDA approval, are currently in use and accepted, and can be incorporated in 
oral dosage forms using existing fabrication techniques. 
 Drug Dissolution and the Gastrointestinal Tract 1.2.
Upon ingestion of a tablet, the active material must be liberated from the dosage form for 
absorption to occur, and one of the rate-limiting steps in the effective oral delivery of any 
pharmaceutical compound is the rate of dissolution. This is described by the Noyes-
Whitney equation, shown in Equation 1.1, 
 
Equation 1.1 
 
where dW/dt is the rate of dissolution, A is the surface area available for dissolution, D is 
the diffusional coefficient, h is the thickness of the boundary layer, Xd is the amount of drug 
dissolved, V is the volume of the dissolution media, and Cs is the solubility of the 
compound. From this equation, it is possible to ascertain how the dissolution rate of a 
compound can be enhanced, even those with limited solubility, such as decreasing particle 
size, optimising wettability, decreasing the thickness of the boundary layer and ensuring as 
close to sink conditions as possible can all be seen as ways to increase the rate of 
dissolution.  
Once it has undergone dissolution, the active compound must reach the absorbing 
membrane, the intestinal epithelium. To achieve this, the drug must pass safely through 
the acidic content of the stomach and the digestive enzymes of the stomach and small 
intestine. The reported pH of the stomach varies between reports but has been shown in 
the rested state to be 2.8 for females and 2.2 for males (Feldman and Barnett, 1991). This 
increases following ingestion of a meal owing to the buffering capacity of food, but is 
normalised after 3-4 hours by the secretion of gastric fluid (Go, 1976). Many weakly acidic 
drugs, such as acetaminophen, are poorly absorbed by the stomach and greatly absorbed in 
the small intestine (Heading et al., 1973). As such, the rate of uptake is greatly related to the 
rate of gastric emptying. The rate of gastric emptying can be affected by many factors. 
Alcohol and some drugs are known to increase the rate of emptying (Kaufman and Kaye, 
𝒅𝑾
𝒅𝒕
=
𝑨.𝑫
𝒉
 . (𝑪𝒔 −  
𝑿𝒅
𝑽
) 
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1979), whilst other factors such as opiate analgesics can decrease the rate of emptying 
(Nimmo et al., 1975). Once the small intestine has been reached, the drug faces a series of 
challenging barriers in order to pass through to the desired site of action (Figure 1.1). This 
process can be summarised using Equation 1.2 to describe the amount of drug that is able 
to reach systemic circulation, otherwise known as bioavailability (F), 
 
 
Figure 1.1. Graphical representation of the bioavailability equation. A compound undergoes liberation from its 
dosage form, and must survive the transition past the intestinal epithelia. The absorbed fraction, fa, gets gradually 
diminished by the action of metabolism within the cell, fg, and subsequent hepatic degradation, fh, before systemic 
circulation is reached.  
 
Equation 1.2 
 
where Fa is the fraction of drug which is absorbed, Fg is the fraction able to survive gut 
metabolism and Fh is the fraction able to escape hepatic metabolism (Pond and Tozer, 
1984). It can be seen from this equation that a drug given by the intravenous (IV) route 
escapes these obstructions entirely, yet as discussed this route of administration is not 
favoured outside of a clinical setting. Collectively, the steps outlined in Figure 1.1 and 
Equation 1.2 are known as the first pass metabolism. Some drugs, such as oxycodone, 
diazepam and methadone, survive well to the systemic circulation, with oral bioavailability 
values of 60-87 % (Poyhia et al., 1992, Poyhia et al., 1993), 97 % (Palm et al., 1997) and 85 % 
F=Fa.Fg.Fh 
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(Dale et al., 2002), respectively. Other drugs, such as morphine and cocaine, have poor 
bioavailability values of around 30 % or less as a result of pre-systemic metabolism (Säwe, 
1986, Fattinger et al., 2000). 
 
 Intestinal Absorption and Transporters 1.3.
A layer of mucosa covers the intestinal epithelial membrane through which a drug must 
penetrate. However, this is generally not a rate-limiting step in absorption (Aungst, 2012, 
Fagerholm and Lennernäs, 1995). The intestinal epithelium may be considered the 
gatekeeper of substrate uptake, with nutrient and xenobiotic ingression occurring through 
a series of complex processes (Figure 1.2), with the specific type of uptake based on several 
physiochemical properties of the compound in question. The paracellular hypothesis 
describes the passive movement of the drug through the monolayer via intracellular tight 
junctions. Primarily, molecular weight/size and flexibility of geometric structure will 
influence the extent of paracellular passage, whilst solubility, chemical composition and 
charge distribution are further considerations (Aungst, 2012, Goole et al., 2010, Artursson 
et al., 1993b). The tight junction macromolecular complex provides this barrier function 
and is the rate-limiting structure to large and/or charged compounds, yet allows ingress to 
small uncharged compounds (Figure 1.2a). A major component of the tight junction 
complex is Zonula occludens (ZO-1), which act by directly binding actin cytoplasmic 
filaments to the transmembrane protein occludens, and so form cell-cell interfaces. Here, 
they play a cardinal role in the exclusion of macromolecules by the paracellular route, 
effectively sealing the apical plasma membranes of the intestinal lumen (Van Itallie et al., 
2009). Transcellular transport of lipophilic molecules can occur through the lipid bilayer, or 
by membrane bound proteins on the apical side (Figure 1.2b), or by transcytosis (Figure 
1.2c) (Goole et al., 2010, Le Ferrec et al., 2001). However, not all transport is absorptive e.g. 
apical to basolateral. A further consideration of drug transport is that of efflux, whereby 
xenobiotics are expelled back into the intestinal lumen (Figure 1.2d). 
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Figure 1.2. Intestinal absorption pathways, showing (A) paracellular, (B) transcellular passive/transporter mediated, 
(C) transporter mediated transcytosis, and (D) transporter mediated efflux. 
 
 The ABC Transporter Systems 1.4.
In addition to acting as an instrument of absorption, the intestine must also act as a barrier 
to xenobiotics, bacteria and other harmful substances. In order to protect specific tissues 
and the body as a whole, the GI tract employs a number of transporters, known as efflux 
transporters, to expel unwanted substances back to the intestinal lumen and prevent them 
from reaching systemic circulation. The purpose of such efflux transporters is believed to 
be in protecting the body from environmental toxins. The most widely reported 
information is on the adenosine triphosphate (ATP)-binding cassette (ABC) transporters 
due to being heavily implicated in the development of multidrug resistance (MDR) in 
cancer cells, where they are over-expressed. ABC proteins involved in drug resistance 
chiefly include P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, 
ABCC1), multidrug resistance protein 2 (MRP2, ABCC2) and breast cancer resistance 
protein (BCRP, ABCG2). These proteins have overlapping specificity, and collectively 
transport a vast range of diverse compounds. 
 
D 
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 P-glycoprotein (P-gp. ABCB1) 1.4.1.
P-glycoprotein (Figure 1.3) was the first of the ABC transporters to be characterised and a 
founding member of the ABC superfamily alongside MRP1. The transporter was first 
discovered after a 170,000 Da protein was isolated from the cell surface of Chinese hamster 
ovary cells which were resistant to colchicine and a plethora of amphiphilic drugs. Owing 
to its effects on permeability, this protein was named P-glycoprotein (Juliano and Ling, 
1976). This protein has since been found in a whole range of tissues, and the influence on 
pharmacokinetics and pharmacodynamics (PK/PD) are widespread: absorption by 
expelling xenobiotics back into the intestinal lumen; distribution by preventing entry 
through the blood brain barrier (BBB); xenobiotic metabolism due to the protein being 
affiliated to cytochrome P450 (CYP); P-gp lining the renal tubes will influence excretion 
(Mizuno et al., 2003, Goole et al., 2010). P-gp shows remarkable levels of broad poly-
specificity, and is capable of compound recognition from 220 Da (cimetidine) to 1202 
(ciclosporin), and even up to 4000 Da in the case of β–amyloid (Pan et al., 1994, Goldberg et 
al., 1988, Lam et al., 2001). The only real common feature of substrates of P-gp is 
hydrophobicity, and membrane partitioning is believed to be the initial step in protein-
substrate interaction. 
Beyond the role of resistance in cancer cells, the transporter has been implicated in 
resistance to other drugs. Western blot analysis has shown that brain P-gp was increased 2-
fold in rats chronically treated with morphine, a P-gp substrate (Löscher and Potschka, 
2005). P-gp homologues have also been implicated in the spread of treatment resistant 
pathogenic bacteria, fungi and parasites (Alcantara et al., 2013, Xu et al., 1998, Cowman, 
1991, Gibbons et al., 2003, Poole, 2005), and, as such, P-gp can be seen at the centre of some 
of the deadliest diseases on the planet. 
This transporter is coded for by the MDR1 gene in humans (mdr1a in rats and other 
organisms) (Schuetz et al., 1998), and is known from human genome nomenclature as 
ABCB1. However, in the GI tract, distribution is not even: the terminal ileum has the 
highest expression, approximately 4 times that of the duodenum and twice as high as the 
colonic regions (Zimmermann et al., 2005), although inter-person variability is observed. 
The impact of ABCB1 on drug uptake is also compounded by the co-expression and co-
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localisation of the transporter with metabolic enzymes, particularly cytochrome P450 (CYP) 
3A4, the major phase I metabolising enzyme (Wacher et al., 1995). CYP3A4 accounts for 30 
% of human hepatic microsomal cytochromes (Shimada et al., 1994) and is the most 
numerous of the enteric cytochromes (Zhang et al., 1999). Additionally, ABCB1 and 
CYP3A4 have known substrate recognition overlap suggesting likely synergism between 
the two (Wacher et al., 1995), making the presence of these proteins a further issue for 
concern in effective oral drug delivery. 
 
 
Figure 1.3. The crystal structure of murine P-gp. The protein consists of two bundles of six transmembrane 
helices. The inward facing formation results in a large internal cavity open to the cytoplasm and inner leaflet. The 
presumed drug binding pocket consists largely of hydrophobic and aromatic residues. The N and C terminal of the 
protein is coloured yellow and red respectively. NBD = nucleotide binding domain. Lipid bilayer location is shown 
in approximation (Protein Data Bank file 3G5U). Diagram adapted from (Aller et al., 2009). 
 
 Multidrug Resistance Associated Protein family (MRP, ABCC) 1.4.2.
The multidrug resistance protein 1 (MRP1/ABCC1) was first identified due to its 
overexpression in small cell lung cancer (SCLC) resistance (Cole et al., 1992) where MRP 
mRNA expression in treatment-resistance cell lines was shown to be 25 times higher than 
non-resistant parental cell lines (Zaman et al., 1993). Alongside P-gp, MRP1 was first of the 
ABC transporter families to be discovered, but only displays around 15 % amino acid 
Pollard J 
43 
 
homology to P-gp (Cole et al., 1992). The MRP isoforms transport both uncharged 
hydrophobic in addition to anionic conjugates. 
Interestingly, Zaman et al (1993) were to conclude that the overexpression of MRP did not 
account for all forms of non-P-gp MDR. Since then, it has emerged that MRP has several 
known isoforms (MRP1-MRP7), some of which overlap in terms of substrate specificity but 
differ in tissue expression. MRP1 is only known to be expressed in the proliferative cells at 
the enterocyte renewal sites of the murine model, where it is suspected to be involved in 
xenobiotic protection of this layer (Peng et al., 1999) and is unlikely to participate in the 
absorption process from the small intestine. In terms of affecting drug absorption, the 
second isoform of MRP, MRP2 (ABCC2), is perhaps the most important of the MRP 
isoforms, as it was first shown to be expressed on the apical border of the small intestine of 
both the rat (Mottino et al., 2000) and rabbit (Van Aubel et al., 2000) models. In a 
comprehensive human subject study, various parts of the intestine were sampled for the 
presence of expression of MRP1-MRP5, in addition to MDR1. In the duodenum, the rank of 
expression was seen MRP3 >> MDR1 > MRP2 (Zimmermann et al., 2005). However 
abundant, MRP3 is known as a bile salt transporter (Hirohashi et al., 2000) and although it 
is known to transport chemotherapeutic drugs, such as vinblastine and methotrexate 
(Hirohashi et al., 1999, Kool et al., 1999), expression of MRP3 is basolateral and, therefore, 
unlikely to impact drug bioavailability. Much like P-gp, MRP2 also displays site-specific 
expression, being almost non-existent in the upper ileum, with the highest concentration in 
the duodenum and disappearing once more in all segments of the colon (Zimmermann et 
al., 2005). Just as co-localisation of P-gp and CYP3A suggests close cooperation of the two, 
MRP2 is often co-expressed with conjugating enzymes which essentially provide for 
exportation the conjugated metabolites (Cao et al., 2006).  
 Breast Cancer Resistance Protein (BCRP, ABCG2) 1.4.3.
Breast cancer resistance protein (BCRP) takes its namesake from the MC-7 human breast 
carcinoma cells from which it was first discovered, after cells became refractory to 
mitoxantrone, doxorubicin, and daunorubicin treatment, and this was demonstrated not to 
be caused by P-gp or MRP1 (Doyle et al., 1998). Later, the murine homologue of the 
transporter was found on the apical membranes of the small intestine in mice (Jonker et al., 
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2000), leading to the possibility of pharmacokinetic intervention during human oral drug 
delivery. Indeed, BCRP expression as well as MRP2 expression have been shown to be 
higher than that of MRP1 in the human jejunum (Taipalensuu et al., 2001). 
The specific inhibitor of BCRP, GF120918, has been used to demonstrate the role of this 
transporter in limiting the uptake of some drugs taken orally. In both wild type and P-gp 
deficient mice, GF120918 increased the oral uptake of topotecan, a known substrate of 
BCRP, by six-fold in the former and nine-fold in the latter, respectively (Jonker et al., 2000). 
In the human subject, the same inhibitor led to an increase in topotecan plasma levels from 
40 % to 97 % (Kruijtzer et al., 2002).  
 ABC-Transporter-Substrate Recognition 1.5.
Given the implications of efflux transporters on drug target engagement at the desired 
dose, the study of structure-activity relationships (SAR) that improve biological activity has 
become a focal point. A typical ‘Rule of 5’ (RO5) that describes 90% of orally active drugs to 
navigate through stage II clinical trials is shown as (a) molecular weight < 500 Da; (b) 
lipophilicity (logP) or the calculated 1-octanol-water partition (ClogP) < 5; (c) the number of 
hydrogen bond donors, OH and NH count to be < 5; and (d) the hydrogen bond acceptor 
(HBA), O and N count to be < 10 (Lipinski et al., 1997). The fundamental RO5 can be 
expanded using a holistic approach to define the physiochemical properties required by a 
compound to be an ABC-transporter substrate, in particular a substrate of P-gp.  
With regards to CNS exposure, six physicochemical properties have been defined which 
effect P-gp efflux by comparing 108 diverse drug candidates with 119 marketed drug 
candidates (Wager et al., 2010). These are ClogP, ClogD7.4, molecular weight, topological 
polar surface area (TPSA), number of hydrogen bond donors (HBDs), and most basic 
centre (pKa, log of the acidic dissociation constant). An analysis of over 1000 structurally 
diverse compounds showed that compounds with a ClogP < 4.0 and with a TPSA between 
40-80Å2 were more likely to circumvent P-gp efflux (Raub, 2006). In an additional study by 
the same group of over 2000 compounds, structures with a TPSA < 60 Å2 with a pKa < 8.0 
were much more likely to be identified as non-P-gp substrates (Desai et al., 2012). 
Increasing passive permeability was also noted as a method of avoiding P-gp efflux.  
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Two models have been proposed for the mechanism of efflux action. The simplest is 
known as the pore model and assumes the protein is expelled from the cell by a protein 
channel. However, the most popular paradigm is known as the “hydrophobic vacuum 
cleaner” model (Raviv et al., 1990). Here, the substrate is able to partition the bilayer as it 
enters the inner leaflet of the membrane (Figure 1.4). It is then taken up into the internal 
binding site, at which point the affinity of the nucleotide binding sites for ATP increases. 
Following ATP binding, a conformational change of the protein presents the substrate to 
the outer leaflet or extracellular space, sterically occluding access to the inner leaflet. ATP 
hydrolysis then returns the protein to the original configuration. This model is supported 
by X-ray crystallography, demonstrating that P-gp has binding sites located at an internal 
cavity located within the transmembrane section, indicating substrate acquisition occurs 
here (Aller et al., 2009). According to the two-step model of substrate binding, P-gp binds 
its substrate in the cytosolic membrane leaflet. As such, a compound rapidly diffusing 
across a membrane will evade P-gp efflux. Indeed, an increase in TPSA, HBD and HBA 
will serve to reduce the passive permeability of a compound and thus increase its chances 
of interactions with an efflux transporter. The dominant role of TPSA, HBD and HBA is 
supported by an in vitro permeability study of 4176 compounds (Hitchcock et al., 2012). Of 
these, 52% of compounds with a TPSA > 90 Å2 were categorised as substrates of P-gp, but 
only 14% with TPSA < 70 Å2 were substrate. For HBD count, 57% of compounds with > 2 
HBDs were categorised as P-gp substrates, with only 9% with no HBD being considered 
substrates. ClogP had little influence on P-gp efflux within the range of drug-likeness 
(Hitchcock et al., 2012). 
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Figure 1.4. The two-step model of substrate transport of P-gp. (A) The substrate (maroon) partitions into the 
bilayer into the inner leaflet. Here, it is able to enter the intramembranous substrate binding pocket. (B) ATP 
(yellow) interaction with the nucleotide-binding domain (NBD) causes a conformational change of the protein, 
exposing the substrate to the extracellular space (Protein Data Bank file 3G5U). Diagram adapted from (Aller et 
al., 2009). 
 
The inhibition specificities of P-gp, BCRP and MRP2 have been shown to be highly 
overlapping. A study testing the inhibition properties of 122 structurally diverse drugs on 
P-gp, BCRP and MRP2 revealed 23 transporter-specific inhibitors and 19 overlapping 
multi-specific inhibitors (Matsson et al., 2009). General inhibitors were found, on average, 
to be more lipophilic (median logD7.4 = 4.5) and aromatic than specific inhibitors, or non-
inhibitors. According to the two-step model of substrate interaction with P-gp (Aller et al., 
2009), discussed above, the ligand partitioning into the plasma membrane allows the 
inhibitors to bind to an intramembranous site. As most of the homology between the ABC 
transporters is found in the nucleotide-binding domain (NBD), the authors suggest that the 
non-lipophilic, negatively charged, multi-specific compounds in this study (silymarin and 
quercetin, logD7.4 = 1.5 and 1.0, respectively) might interact with the transporters in a 
similar manner to the negatively charged phosphate moiety in ATP (Matsson et al., 2009). 
Binding site differences between transporters may also play a role in specificity, as BCRP-
specific inhibitors generally contained more nitrogen atoms than P-gp specific inhibitors, 
suggesting hydrogen bond π-π or π-cation interactions may be important for BCRP 
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binding (Matsson et al., 2009). In contrast, P-gp inhibitors contained more carbonyl oxygen, 
which are less likely to participate in hydrogen bond formation, consistent with the 
hydrogen bond acceptor patterns of P-gp substrates already discussed. The low 
lipophilicity of BCRP and MRP2 inhibitors is suggestive of a less important role of plasma 
membrane partitioning for these transporters, and that the substrate binding sites for these 
transporters lies within a cytosolic location, in contrast to P-gp (Aller et al., 2009). The true 
distinction between ABC-transporter substrate recognition and inhibitor recognition 
remains to be further determined, as ABC-transporters belong to a diverse group of 
membrane-bound proteins, many of which are currently lacking structural information 
(Klepsch and Ecker, 2010). Current information is, therefore, based on examination of 
known substrates and inhibitors. 
  Commonly Utilised Models of Intestinal Absorption 1.6.
Of cardinal importance in drug development and formulation is to have a predictive model 
for the absorption of the compound in man. By definition, any biological model has its 
limitations in terms of the overall similarity to the in vivo tissue to which it should replicate. 
This includes, but is not restricted to, representative physiology, metabolic enzymes and 
efflux transporters. As such, there are a number of models which are available to drug 
delivery scientists who wish to replicate faithfully the transport that occurs at the site of the 
majority of drug uptake.  
 In Vivo Models of the Gastrointestinal Tract 1.6.1.
The in vivo method of modelling has many advantages, coupling the presence of a mucus 
layer with a functional circulatory system. Aside from human voluntary trials, the rattus 
model is perhaps the most popular ahead of the canine model. Not only does this latter 
model represent something of a moral dilemma for using canis familiaris, from a purely 
scientific perspective the canine model is often cited as being an overestimation of the 
model of metabolism in comparison to the human model. One study comparing the 
fraction absorbed in dog and man only found an r2 correlation value of 0.512 (Chiou et al., 
2000). The same authors previously found a much better correlation, with an r2 value of 
0.975, between human and rat bioavailability (Chiou and Barve, 1998). In a study 
examining compounds with varying mechanisms of uptake (P-gp-mediated, organic cation 
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transporter-mediated, and passive diffusion), it was found that overall fraction absorbed of 
all compounds was closely correlated (r2 = 0.8) (Cao et al., 2006) despite moderate (r2 = 0.56) 
correlation in transporter expression. Despite having a quicker intestinal transit time, some 
drug uptake profiles in dogs appears more complete, often associated with larger villi 
compared humans in addition to increased canine bile secretion, which could aid 
solubilisation of poorly water-soluble compounds (Kararli, 1995). It is also not possible to 
delineate the different mechanisms of absorption and identity of rate limiting steps. As 
such, in vivo testing has to be carefully considered. 
An extension of the in vivo modelling system is the in situ model of the small intestine 
(Figure 1.5), which offers the advantages of using living tissue coupled with the mucus 
layer and a live blood flow to the tissues in question. Typically, an animal has been 
surgically manipulated under the influence of an anaesthetic to display the mucosal fascia. 
The disappearance of drug from the intestinal lumen is then monitored as a measure of 
drug absorption. Generally, the in situ model is validated using different marker 
compounds such as PEG 4000, mannitol and D-glucose, usually radiolabelled, in order to 
assess how the volume of drug solution changes in response to water absorption, and to 
monitor intestinal viability in a similar manner to TEER values for in vitro monolayers, 
discussed later. However, the choice of anaesthetic used is critical, as it has been shown to 
have a strong influence on intestinal absorption (Yuasa et al., 1993). This model has two 
main variations. The Doluisio method utilises the whole small intestine of the rat (Doluisio 
et al., 1969), whereas the single pass intestinal perfusion (SPIP) utilises just a single 10 cm 
section of the intestine, typically the jejunum (Amidon et al., 1988). Both have shown 
excellent correlation to the effective permeability (Peff) of both passively absorbed and 
carrier mediated transport. In a recent study, both variations of the technique were shown 
to have an r2 value of 0.93 (Lozoya-Agullo et al., 2015). 
 
 
Pollard J 
49 
 
 
Figure 1.5. Experimental set up of the in situ technique. Freshly excised intestine of the anesthetised rat is exposed 
and the test compound is introduced via the syringe at a controlled rate. Samples are then collected at the desired 
point further down the tract to determine the degree of compound uptake. This can either be the whole intestinal 
tract (Doluisio model) or a 10 cm section (single pass intestinal perfusion (SPIP) model) (Barthe et al., 1999). 
 
Of course, there exists a method of testing absorption on the human subject as well. In its 
most advanced form developed by Lennernäs et al (Figure 1.6), the intestinal perfusion 
method involves using a multichannel sterile tube which is able to inflate two balloons in 
order to section off a 10 cm section of the intestine (Lennernäs et al., 1992). Introduced 
orally after local anaesthetic, the sectioned off segment of intestine is exposed to the free 
drug perfusate. Owing to its technical complexity and reliance on human volunteers, this 
technique is not suitable for widespread usage, but has shown good correlation to 
pharmacokinetic studies including Biopharmaceutics Classification System (BCS) 
prediction and correlation of carrier mediated transport (Lennernäs, 1997). 
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Figure 1.6. Intestinal perfusion technique in man. Once the balloons are inflated, the sectioned-off area of the 
intestine serves as a model barrier. The closed section is then rinsed in drug-free buffer, and then the drug solution 
added. Intestinal integrity is measured simultaneously using the retention of a non-absorbed marker compound 
such as PEG 4000 (Barthe et al., 1999). 
 
 In Vitro Models of the Gastrointestinal Tract 1.6.2.
 Ussing Chamber 1.6.2.1.
The Ussing chamber model (Figure 1.7) is still a mainstay of transport studies through 
semipermeable biological membranes, with its origins dating back over 60 years (Ussing 
and Zerahn, 1951). In the format of intestinal transport, a small sheet of enteric tissue is 
clamped between two buffer-containing chambers, which are oxygenated to aid sample 
viability. The test compound is then added to the donor compartment and ingress is 
monitored in the receiver compartment, analogous to mucosal to serosal transport. 
However, bidirectional transport is also possible. An advantage of the system is that it can 
be used for transport studies on special tissues of the GI tract. Just like TEER, electrical 
resistance is used to monitor the viability of the tissue sample – a short circuit indicating 
the integrity of the barrier (Yeh et al., 1994). As with all models, the Ussing chamber is 
disadvantaged by the limitations of the tissue from which the membrane was sourced. 
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Figure 1.7. The Ussing chamber. Two transport buffers are separated by the intestinal membrane clamped in place. 
The electrical resistance of the membrane is constantly monitored in order to ensure membrane integrity. The test 
compound can then be introduced to one compartment and its ingress monitored to the other compartment 
(Barthe et al., 1999).  
 
 Everted Gut Sac 1.6.2.2.
Just like the Ussing chamber, the everted gut sac model (Figure 1.8) is still a popular model 
despite the older vintage (Wilson and Wiseman, 1954). Unlike the Ussing method however, 
the whole of the rat intestinal tract can be used. This is excised from starved rats and 
transferred to oxygenated media and everted using a glass rod. Individual parts are then 
sectioned off with a silk suture. Whilst visual inspection and monitoring of glucose and 
amino acid consumption ensure viability of the sample, the test solution is then incubated 
with the sac for various amounts of time. As the full array of efflux transporters are present 
in the sample, it is possible to get kinetic data relating to this type of transport as well, and 
for screening for potential efflux inhibitors, which may be drugs or excipients (Barthe et al., 
1998, Hubbard et al., 2015). The model can be used to examine site-specific transport 
depending on which part of the sac was sectioned off. Once more, such a model follows the 
limitations of the animal tissue from which the tissue was derived. 
Chapter 1 
52 
 
 
Figure 1.8. Everted gut sac model. Freshly excised gut sac is inverted over a glass rod and tied at both ends after 
introducing the test compound. The transport process can then be monitored by the appearance of the compound 
to the incubation medium (Barthe et al., 1999).  
 
 Cell Based Models 1.6.2.3.
Cell based models not only reduce the burden of animal research, they are relatively simple 
to produce and, when grown in specifically designed plastic inserts, have well developed 
protocols for ease of data analysis. Due to the non-proliferative nature of small intestinal 
epithelial cells, the most widely accepted in vitro model remains cell lines of colonic origin. 
From these, the polarised and differentiated human adenocarcinoma (Caco-2) cells are 
known to express microvilli and enzymatic components resembling those of the intestinal 
epithelium (Wilson et al., 1990). However, this model is also not without its limitations. 
Cytochrome P450 and its isoforms, the enzymatic barrier to oral absorption and part of the 
first-pass pass effect, is weakly expressed in comparison to the levels observed in vivo, 
although this can be addressed using vector transfection (Hu et al., 1999). The expression of 
ABCB1 is also higher than that of the human colon (Englund et al., 2006). Therefore, the 
interpretation of Caco-2 data requires careful consideration, and studies have shown huge 
differences in inter-laboratory variability among data sets, with discrepancies often 
attributed to different culture conditions and the selection of varying cells from a 
heterogeneous subpopulation of cells (Walter and Kissel, 1995), amongst others. Despite 
these drawbacks, the Caco-2 cell line is highly regarded as the in vitro ‘gold standard’ 
model for drug absorption across the small intestine and remains in widespread usage, 
most commonly when seeded in Transwell® inserts, whereby cells are grown to full 
differentiation over a three week period on these semipermeable polycarbonate 
membranes (Figure 1.9). 
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Figure 1.9. Experimental setup of Caco-2 Transwell® model. Cells are grown for 21 days to allow full 
differentiation. For apical to basolateral (AP to BL) transport studies, functionally analogous to mucosal to serosal 
transport, cells are washed in buffer and the drug-containing buffer added to the apical compartment and drug-
free buffer to the basolateral compartment. Samples are then taken from the basolateral compartment at fixed 
intervals. For basolateral to apical (BL to AP) transport, the drug-containing solution is added to the basolateral 
compartment and samples taken from the apical compartment. 
 
Following full differentiation, epithelial integrity is measured indirectly using 
transepithelial electrical resistance (TEER); that is, the resistance of an electrical current 
passed across the monolayer. By short-circuiting the membrane, interference of electrical 
current generated by ion transport is negligible and, therefore, follows that an increase in 
TEER correlated to monolayer integrity, and so a decrease in paracellular transport. By 
sampling the basolateral media, the progress of compound transport can be monitored and 
the apparent permeability coefficient (Papp) calculated using Equation 1.3, 
 
        Equation 1.3. 
 
where dQ/dt is the rate of appearance of the test compound on the basolateral side (ng s-1), 
C0 is the initial concentration on the apical side (mg mL-1) and A is the surface area of the 
monolayer (cm2). Papp has units of cm s-1. Apparent permeability coefficients data obtained 
from Caco-2 cells have been shown to correlate to those of the human intestine (Irvine et 
al., 1999, Wilson et al., 1990). 
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A development of the Caco-2 model can be seen in the numerous subclones of the parental 
cell line that can also be selected for various characteristics after exposure to various 
compounds or early to late passage numbers. Most notably, the TC-7 subclones were 
selected for increased taurocholic acid transport (Caro et al., 1995). These subclones 
displayed higher growth rates, and higher expression of phase II metabolic enzymes, such 
as UDP-glucuronyltransferases, which are known to be deficient in the parental cell line. 
Despite functional analysis of the P-gp substrate ciclosporin transport demonstrating lower 
levels of this transporter, both cell lines demonstrated correlation between absorption in 
humans and Papp values in vitro (Grès et al., 1998). 
Madin Darby canine kidney cells (MDCK), isolated by Madin  Darby (Gaush et al., 1966), 
rose to prominence in the field of viral research for decades in the literature, in addition to 
their nominal role in renal transport experiments. This cell line is heterogeneous and comes 
in two strains: the ‘tight’ epithelium MDCK I and the leaky epithelium MDCK II 
(Richardson et al., 1981). Later, this cell line was harnessed as a molecular barrier model for 
compounds of pharmaceutical interest (Cho et al., 1989), and now frequently appears in 
literature as such, favoured for the much shorter amount of time required in order to reach 
confluence compared to the 3 week growth time of Caco-2. As with the Caco-2 model, 
MDCK cells form polarised epithelium with brush borders and tight junctions when grown 
on semi permeable membranes. Despite the absence of P-gp in MDCK cells, viral 
transfection has been used successfully to transfer the MDR1 gene product to the 
monolayers, allowing the apical expression of this transporter (Pastan et al., 1988). These 
are known in the literature as MDCK-MDR1 cells. Likewise, comparative research can 
conducted following MRP2 and BCRP transfection, known as MDCK-MRP2 and MDCK-
BCRP cells, respectively. 
 Excipient-Efflux Transporter Interactions 1.7.
It has been reported that P-gp function is dependent on the maintenance of the lipid-
protein interface (Callaghan et al., 1997). By increasing the water content of the membrane 
proteins, surfactants may interfere with the function of P-gp (Dudeja et al., 1995). 
Surfactants are capable of interacting with lipid bilayers and disrupting hydrogen or ionic 
bonding, or may insert themselves into the bilayer itself. Because of this, a large number of 
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surfactants have been reported to exhibit efflux transporter inhibition. However, the other 
ABC transporters are more deeply-embedded within the lipid membrane, allowing for a 
more robust function in the face of surfactant interaction (Batrakova et al., 2004). As such, 
the volume of literature regarding excipients with a biological effect against P-gp is, under 
the circumstances, considerably asymmetric when compared to that of other ABC 
transporters. Moreover, the latter discovery of the other ABC transporters may have 
produced a lag in the discovery of suitable probe substrates. 
 
 The Biological Effects of Excipients on P-gp Activity 1.7.1.
 PEGs and PEGylated Surfactants 1.7.1.1.
Polyethylene glycols (PEGs), synthetic polyethers, are amphiphilic water-soluble polymers 
available in a plethora of molecular weights, which are well tolerated in vivo. As such, 
PEGs and PEGylated excipients have an illustrious role in pharmaceutical formulations as 
plasticisers in film coating (Okhamafe and York, 1985), putative lubricants (Al-Nasassrah et 
al., 1998), binder augmentation (although a poor binder per se (Elgindy et al., 1988)), and 
solubility and dissolution enhancing agents in the form of solid dispersions (Geneidi et al., 
1981). Lower molecular weight PEGs, such as PEG 400, are liquid, and become more solid 
as a function of the molecular weight, becoming waxy at 1000 Daltons (PEG 1000) and 
crystalline powders over 4000 Daltons (PEG 4000). Over 100,000 Daltons, the nomenclature 
changes to poly(ethylene) oxide (PEO). The ether bond of PEG is extremely useful in 
solubilising poorly soluble entities, and PEGs are often found as the hydrophilic moieties 
of a number of surfactants. 
The paradigm of the biological effect of PEGylated excipients first appeared in the 
literature regarding the reversal multiple drug resistant (MDR), the phenomenon in which 
solid tumour cells become refractory in nature by the up-regulation of the MDR1 gene 
encoding P-glycoprotein (Ueda et al., 1987). Polyethyloxlated castor oil, Cremophor EL, 
was shown to sensitise the MDR cell lines R100 and K562 to the chemotherapeutic drug 
daunorubicin (Woodcock et al., 1990). The study was later expanded using mouse P388 
MDR tumour cells using the surfactants Cremophor EL, Tween 80 and Solutol HS15, 
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further demonstrating the efflux inhibition effects of the polyethoxylated moiety. As the 
implications of P-gp inhibition of PEGylated excipients became clear, further groups began 
testing such excipients on the absorptive tissues of the intestine. Initial in vitro studies on 
rat jejunal tissues showed the efficacy of PEGs and Pluronic P85 on increasing the serosal to 
mucosal (s to m) transport of the P-gp substrate digoxin (Johnson et al., 2002b). Studies 
during the same year established the Caco-2 cell line as a model for demonstrating the 
effects of excipients against P-gp, with PEG 300 (Hugger et al., 2002a), and in a later study 
with PEG 300, Cremophor EL and Tween 80 using the Caco-2 and MDCK-MDR1 cell line 
(Hugger et al., 2002b). The study found that 20 % (v/v) PEG 300 was able to completely 
inhibit P-gp efflux transport of Caco-2 monolayers using the P-gp –substrate anti-cancer 
drugs doxorubicin and taxol (Hugger et al., 2002a). In the follow-up study, the same team 
then used MDR1 transfected Madin Darby Canine Kidney (MDCK-MDR1) cell line, and 
found that PEG 300 (20 % v/v) was again enough to achieve complete P-gp inhibition 
(Hugger et al., 2002b). Using the in vitro everted gut sac model and in vivo improved single 
pass perfusion model studies, PEG 400 has been shown to increase the permeability of the 
lipophilic compound ganciclovir in the range of 0.1 – 1 % (w/v). Furthermore, no regional 
differences were observed, and the effect was not dose-dependent (Li et al., 2011b). The 
role of PEG 400 as a permeability enhancer has been further supported by another study 
examining the role of the polymer in digoxin efflux and verapamil (VER) metabolism to 
test for the inhibition of cytochrome P540 3A (CYP3A) using rat jejunal tissue (Johnson et 
al., 2002b). The study showed that the presence of PEG 400 between 1 % and 20 % (w/v) 
was enough to inhibit serosal to mucosal transport of digoxin between 47 % to 64 %, 
respectively, and VER metabolism by 54 % to 100 %, respectively. In an extended study 
using a broad range of PEGs and PEGylated compounds further demonstrated the role of 
these compounds as efflux inhibitors. PEGs 400, 2000, 20000, monooleate, monostearate 
and monolaurate, in the range 0.1 – 20 % (w/v), were all shown to inhibit the efflux of the 
P-gp substrate rhodamine 123 (R-123) across rat intestinal membranes (Shen et al., 2006). 
Lipid nanocapsules, developed as a drug delivery device, have been shown to increase the 
level of cytotoxicity of the anticancer drug etoposide in C6, F98 and 9L glioma cell lines 
with increased retention of the cytotoxic compounds (Lamprecht and Benoit, 2006). A 
component of these lipid nanocapsules was polyethylene glycol-660-hydrostearate, 
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previously demonstrated as a P-gp inhibitor (Coon et al., 1991, Buckingham et al., 1995), 
and the phenomenon of overcoming MDR was believed to be attributed to the polymer in 
this case. 
PEGylated surfactants were amongst the first of the excipients known to have efflux-
inhibiting effects, and the mode of action is often multifaceted. Using 0.0025 – 0.01 % 
Tween 20 increased the sensitivity of MDR cells for a range of anticancer drugs, with 
specific increased accumulation of doxorubicin. RT-PCR analysis confirmed that low 
concentrations of Tween 20 could down-regulate the expression of P-gp in HepG2/R cells, 
effectively reversing MDR (Yang et al., 2012). A further study showed that Tween 20, 
Tween 80, Myrj 52 and Brij 30 could increase the intracellular accumulation of epirubicin in 
Caco-2 cells, whilst decreasing basolateral to apical efflux, and increased the mucosal to 
serosal absorption in rat jejunum and ileum (Lo, 2003). This study also found that the 
optimal hydrophilic to lipophilic balance of the compounds for increased uptake was in the 
range 10-17, and the optimal inhibition was observed for compounds containing 
polyethylene chains and intermediate chain length fatty acids and fatty alcohols. 
The transport of taxol has been examined in the presence of the PEGylated surfactants 
Cremophor EL 35 and Tween 80 at 0.1 % (v/v) and 0.05 % (v/v), respectively, using both the 
Caco-2 and MDCK-MDR1 cell lines (Hugger et al., 2002b). Both excipients were inactive as 
inhibitors of P-gp in MDCK-MDR1 cells and only partial inhibitors of P-gp in Caco-2 cells 
in the concentrations used. The difference in activity was suggested to be because of the 
differences in the interactions of the surfactants with the different cell membranes. 
However, Cremophor EL 35 and Tween 80 have been shown to be full inhibitors of P-gp 
using ganciclovir as the P-gp substrate during in vitro everted gut sac and in situ improved 
perfusion model experiments, using a higher concentration range than in the previous 
study (0.1-1 % w/v) (Li et al., 2011b). Numerous other findings have demonstrated the 
inhibition of P-gp by Cremophor EL 35 (Shono et al., 2004, Rege et al., 2002, Cornaire et al., 
2004) and Tween 80 (Shono et al., 2004, Li-Blatter et al., 2009, Rege et al., 2002). 
Poloxamers, triblock copolymers also known as Pluronics, have also shown inhibition 
activity towards efflux transporters. This effect was first demonstrated using Pluronic P85 
(Alakhov et al., 1996), and since then these materials have been comprehensively studied 
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for the structure/function relationship to P-gp inhibition. Using bovine brain microvessel 
endothelial cell line (BBMECs), poloxamers of differing hydrophilic-lipophilic balance 
(HLB) values were tested for efficacy against the efflux transporter (Batrakova et al., 2003). 
It was found that poloxamers with a propylene oxide between 30-60 units had the greatest 
impact on efflux inhibition. The most efficacious of the materials had a HLB value below 
20. Poloxamers within this range showed strong membrane fluidisation tendencies 
alongside reduction in ATPase activity. The efficacy of poloxamers is attributed to the 
monomers, as activity is known to decrease after the critical micelle concentration (CMC) 
has been reached (Miller et al., 1997). 
The amphiphilic surfactant D-α-tocophyheryl polyethylene glycol succinate (TPGS) has 
been demonstrated as a reversal agent of MDR in P-gp expressing (MDR1 transfected) 
G185 cells. These cells are typically resistant to the cytotoxic drugs doxorubicin, 
vinblastine, colchicine and paclitaxel by 27-135 fold. TPGS increased the sensitivity of G185 
cells to these compounds, whilst decreasing basolateral to apical permeation in a 
concentration-dependent manner. This concentration was well below the critical micelle 
concentration of TPGS (0.02% w/w); it was suggested that this was not the method of 
inhibition of P-gp (Dintaman and Silverman, 1999). In agreement with this, a similar study 
using amprenavir, a HIV protease inhibitor and P-gp substrate, TPGS could inhibit the 
efflux action of P-gp to the same extent as P-gp inhibitors, such as verapamil (Yu et al., 
1999). In another study, the different chain lengths of TPGS were synthesised to examine 
their inhibitory effects on R-123 efflux; whilst TPGS-1000 showed optimal inhibition, chain 
lengths between 238 and 3400 also showed notable potency as inhibitors of P-gp, with the 
results following Weibull distribution. Interestingly, the degradation products of TPGS-
1000, vitamin E, vitamin E succinate and PEG 1000 had no effect on R-123 efflux at the 
concentrations used (Collnot et al., 2006). Inhibition of P-gp by TPGS has been suggested to 
occur by membrane rigidisation (Rege et al., 2002). 
Dendrimers, also known as dendritic polymers, are multi-branched excipients that can be 
used as a polymeric carrier. Emanating from a central core, the branches have the potential 
to be functionalised or conjugated to a desired compound. The biological effects of 
dendrimers was first demonstrated by conjugating the P-gp substrate propranolol to 
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Generation 3 (G3) polyamidoamine (PAMAM) dendrimers, which resulted in an increase 
in the apical to basolateral transport of the drug through Caco-2 monolayers (D'Emanuele 
et al., 2004). In another study using the same material conjugated to paclitaxel, 
permeability through Caco-2 monolayers was improved 12-fold, with the basolateral to 
apical transport being statistically higher in the first instance, implicating the role of P-gp 
in paclitaxel transport (Teow et al., 2013). Conjugated to doxorubicin, G3 PAMAM has also 
been shown to increase the cellular accumulation of the drug in brain capillary endothelial 
cells (BCECs), whilst also increasing the uptake of the drug 6-fold in the in vivo murine 
model across the blood brain barrier (Cui et al., 2009).  
Generation 3.5 (G3.5) and Generation 4 (G4) dendrimers were able to increase the oral 
uptake of the P-gp substrate camptothecin in the murine model (Sadekar et al., 2013). 
Interestingly the transport of mannitol was not increased, suggesting that tight junction 
modulation was not a significant mechanism. In contrast, dendrimers have been shown to 
be able to reversibly modulate tight junctions, shown by ZO-1 staining (Liu and Chiu, 
2013). In another study, dendrimer G3.5 transport in Caco-2 cells was shown to be 
dynamin-dependent and clathrin-dependent, indicative of receptor-mediated endocytosis 
for transepithelial transport (Goldberg et al., 2010). In a more recent study, PEGylated 
Generation 5 PAMAM (G5 PEG) modified nanoliposome was used to increase the oral 
uptake of probucol in the in vivo murine model (Ma et al., 2015). In the same study, the 
increase was shown to be related to P-gp on the Caco-2 model, but independent of caveolae 
endocytosis pathway by transfecting and up-regulating expression of Caveolin 1 (Cav-1), a 
protein crucial to the maintenance and structure of the caveolae. These up-regulated cells 
showed no change in transport of probucol-G5 PEG compared to non-transfected cells. 
Furthermore, the transport of dendrimers through monolayers has not been shown to be 
temperature dependent, indicating that the polymers themselves are not P-gp substrates 
(El-Sayed et al., 2003). 
 Natural Polymers 1.7.1.2.
In the only study of natural polymers on the inhibition of efflux transporters, the anionic 
xantham gum and gellan, and sodium alginates flavivam and ascophyllum have been 
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shown to accumulate the P-gp substrates vinblastine and doxorubicin in the everted gut 
sac model (Carreno-Gomez and Duncan, 2002). 
 Cyclodextrins 1.7.1.3.
Cyclodextrins, enzymatically modified starches, have the ability to form inclusion bodies 
which increases the solubility of lipophilic drugs (Goole et al., 2010). The most potent 
compound of the class at forming these inclusion bodies is 2, 6-di-0-methyl-β-cyclodextrin 
(DM-β-CyD). This compound has shown a strong ability to inhibit the efflux capacity of P-
gp, and thus increase the apical to basolateral permeation of 2P,7P-bis(2-carboxyethyl)-5(6)-
carboxyfluorescein (BCECF), a P-gp and MRP2 substrate. Furthermore, DM-β-CyD was 
demonstrated to remove MRP2 and P-gp from the apical membrane into the buffer, whilst 
decreasing the level of cholesterol in the membrane (Yunomae et al., 2003). The same 
compound was also shown to increase the oral bioavailability of the poorly water-soluble 
drug ciclosporin by inhibiting these efflux transporters (Oda et al., 2004). 
 Lipid Excipients 1.7.1.4.
Few studies have been conducted on the biological effect of lipid excipients. Peceol and 
Gelucire 44/14 have been shown to be able to inhibit P-gp at concentrations below 0.5 % 
(v/v) to a comparable level to that of verapamil, a known P-gp inhibitor, in Caco-2 
monolayers. Using Western blot, it was revealed that this inhibition was by reduced down-
regulation of MRD1 gene expression (Sachs-Barrable et al., 2007). 
 Thiomers 1.7.1.5.
Thiomers are surfactants that utilise the thiol component of their structure in much the 
same way the PEGylated moiety, and these polymers can also have a biological effect. 
Interestingly, these materials have been shown to have higher efficacy in comparison to 
Pluronic P85 (Greindl et al., 2009), one of the most potent modulators of P-gp mediated 
transport (Batrakova et al., 2003). The functional efficacy of thiomers is related to molecular 
mass and degree of thiolation (Grabovac et al., 2015). 
 The Biological Effect of Excipients on MRP2 Activity 1.7.2.
Although the effects of many excipients on the P-gp transporter are now well established in 
the literature, the same cannot be said for their effect on MRP2. The first mention in 
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literature appears in a study comparing several non-ionic surfactants on their propensity to 
inhibit efflux of the probe substrates of P-gp (rhodamine 123, R-123) and MRP2 (5-
chloromethylfluourecein, CMF) using the transfected MDCK cell line (Bogman et al., 2003). 
Although this study provides perhaps one of the first attempts at pharmacokinetic 
categorisation of the effects of excipients against these transporters, the authors 
acknowledge that cellular damage may have been a contributing factor to the damage of 
intracellular esterase, known to convert the prodrug CMFDA into the fluorescent 
compounds, and prevented the establishment of data relating to ABCCC2 transporter 
system. Another group demonstrated the efficacy of Cremophor EL and PEG 2000 on the 
ABCC2 transport system on the Caco-2 cell line (Li et al., 2013a), later expanding the study 
to include Cremophor RH and poloxamer 407 (Li et al., 2014b). Additionally, thiolated 
poly(acrylic) acid-cysteine polymers have been shown to have a biological effect against 
MRP2 mediated transport (Greindl et al., 2009). Taken together, these studies are the extent 
of the knowledge of biological effects of PEGylated excipients on the MRP2. 
 The Biological Effects of Excipients on BCRP Activity 1.7.3.
Information on the biological effects of these excipients against BCRP has an equally sparse 
footing in the literature as those against MRP2, and is dominated by a single group. 
Yamagato et al tested the effects of Pluronic P85 and Tween 20 on the mouse model 
(Yamagata et al., 2007b). In the presence of both excipients, the bioavailability of topotecan 
was increased in wild type mice but not BCRP knockout mice. In the same set of 
experiments, the mucosal to serosal absorptive transport was monitored in everted mouse 
ileum; once more uptake was only increased in wild type ileum and not those of the BCRP 
knockouts (Yamagata et al., 2007b). Using MDCKII-BCRP cells, Tween 20 and Pluronic 
P85were shown to reversibly modulate the transport of the BCRP substrate mitoxantrone. 
Interestingly, the effects of P85 diminished at high substrate concentration, implying that 
the mechanism of action of this excipient may be competitive; the same result was not seen 
for Tween 20, which was believed to be non-competitive or mixed type (Yamagata et al., 
2009). The excipient set was then diversified to a number of different surfactants, and it 
was found that Cremophor EL, Span 20, Brij 30, in addition to P85 and Tween 20, were able 
to increase the uptake of mitoxantrone in MDCKII-BCRP cells. Interestingly, intracellular 
ATP levels were not altered (Yamagata et al., 2007a). 
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 Model Substrate Drugs and Fluorescent Probe Substrates 1.8.
In order to develop an assay to study the efflux transporters, consideration must be taken 
to known substrates and the specificity of each. In this respect, fluorescent molecules that 
are probes of efflux transporters are held in high merit for their ability to aid high-
throughput, without the need for lengthy analytical techniques, such as High Performance 
Liquid Chromatography (HPLC). Similarly, any assay screening for efflux inhibition must 
first be validated against known modulators of the transporters of interest. 
 Rhodamine 123 and 5 (6)-Carboxy-2’,7’-dichlorofluorescein 1.8.1.
The P-gp substrate rhodamine 123 (R-123, Figure 1.10a) and the MRP2 substrate 5(6)-
carboxy-2’,7’-dichlorofluorescein (CDF, Figure 1.10b), are both widely employed to probe 
activity of their respective efflux transporters. R-123 is able to enter the cell via direct 
diffusion across membranes, whereas, CDF is unable to directly cross membranes and so is 
used for assay studies as the premoiety 5(6)-carboxy-2’,7’-dichlorofluorescein diacetate 
(CDFDA, Figure 1.10c), which is freely able to diffuse across membranes. Once inside the 
cell, this prodrug is converted to a highly fluorescent array of compounds, chiefly CDF, 
which can only escape the cell via the MRP2 transporter (Zamek-Gliszczynski et al., 2003). 
It is the innate fluorescence of these two entities that helps facilitate rapid high-throughput 
screening of P-gp and MRP2 transporter activity. 
 
Figure 1.10. The chemical structures of A) rhodamine 123, B) 5(6)-carboxy-2’,7’-dichlorofluorescein and C), the 
5(6)-carboxy-2’,7’-dichlorofluorescein premoiety 5(6)-carboxy-2’,7’-dichlorofluorescein diacetate. 
 
A          B 
 
 
 
 
 
   C 
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At low concentrations, the uptake of R-123 has been shown to be a saturable process that 
can be inhibited by the organic anion-transport (Oat)1a4 substrates digoxin, quinine, 
amongst others, in the rat model. Oat1a4 is orthologous to human OATP1A2, suggesting 
the potential of active uptake of the fluorescent probe (Annaert and Brouwer, 2005). CDF 
also appears to be a substrate of Oatp1 transporter system (Zamek-Gliszczynski et al., 
2003). However, the contribution of Oat transporters as a whole on fluorescent dye 
transport is negligible. The Michaelis-Menten constant (Km) for Oatp-mediated transport of 
R-123 is 0.3 µM, with a Vmax  of 6.8 µM (Annaert and Brouwer, 2005). For P-gp-mediated 
active transport, the Km is 17.5 µM and the Vmax is 20.4 µM (Forster et al., 2012). 
At higher concentrations, the uptake of R-123 is by passive diffusion. As an amphiphilic 
molecule, R-123 is able to traverse the lipid bilayer by rare inversions known as ‘flip flop’ 
events. R-123 excluded by P-gp is free to continuously re-enter the cell by a process in 
which the hydrophobic elements of the compound initially bind to the acidic head groups 
of the phospholipids. The efflux of R-123 by P-gp is mediated by pairs of the probe binding 
simultaneously to the protein (Wang et al., 2006). Although MRP1 has been suggested to 
have a role in R-123 transport (Daoud et al., 2000), expression of this efflux transporter is 
low on the Caco-2 cell line (Prime-Chapman et al., 2004), suggesting a negligible 
contribution of the transporter, and hence specificity of the probe to P-gp. Only mutated 
BCRP is capable or transporting R-123 whilst the wild-type BCRP cannot (Honjo et al., 
2001). A summary of the transport of these probes is presented in Figure 1.11. 
 
Figure 1.11. Schematic diagram of the uptake of the fluorescent probe substrates. The relative contribution of 
BCRP and MRP1 in the transport of R-123 is assumed negligible on the Caco-2 cell line. However, the influx 
transporter OATP cannot be excluded in the ingress of R-123 and CDF. 
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 Inhibitors of P-gp Efflux 1.8.2.
Verapamil (VER, Figure 1.12) is an L-type calcium channel blocker used in the treatment of 
hypertension. The ability of this drug to overcome MDR was first noticed in the 1980s 
(Tsuruo et al., 1981). However, this drug proved useless as an inhibitor in vivo due to the 
unacceptable levels of toxicity attributed to the high serum levels required to achieve efflux 
inhibition. From the potential usage in efflux assays, VER is one of the most commonly 
used inhibitors of P-gp in the literature (Burton et al., 1993). Used in conjunction with R-
123, VER is a powerful tool for assessing the P-gp functionality of a cell line. VER is a 
known substrate of P-gp, but is able to traverse the cell membrane rapidly with an 
apparent permeability (Papp) value of 12.6 x 10-6 cm s-1 (Pauli-Magnus et al., 2000), which is 
able to quickly saturate the transporter and render it ineffective at the transport of other 
compounds. VER has been shown to be a non-competitive inhibitor, suggesting that P-gp 
has separate binding sites for both R-123 and VER (Wang et al., 2006).  
 
Figure 1.12. The chemical structure of verapamil hydrochloride, the most widely utilised form of the drug. 
 
Ciclosporin (CsA, Figure 1.13) is an immunosuppressant drug commonly used to prevent 
allograft rejection after transplant. Much like VER, CsA has long been known as an 
inhibitor of MDR (Slater et al., 1986) yet failed to translate into the clinical setting due 
toxicity issues. CsA, like VER, interferes with substrate-recognition by second-site binding 
(Tamai and Safa, 1991), yet CsA is a better inhibitor of taxol and colchicine resistance, 
whereas VER is a superior inhibitor of vinblastine and daunorubicin transport, all P-gp 
substrates (Cardarelli et al., 1995), suggesting subtle but different affinities in binding site. 
The multi-faceted transport of P-gp gets even more convoluted by the fact both VER and 
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CsA are competitive inhibitors of each other, implying a common binding site, or sites 
(Naito and Tsuruo, 1989). 
 
Figure 1.13. The chemical structure of ciclosporin. 
 
 Inhibitors of MRP Efflux 1.8.3.
Indometacin (IND, Figure 1.14) is a member of the non-steroidal anti-inflammatory 
(NSAID) group of drugs. Although IND contains two carbonyl groups of the carboxylic 
and amine moieties which are polar and therefore capable of hydrogen bonding, the large 
nature of the molecule and the hydrophobic ring system makes IND practically insoluble 
in water. Under the BCS, indometacin is a class II compound, meaning that it has low 
solubility but high permeability (Löbenberg and Amidon, 2000).  
 
Figure 1.14. The chemical structure of indometacin. 
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In addition to being a model Class II compound, IND and probenecid (PBD), a uricosuric 
and renal tubular transport blocking agent (Figure 1.15), are known inhibitors of organic 
anion transporterss such as the MRP family of efflux proteins (Holló et al., 1996, Feller et 
al., 1995). Moreover, the degree of expression of the various MRPs has been discussed, and 
the relative efflux contribution of each is negligible when compared to the higher 
expression profiles of the MRP2 transporter on the Caco-2 cell line. 
 
Figure 1.15. The chemical structure of probenecid. 
 
 Paracetamol 1.8.4.
Paracetamol, also known as acetaminophen (APAP, Figure 1.16), is an analgesic typically 
used to treat pain and pyrexia. APAP is a poor choice as an efflux substrate as it is not a 
well-defined ABCB1 or ABCC2 substrate, and is able to rapidly cross the membrane with a 
Papp value of 23.7-100 x 10-6 cm s-1 (Yamashita et al., 2000, Irvine et al., 1999) on the Caco-2 
model. Additionally, APAP has roughly 80 % fraction absorbed in humans (Irvine et al., 
1999). However, owing to its low toxicity, APAP is commonly used in early phase tablet 
formulation development. 
 
Figure 1.16. The chemical structure of APAP. 
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 Ibuprofen 1.8.5.
Ibuprofen (Figure 1.17) is another member of the NSAID group of drugs. The uptake of 
ibuprofen is almost complete in humans, with the fraction absorbed around 95 % (Zhao et 
al., 2001). Furthermore, ibuprofen has a Papp value between 5.64-6.98 x 10-5 cm s-1, and is not 
described as a substrate for efflux (Faassen et al., 2003, Hellinger et al., 2010). However, the 
drug is known for its high degree of cohesion, resulting in poor flow properties as well as 
bad compaction (Rasenack and Müller, 2002), in addition to having a bitter taste (Gryczke 
et al., 2011). Therefore, ibuprofen is an excellent candidate as a model drug for coating 
trials. 
 
Figure 1.17. The chemical structure of ibuprofen.  
 
 Orally Disintegrating Tablets 1.9.
 Overview 1.9.1.
The Noyes-Whitney equation describes how surface area, amongst other factors, can be 
optimised to increase the rate of drug dissolution, and therefore absorption. One strategy 
to rapidly increase surface area, and thereby accelerate dissolution and enhance drug 
uptake, is to formulate an orally disintegrating tablet (ODT) (Shangraw et al., 1980). As 
ODTs require no water for administration, they are easy to administer and are ideal dosage 
formulations for medical conditions where severe nausea and vomiting is common, such as 
migraines, where an ordinary dosage formulation may be partially or completely expelled. 
Additionally, faced with the extreme cost and length of time taken to take a new chemical 
entity (NCE) to the market, many companies have considered new methods of 
administration of old drugs, which can combine recent advances in excipient or 
manufacturing technologies, coupled with extension of patent life. 
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One major application of the ODT is for patients with difficulty swallowing. Dysphagia is a 
common condition prevalent in around 35 % of the population in general and an additional 
40 % of geriatric patients, and often, tablet size and taste play a role in tablet acceptance 
(Sastry et al., 2000). Recent progress has been made on ODTs which have the ability to 
disintegrate within the oral cavity, without access to water. Such formulations have even 
been shown to increase bioavailability of the drug by increasing the rate of dissolution on 
human trials (Ahmed and Hassan, 2007).  
 Formulation Strategies for Making ODTs 1.9.2.
Three general techniques exist for the production of ODTs currently on the market (Table 
1.1). These are: 
 Freeze Drying 
 Moulding 
 Direct Compression 
 
Table 1.1. Overview of commonly used production techniques, marketed formulations and associated advantages 
and disadvantages. 
Production Technique Marketed Example Advantages Disadvantages 
Freeze-drying Imodium® Instants - 
2mg Loperamide 
hydrochloride 
Immediate 
Dissolution 
Incompatible with 
water soluble drugs  
Poor hardness 
    
Moulding Ralivia FlashDose® - 
50 mg Tramadol 
Fast Dissolution High production costs  
Low strength 
    
Direct Compression Nurofen® Meltlets - 
200 mg ibuprofen 
Standard Equipment 
Low production cost 
Disintegration and 
porosity reliant upon 
excipient choice 
 
 
 Freeze drying 1.9.2.1.
Freeze-drying, known also as lyophilisation, is one of the most common techniques. In this 
method, the formulation is frozen below -18 oC, and decreased pressure removes the 
solvent from a frozen solution containing infrastructure-forming excipients (Nail and 
Gatlin, 1993). The resulting dosage forms are highly porous with a large surface area, 
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allowing rapid dissolution and disintegration. This technique is particularly useful for 
heat-sensitive APIs. Zydis® was the first of the freeze-dried ODTs, and the system favours 
drugs with low water solubility or complete insolubility as they are reluctant to form 
eutectic mixtures during the freezing process (Seager, 1998). Although disintegration times 
are regarded as excellent, freeze-dried ODTs are often fragile, requiring specialised 
packaging that adds to the manufacturing costs (Chang et al., 2000). However, the bulking 
agent can reach a glassy state, which can also be imparted on to the API to form 
amorphous drug. 
 Moulding 1.9.2.2.
Moulded ODTs can be prepared in two ways. Compression moulding as the name 
suggests, involves compressing a powder mixture that has been softened with a solvent 
(typically water or ethanol). The second variation on this technique involves dissolving the 
drug in a molten matrix, known as heat moulding. The outcome of both techniques is a 
solid dispersion. The drug in these dosage formulations can remain in discrete particles or 
microparticles. If the drug is completely dissolved in the matrix, it is known as a solid 
solution, although it can also exist partially dissolved in the carrier. As these tablets are 
much less compact compared to compressed tablets, they have favourable porosity 
characteristics. Conversely, moulded tablets suffer from poor mechanical strength, 
although this can be addressed by adding binders such as sucrose, acacia or 
polyvinylpyrrolidone to the solvent phase (Chang et al., 2000).  
 Compression 1.9.2.3.
Whilst freeze-drying and moulding are effective in porosity forming, fast disintegrating 
tablets, the technology remains expensive and time consuming, requiring special 
equipment. Tablets made by freeze drying often exhibit poor mechanical strength. 
Therefore, direct compression is the most commonly used manufacture method for ODTs 
as it utilises existing techniques and excipients with a low number of processing steps, 
whilst allowing high API doses to be incorporated. For directly compressed tablets, 
disintegration is largely based on the choice of disintegrant(s). 
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 Role of Disintegrants in Directly Compressed ODT Systems 1.9.3.
The role of disintegrant excipients is to break the tablet upon contact with water. The 
ingress of water is essential for overcoming the binding properties of the tablet. This is 
typically achieved by wicking or swelling (Kornblum and Stoopak, 1973). Disintegrants are 
generally water-insoluble components, and ideally swelling does not lead to gel formation 
that may impede the access of water to the tablet.  
Several main disintegrants and the veritable ‘superdisintegrants’ exist on the market (Table 
1.2). Crospovidone (cross-linked polyvinylpyrrolidone), is commonly known by the 
marketed name Kollidon, produced by BASF, and come in a range of particle sizes. 
Polyplasdones are also crospovidones produced by ISP. Ac-Di-Sol is composed of cross-
linked carboxymethylcellulose, and Primojel is composed of cross-linked 
carboxymethylation (Quadir and Kolter, 2006). 
 
Table 1.2. Overview of commonly used disintegrants and their particle size. 
Disintegrant Brand Particle Size (μm) 
Crospovidone 
Kollidon CL 110-130 
Kollidon CL-F 20-40 
Kollidon CL-SF 10-30 
Kollidon CL-M 3-10 
Polyplasdone XL 100-130 
Polyplasdone XL-10 30-50 
Croscarmellose sodium Ac-Di-Sol 49 
Sodium Starch Glycolate Primojel 41 
 
For direct compression, the choice of disintegrant depends upon the formulation and 
preparation techniques. Crospovidone has been used at 2.5-8 % (w/w) (Okuda et al., 2012), 
5 % (w/w) (Mishra et al., 2006) and 7 % (w/w) (Shu et al., 2002). In one study, it was found 
that increasing the level of crospovidone from 4 to 12 % (w/w) had no impact upon 
disintegration time (p > 0.05), although wetting time increased significantly (p < 0.05) with 
increased levels (Okuda et al., 2012). At 3 % (w/w), crospovidone of various grades 
(Kollidon CL, CL SF, CL M and CL F) were found to be superior to croscarmellose sodium 
and microcrystalline cellulose, with disintegration times under 30 seconds in comparable 
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formulations (Amelian and Winnicka, 2012). More recently, crospovidone has been 
optimised at 4 % to produce satisfactory tablets for a disintegration time of 33 seconds for 
directly compressed tablets of montelukast sodium (Usmani et al., 2015). However, in 
another study, croscarmellose sodium was found to be superior to crospovidone as well as 
sodium starch glycolate (Amrutkar et al., 2007), highlighting the importance of disintegrant 
selection in formulation evaluation. 
Microcrystalline cellulose (MCC) is semi-depolymerised cellulose commonly used as an 
excipient under the brand names Emcocel, Vivacel, and more commonly Avicel. MCC is 
the most common of the cellulose-based excipients, and exhibits good binding properties 
owing to its plastic deformation under pressure that occur through hydrogen bonding to 
adjacent MCC particles (Al-Khattawi and Mohammed, 2013). Using direct compression, 
MCC and low-substituted hydroxypropyl cellulose (L-HPC) used as disintegrants have 
shown quick disintegration time in the ratio 8:2-9:1 (Watanabe et al., 1995). This study 
demonstrated the feasibility of using MCC for ODTs, and remains one of the earliest 
examples in literature. Tablets containing Avicel PH-101 grade have been shown to exhibit 
superior hardness although with slower disintegration time compared to Avicel PH-102 
when made under direct compression (Lahdenpää et al., 1997). As such, PH-102 grade is 
generally favoured due to flow properties. Tablets produced using this grade of MCC have 
been shown to be sensitive to magnesium stearate content up to 1 %, although not 
significantly. Disintegration time was unaffected by the presence of the lubricant (Mitrevej 
et al., 1996). In orally disintegrating tablets, MCC has been shown to have a gritty mouth 
feel, and this can be eliminated using fine particle size PH-M (Ishikawa et al., 2001). Further 
micronisation of MCC is possible; PH-M-06, with a lower particle size of 7 µm, was found 
to be superior to PH-102 in terms of mouth feel.  
 Taste Masking 1.9.4.
Taste masking is also an important factor in ODT development. In one study, 90 % of 
paediatricians have reported that taste was a major barrier in patient compliance (Milne 
and Bruss, 2008). As ODTs rapidly disintegrate, they deliver the active substance directly to 
the tongue and, therefore, the taste buds, making taste masking an important issue for the 
formulation. Several techniques have been employed for taste masking purposes, including 
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but not limited to complexation (Dinge and Nagarsenker, 2008), hot melt extrusion 
(Gryczke et al., 2011), microencapsulation and traditional sweeteners. Of the latter, sugar-
based materials are highly favoured as they are highly soluble in water, so dissolve quickly 
in saliva. Mannitol is one of the most common of the sugars used in this process and is 
known for its pleasant taste and cool mouth feel. Similarly, aspartame and citric acid are 
commonly used, as are other recognised flavours such as lemon and strawberry. Those 
extreme tastes that cannot be covered using sweeteners require encapsulation to ensure the 
drug does not undergo dissolution in proximity to the tongue. However, the choice of taste 
masking is important as not to interfere with the existing tablet dynamics, such as 
disintegration time, and the amount of additional taste-masking materials must be kept 
low to prevent excess gains in tablet weight and size. 
 Assessment of ODT Physical Characteristics 1.9.5.
The time taken for a tablet to disintegrate underlies the ODT formulation process. The 
disintegration test is designed to mimic the conditions of the mouth, and the FDA 
recommends a disintegration time of 30 seconds or less based on the USP disintegration 
test (McLaughlin et al., 2009). Using USP 30 apparatus (Figure 1.18) the tablet is placed in 
the disintegration tube within the basket assembly and the time for the tablet to pass 
through the mesh is recorded whilst the basket is raised and lowered. The disintegration 
medium is held at 37 ± 2 oC. 
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Figure 1.18. Overview of the disintegration equipment. Tablets are added to the cylinder whilst the basket 
assembly is in motion in warmed disintegration media. The time taken for the tablet to pass through the mesh is 
then recorded as the disintegration time. Disks, as required, are placed on top of the tablet to aid disintegration but 
may interfere with tablets that are gel-forming in nature (USP, 2012b).  
 
Hardness is an important characteristic for production, post-production processing such as 
coating, and maintaining a consistent dissolution profile. Typically hardness is conducted 
by crushing the tablet diametrically between two metal plungers on equipment which has 
been routinely calibrated (USP, 2012c). If the tablet is too hard, it may not undergo desired 
disintegration or drug dissolution; conversely a tablet too low in hardness will not survive 
processing. However, no restrictions are placed on hardness acceptably that must be 
established during the tablet formulating stage. 
Friability is a measure of tablet strength and indicates how a tablet may behave during 
processes and transport post-manufacture. The USP standard test is 100 revolutions in a 
friabilator at 25 RPM (Figure 1.19).  
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Figure 1.19. Overview of Friability Equipment. Tablets are weighed, added to the equipment and rotated at 25 rpm 
for 4 minutes. The tablets are then removed, brushed clean and then reweighed. Percentage friability is then 
calculated (USP, 2013). 
 
Tablets are weighed before and after the procedure and the friability, expressed as a 
percentage, is calculated based on Equation 1.4, 
 
Equation 1.4 
 
where F is the percentage friability, w0 is the collective weight of the tablets before testing 
and w is the weight of the collective tablets after testing. For ODTs, friability regulations 
follow the 1 % recommended for all non-coated tablets produced via direct compression 
(USP, 2013). 
𝑭 = 𝟏𝟎𝟎. (
𝟏 − 𝒘
𝒘𝟎
) 
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 Thesis Aim and Objectives 1.10.
Due to the role in limiting the ingress of compounds through epithelial barriers, the 
collective efflux transporter system is of interest from the pharmacodynamic and 
pharmacokinetic perspectives in anticipating the behaviour of a drug in vivo. The 
interaction of commonly used excipients with intestinal efflux transporters has come under 
increasing attention, as formulation scientists seek innovative ways to improve the 
absorption of pharmaceutical compounds displaying low bioavailability. Whilst literature 
is already enriched with keynote examples of materials that have a biological effect, few are 
quantified or appropriately modelled, allowing scope for augmentation of existing 
knowledge whilst exploring the vast quantities of materials still awaiting evaluation. 
Combining the information provided by Noyes-Whitney (Equation 1.1), whereby an 
increase in surface area (e.g. rapid disintegration times) can increase the rate of dissolution, 
and the bioavailability formula (Equation 1.2) showing how an increase in any fraction 
propagates through the equation to result in an increase in overall bioavailability, indicates 
how a superior oral dosage formulation can be produced. 
The review of the existing literature reveals an extensive yet disparate list of excipients that 
elicit an effect against the ABC efflux transporters, chiefly P-gp. Such information is rarely 
quantified in the kinetic terms that could be of use to a formulation scientist wishing to 
increase the bioavailability of drugs that fall victim to efflux.  
As such, the central aim of this thesis is to develop and validate a high-throughput 
screening assay to detect and quantify the effects of commonly used excipients against the 
ABCB1 and ABCC2 efflux transporter systems, and to utilise this knowledge to design and 
manufacture an oral dosage platform with the capability to achieve enhanced delivery of 
drugs with poor bioavailability. In order to achieve this, a number of objectives must be 
met. 
 The first is the development and validation an in vitro high-throughput screening 
assay using the Caco-2 model for the detection of commonly used excipients with a 
biological effect against ABCB1 and ABCC2. The development of such an assay 
requires careful consideration of the types of model drugs and probes. The 
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specificity and kinetics of the probes needs to be carefully considered, in addition to 
their routes of ingress through the model. 
 
 The second objective is the additional development of modelling techniques, which 
can quantify this data in such a way to predict the quantity of material needed in 
order to elicit such a desired effect, whilst establishing a framework from which the 
data can be compared to known inhibitors of the efflux transporters. This objective 
requires the careful consideration of commonly used inhibitors of the respective 
efflux transporters. 
 
 The third and final objective is the design and manufacture of an ODT delivery 
system incorporating the theoretical content of biologically active material in order 
to elicit the appropriate biological effect in vivo. Once more, the challenges in 
developing an ODT must first be understood if this objective is to be achieved. 
Pollard J 
77 
 
 
 
 
Chapter 2 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
78 
 
 2. Materials and Methods 
 Materials 2.1.
Caco-2 cells were purchased from Public Health England and used at passage numbers 49-
55. L-Glutamine, Foetal Calf Serum (FBS), Hank’s Balanced Salt Solution (HBSS), Penicillin-
Streptomycin, Dulbecco’s modified Eagle’s medium (DMEM), and non-essential amino 
acids (NEAA) were purchased from BioSera (East Sussex, UK). 0.5 % trypsin-EDTA, 
indometacin (IND), Lucifer yellow (LY), rhodamine 123 (R-123), 5(6)-carboxy-2’,7’-
dichlorofluorescein diacetate (CDFDA), MTT, Pluronic® F127 (poloxamer 407), Tween® 80, 
Tween® 20, PEG 400, PEG 4000, PEG 8000, PEG 12000 and PEG 20000 were purchased from 
Sigma Aldrich (Dorset, UK). Capmul® MCM, Capmul® MCM C8-2, Capmul® PG-12, 
Capmul® PG-8, Acconon® C-44 and Acconon® MC-8 were a kind gift from ABITECH 
Corporation (Columbus, USA). Poloxamer 182, Span 20, Arlatone TV, Crovol A-70, Etocas 
29, Brij S-10, poloxamer 184, Etocas 40, Brij CS-12, Acconon C-44, NatraGem S140, Acconon 
MC8-2, Cetomacrogol 1000, Myrj S-40, poloxamer 335, Myrj S-100 and poloxamer 188 were 
kind gifts from Croda (Goole, UK). Crospovidone Kollidon® CL, CL-F, CL-SF and CL-M 
were a kind gift from BASF (Ludwigshafen, Germany). Microcrystalline cellulose (MCC) 
Avicel® PH-102 was purchased from FMC (Cork, Ireland). Mannogem® 2080 mannitol was 
a kind gift from SPI Pharma (Lewes, USA). Granular acetaminophen (APAP) Compap™ 
PVP3 was obtained from Mallinckrodt Pharmaceuticals (Dublin, Ireland). Poloxamer 407 
and ETHOCELTM Ethylcellulose 7 FP were obtained from DOW (Midland, USA). 
Compritol® 888 ATO was a kind gift from Gattefossé (Saint-Priest, France). Kollicoat IR was 
obtained from BASF (Alabama, USA). POLYOXTM N-10, Starch 1500® and StarCap 1500® 
were obtained from Colorcon (Harleysville, USA). In order to compare the tablets to 
existing marketed formulations, Nurofen® Meltlets (Reckitt Benckiser), Calpol® SixPlus Fast 
Melts (NcNeil Products Ltd) and Imodium® Instants (McNeil Products Ltd) were 
purchased over the counter. 
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  In Vitro Methods for the Detection of Efflux Inhibition 2.2.
 Initial Screening Protocol: The In Vitro Caco-2 Transwell® Model 2.2.1.
The Caco-2 model is well known for being the ‘gold standard’ workhorse of cell based in 
vitro drug transport. With this in mind, the project started with the development of a 
protocol for using the Transwell® model. This model takes 21 days for full differentiation, 
and is both time and resource heavy. In addition, there are multiple routes by which a 
molecule can pass through the monolayer, and consequently the model has to be carefully 
validated and cellular damage excluded from data.  
 Stock Solutions 2.2.1.1.
As IND concentrations as high as 500 μM has previously been shown to lead to consistent 
and reproducible damage to Caco-2 monolayer integrity (Tang et al., 1993), the drug 
concentration for all studies was kept at or below 100 μM. Drug stock solution was 
prepared overnight in HBSS the absence of solvents prior to experimentation and filtered. 
The excipient solutions were made up fresh before use. 
 General Cell Protocol 2.2.1.2.
Due to the non-proliferative nature of small intestinal epithelial cells, the most widely 
accepted in vitro model remains cell lines of colonic origin. From these, polarised and 
differentiated adenocarcinoma (Caco-2) cells are highly regarded as the in vitro ‘gold 
standard’ as a model for the small intestine, expressing microvilli and enzymatic 
components resembling those of the intestinal epithelium (Wilson et al., 1990). Caco-2 cells 
from frozen stock were grown in 75 cm2 (T75) vented flasks at 37 °C in 5 % CO2 with 90 % 
relative humidity in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 
% foetal bovine serum (FBS), 1 % non-essential amino acids (NEAA), 2 mM L-glutamine 
and 1 % penicillin-streptomycin (pen-strep). Media was renewed every 48 hours. 
 Transwell® Protocol for Differentiated Caco-2 Monolayers 2.2.1.3.
The cells were harvested after reaching 80 – 90 % confluency within the T75 flasks, the 
optimal level for enhanced P-gp expression in long term cultures (Anderle et al., 1998) 
using trypsin-EDTA (3 mL, 0.5 % trypsin w/v). The basolateral compartment of each insert 
was filled with 2.5 mL of media and allowed to equilibrate in the incubator whilst the cells 
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were being split. These cells were then seeded onto the apical fascia of six well Transwell® 
inserts (0.4 μm pore size, 24 mm diameter), to a density of 2 x 105 cells per well. Cell media 
was replaced every 48 hours (1.5 mL apical, 2.5 mL basolateral). 
 Indometacin Permeability through Caco-2 Monolayers 2.2.1.4.
In order to study the transport of IND as a probe substrate, its transport in vitro must be 
carefully examined. After 21-25 days post-seeding, confluence was confirmed by ensuring 
the transepithelial electrical resistance (TEER) values exceeded 400 Ω.cm2 (in practice, all 
monolayers initially exceeded 500 Ω.cm2) adjusted for membrane resistance, using a 
Millicell® ERS device (Millipore, MA, USA) before and after each study, previously 
demonstrated to correlate with the formation of established tight junctions, established in 
fresh DMEM (pH 7.4 at 37 °C). To exclude the influence of a pH gradient on the passive 
transport of IND (pH hypothesis) all apical and basolateral solutions were buffered using 
25 mM HEPES (pH 7.4 at 37 ºC).  
 Apical to Basolateral Concentration-Dependent Transport of Indometacin 2.2.1.5.
As a transport protein, P-gp is governed by Michaelis-Menten kinetics. The key parameters 
to determining the substrate concentration are the Vmax, the maximum output of the system, 
and Michaelis-Menten constant (Km), the substrate concentration required to achieve the 
rate of half of Vmax. In order to obtain excellent detectability, the IND concentration must be 
sufficiently high, yet not as high as to saturate the transporter. Above the Km, any efflux 
inhibition will be more difficult to detect as transporter is effectively fully inhibited and the 
drug is able to pass through the monolayer without ATP-driven repulsion back to the 
apical compartment of the Transwell®. At higher concentrations still, toxicity imparted by 
the drug may occur. As such, the movement of drug from the apical to basolateral (AP-BL) 
chambers was examined over a drug concentration range from 10 – 100 μM. Cells were 
twice washed in HBSS to remove FCS and incubated for 30 minutes in fresh HBSS. The 
Transwell® inserts were than randomised to new clusters in fresh 6-well plates and DMEM-
HEPES was added to the basolateral receiver compartment (2.5 mL). The medium 
containing the drug was added to the apical side (1.52 mL) to initiate the experiment, and 
the initial apical concentration was determined by sampling 200 μL from the apical well, 
functionally analogous to the intestinal lumen. The cells were then incubated at 37 °C on an 
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orbital shaker with 100 RPM rotation to ensure agitation of the cell-drug boundary layer. 
Sample aliquots (200 μL) were taken at set time intervals from the basolateral 
compartments, to be replaced by an equal volume of pre-warmed drug-free DMEM-
HEPES.  
 Basolateral to Apical Transport of Indometacin  2.2.1.6.
The ratio of the Papp values in the basolateral to apical (BL-AP) and apical to basolateral 
(AP-BL) gives an indication as to the degree of efflux a drug is subjected to. This is known 
as the efflux ratio. For BL-AP concentration-dependent uptake studies, various 
concentrations of drug-containing DMEM-HEPES (10-100 μM) were added to the 
basolateral compartment. The experiments were initiated by adding fresh DMEM-HEPES 
to the apical compartment. This was sampled at discrete time points and replaced using 
fresh DMEM-HEPES.  
 Permeability of Indometacin in the Presence of the PEGylated Excipients PEG 2.2.1.7.
400, PEG 8000, POLYOXTM N-10 and Poloxamer 407 
As P-gp resides on the apical compartment of intestinal cells, any excipients that inhibit 
this efflux transporter will increase the permeability in the apical to basolateral (AP-BL) 
direction of transport. The AP-BL permeability of IND in the presence of various 
concentrations of the respective excipients, representing intestinal lumen to blood capillary 
transport in the presence of clinically-significant concentrations of excipients, were 
conducted as described by adding the respective amount of polymer within the drug-
containing DMEM-HEPES to the apical well and sampling the basolateral at the same 
discrete time points. Results were tested in triplicate. As the influence of P-gp is restricted 
to the apical membrane of the Caco-2 cells, the effects of excipients which are efflux 
inhibitors should not increase IND permeability in the basolateral to apical (BL-AP) 
direction of transport. To test this, the transport studies were conducted in the BL-AP 
direction by adding the same concentrations of the drug and polymer to the basolateral 
compartment as described, and monitoring drug ingress at the apical compartment. 
 Lucifer Yellow Transport for the Monitoring of Monolayer Integrity 2.2.1.8.
As indometacin is being examined as an efflux substrate, any increase in permeability must 
exclude the possibility of transporter system bypass by simple modification of the 
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paracellular route or loss of membrane integrity. Whilst this mechanism may provide a 
way for a molecule to escape efflux and so increase its permeability, the focus of the 
investigation is to examine materials which are able to modulate these transporters 
directly. As such, the AP-BL flux of Lucifer yellow (LY), a small compound that undergoes 
paracellular transport but which is not a P-gp substrate, was tested in the AP-BL direction 
by replacing IND with 100 μM of the compound in the presence of the highest 
concentration (1.19 mg mL-1) of either PEG 8000 or POLYOX N-10. Preliminary 
spectrophotometer results indicated that LY and DMEM, specifically the pH indicator 
phenol red of DMEM, exhibited the same absorbance bands. As such, the serum-free media 
was exchanged with HBSS. Transwell® inserts were washed in warm buffer and the test 
solutions added. The cells were then placed in the incubator for 60 minutes with shaking at 
100 RPM. During this time, a calibration curve was established using LY in HBSS by 
pipetting 200 μL of test solution in triplicate to a black 96-well plate. Fluorescence was 
measured using a Unicam Heλios 96-well plate reader (excitation λ 428 nm, emission λ 540 
nm). After 60 minutes, 200 μL of HBSS was taken from the receiver compartment of the 
Transwell® and pipetted on to a clean black 96-well plate for reading. 
 High Performance Liquid Chromatography (HPLC) Analysis of Indometacin 2.2.1.9.
Samples were analysed by HPLC, obtained using a Shimadzu LC2010AHT HPLC system 
with autosampler (Shimadzu Corporation, Kyoto, Japan). Separation was performed using 
Phenomenex Gemini C18 (150 X 4.6 mm, 5 μm) analytical column maintained at 19 ˚ C, 
with detection at 264 nm. Elution was conducted using an isocratic method with a binary 
phase consisting of acetonitrile and double distilled water with 0.2 % TFA (50:50, v/v), with 
a flow rate of 1.2 mL min-1. The apparent permeability coefficient (Papp) was then calculated 
using Equation 1.3. 
 High-throughput Protocol for the Detection of Materials with a Biological Effect: 2.3.
Development and Validation 
The slow turnover rate of data from the Transwell® model prompted an overhaul in the 
approach to in vitro screening. Indometacin requires time-consuming analytical processing 
on the HPLC to produce data. Additionally, the high amount of time and resources taken 
to produce a single 6-well Transwell® is out of all proportion to the data which it is able to 
Pollard J 
83 
 
yield. As such, attention was turned to the development of a high-throughput (HTS) 
screening protocol. Keeping the Caco-2 platform, the format was redesigned to maximise 
throughput by the addition of high-affinity fluorescent probes, which can be analysed and 
quantified in seconds. Growth time was also scrutinised in order to yield the maximum 
amount of data possible with the shortest amount of time and resources. In principle, this 
technique follows the ingress of fluorescent components into the cells. Once inside, the rise 
in fluorescent signal of inhibited cells is consistent with efflux inhibition (Figure 2.1).  
 
 
 
Figure 2.1. Graphical representation of the fluorescent HTS screening model. Once the probe has achieved ingress 
into the cell, the only way for it to escape is by efflux. With increased concentrations of inhibitor, this is no longer 
possible and the cells most inhibited retain the highest concentration of dye. This is subsequently detected by a rise 
in fluorescent signal. 
 
During the early phase of development of this assay, it became apparent that the volume of 
literature concerning the effects of excipients against MRP2 was vastly under studied. The 
scale of this disparity is highlighted in Figure 2.2. Several reasons are possible for this 
knowledge gap; the MRP transporters have been more recently implicated in MDR than 
the veritable P-gp, and the role of effluxing medicinal compound in the intestine is also 
subordinate to that of P-gp in terms of substrate diversity. Furthermore, suitable 
fluorescent probes took time to develop which could be used in HTS. In order to address 
this, a specific probe of this transporter was incorporated into the HTS assay, 5(6)-carboxy-
2’,7’-dichlorofluorescein diacetate (CDFDA), which gets converted to 5(6)-carboxy-2’,7’-
dichlorofluorescein (CDF) within the cells (Figure 2.3). With this novel probe, the intention 
was to complement the existing literature using a novel HTS platform validated for the 
detection of inhibitors against P-gp and MRP2. 
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Figure 2.2. The volume of literature concerning the biological effects of commonly used excipients against P-gp 
and MRP2, using the keyword search ‘excipient P-gp’ or ‘excipient MRP2’. 
 
 
Figure 2.3. Graphical representation of the conversion of CDFDA to CDF. CDFDA solution is colourless, but 
gets converted to a cascade of fluorescent compounds by the action of intracellular esterases, chiefly CDF. 
 
 Stock Solutions 2.3.1.
Stock solutions of excipients were made in fresh Krebs-Henseleit (KH) buffer (118 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.25 mM CaCl2, 1.2 mM KH2PO4, 25 mM NaHCO3, 11 
mM glucose) to a final concentration of 10 % (w/v). Fluorescent probes were made to 20 
µM in DMSO and stored at -80 oC until use. Experimental usage of DMSO never exceeded 
0.0125 % (v/v), which was not considered to have a significant impact on the study. 
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 General Cell Protocol 2.3.2.
Caco-2 cells obtained from Public Health England were grown from a 25 cm2 (T25) vented 
flasks at 37 °C in 5 % CO2 with 90 % relative humidity in DMEM supplemented with 20 % 
foetal bovine serum (FBS) for seeding media or 10 % FBS for growth media, 1 % non-
essential amino acids (NEAA) and 2 mM L-glutamine and in the absence of antibiotics. 
Media was renewed every 48 hours, and experiments were always conducted within 24 
hours of feeding. 
 Fluorescence Microscopy 2.3.3.
Cells were seeded in 6 well plates to a density of 4 x 104 cells per well and grown for 7 days, 
with media changed every 48 hours. On the day of the study, cells were washed in HBSS 
and incubated for 1 hour using 10 or 100 μM verapamil (VER). R-123 was then added to a 
final concentration of 10 µM and incubated for 60 minutes prior to imaging (Leica DMI 
4000B) using the excitation wavelength 485 nm and emission at 585 nm. 
 Cytotoxicity Measurements using the MTT Assay 2.3.4.
To determine a non-toxic concentration range to use for testing of the excipients, 
mitochondrial activity was measured by the reduction of MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5- diphenyltetrazolium bromide; thiazolyl blue) to the insoluble product formazan. 
Culture media of confluent 96 well plates was exchanged for 200 µL test solution 
containing increasing concentrations of the excipient or drug solutions and incubated for 4 
hours in order to encompass an incubation period longer than operational exposure time of 
the cells during assay conditions. The wells were then emptied and refilled using 100 µL of 
0.5 mg mL-1 MTT and incubated for 3 hours. The formazan was then dissolved using 100 
µL of 0.1 N HCl in isopropanol and absorbance then read at 570 nm. Non-treated control 
wells were set to 100 % viability. 
 Cellular Accumulation of Tracer Dyes 2.3.5.
At 90 % confluence, cells were split from a T75 and centrifuged for 5 minutes at 1440 RPM 
for 5 minutes. Cells were re-suspended in warm media and redistributed to a density of 4 x 
104 cells per well in clear 96 well plates and grown for up to 7 days. Confluence was 
confirmed using light microscopy. Monolayers were washed twice using KH (pH 7.4) and 
left to equilibrate for up to 30 minutes. The wells were then refilled using 200 µL KH buffer 
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containing the excipient of study over a logarithmic concentration range. Following 30 
minutes pre-incubation with the selected excipient or inhibitor, the wells were emptied and 
refilled with the same concentrations of excipient or inhibitors which had been well mixed 
with 2.5 μM of either R-123 or CDFDA. This step was necessary in order to negate the 
influence of excipient viscosity acting to prevent dye ingress. Following 2 hours incubation 
with the transporter probes, the cells were washed 3 times using ice-cold water and snap-
frozen at – 80 oC for 5 minutes or overnight. Cells were then lysed in double distilled water 
under refrigeration and the lysate was transferred to black 96-well plates for fluorescence 
reading (ex 485, em 535). In order to assess the degree of membrane damage imparted by 
the excipients, the 7-day old monolayers grown in 96-well plates were incubated with 
excipient for 2 hours at 37 oC as previously described. The cells were then washed and 
cooled to 4 oC in order to arrest all ATP-driven processes (e.g. efflux) after which the cells 
were exposed to 100 nM R-123 for 30 minutes. Cells were then washed and lysed as 
previously described. 
 Calculation of Kinetic Parameters 2.3.6.
In order to quantify the biological effects of excipients, half of the maximal inhibitory 
concentration (IC50) values, the concentration of the tested compound which is able to 
reduce transporter activity by 50 %, were calculated using non-linear regression of 
GraphPad Prism Software (Version 6.0) to 95 % confidence. Data was normalised against 
control (non-treated cells), which were set to 100 % efflux activity. These IC50 values were 
then used for direct comparison to known inhibitors of efflux transporters. 
  The Design, Manufacture and Production of ODTs Incorporating Biologically-2.4.
Active Excipients 
Having developed and validated a HTS assay for the detection of excipients that could 
modulate efflux-mediated transport, the confluence of the in vitro screening was the design 
and manufacture of an ODT tablet that takes advantage of this knowledge in order to 
achieve enhanced drug delivery capability. The following work was completed as part of a 
6-month placement at the Colorcon facility in Dartford, UK. Here, two alternative ODT 
platforms were created, a ‘low-dose’ 295 mg tablet and a ‘high-dose’ 795 mg dosage form. 
The model drug at this stage was intended to be atorvastatin, which is a substrate of both 
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P-gp and MRP2, and has limited bioavailability. This drug comes in a 10 mg, 20 mg, 40 mg 
and 80 mg tablet strength. However, owing to the safety considerations of using this drug 
in an industrial pharmaceutical laboratory, paracetamol (acetaminophen, APAP) was 
chosen as an early stage formulation alternative API to be converted to atorvastatin at the 
late stage of development. The high-dose ODT was developed as a stand-alone dosage 
formulation with the sole purpose of loading APAP. 
 Design of Experiments 2.4.1.
A Design of Experiments (DoE) approach was used to evaluate the impact of various 
multi-purpose excipients on the physical characteristics of the tablets using JMP 12 
software. This initially examined the impact of various Starch 1500, mannitol and MCC 
content on tablet hardness, disintegration times, tablet friability, tablet thickness, tablet 
width, and tablet weight. However, only the hardness and disintegration times were 
affected by the filler composition. Later, StarCap 1500 was examined in lieu of Starch 1500.  
 Tablet Fabrication – Single Press 2.4.2.
Materials were combined and mechanically mixed in a tumbler for 5 minutes in the 
absence of the lubricant. Batch size for single compression was 40 g. The lubricant glyceryl 
behenate (Compritol® 888 ATO) was then added and the mixture shaken for a further 
minute. Tablets were made by direct compression by adding the 295 mg of low-dose mixed 
to a 10 mm die using normal convex geometry or 795 mg of high-dose powder to a 13 mm 
die with flat faced tooling. Compression was achieved at 1 MT using an Atlas Auto T8 with 
no dwell time.  
 Tablet Fabrication – Rotary Press 2.4.3.
Materials were combined and mechanically mixed for 15 minutes in the absence of the 
lubricant using Pharmatech Omogenizator rotary mixer at 22 RPM. Batch size for rotary 
compression was 1 kg. Compritol® 888 ATO was then added and the mixture shaken for a 
further 5 minutes. Tablets were made by direct compression by adding the 295 mg of low-
dose mixed to a 10 mm die using convex geometry. Compression was conducted at 0.6, 1.2, 
1.8 and 2.3 MT using a 10-station rotary press (Picolla, Riva) with a turret rotation at 25 
RPM. However, only 5 of the 10 die positions in the turret were fitted, the remaining left 
blank. 
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 Physical Characterisation 2.4.4.
 Hardness 2.4.4.1.
Hardness is an industrial consideration for the production of the tablet, subsequent 
processing, transport, and in maintaining a consistent dissolution profile. If the tablet is too 
hard, it may not undergo desired disintegration or drug dissolution; conversely a tablet too 
low in hardness will not survive processing. Hardness was tested using the 4M hardness 
testing equipment (Thun, Switzerland) using 10 randomly selected tablets, with data 
displayed as the mean ± SD. 
 Disintegration Times 2.4.4.2.
Disintegration time is of central importance to the development phase of an ODT, and is 
regulated to 180 s according to the European Pharmacopeia (European Pharmacopeia, 2009) 
and 30 seconds according to the United States Pharmacopeia (McLaughlin et al., 2009). It is 
described as the time for a tablet to completely pass through a mesh with an aperture size 
of 0.60-0.655 mm. Disintegration was conducted at 37 °C using Erweka TT3 dissolution 
testing equipment in 900 mL distilled water (Frankfurt, Germany) according to the 
guidelines outlined in the USP (USP, 2012b). During initial disintegration testing, tablets 
were observed to stick to the plastic disc inserts covering each tube. Consequently discs 
were excluded. Data are reported as the mean disintegration times of 6 tablets ± SD. 
 Friability 2.4.4.3.
Similar to hardness, friability is another consideration that will predict the likely survival 
of tablet integrity following manufacture. Friability was conducted according to the USP 
(USP, 2013). Ten pre-weighed tablets were rotated at 25 RPM for 4 minutes using F2 
rotation equipment (Sotax, Basel, Switzerland). Tablets were then dusted off and 
reweighed and the percentage loss of weight was calculated. Extended friability testing 
was then conducted using an additional 400 rotations, followed by dusting and re-
weighing. In both cases, data is reported as the percentage loss of mass. 
 Physical Parameters 2.4.4.4.
Monitoring changes in the tablet composition during manufacture ensures consistency 
within the batch and that it conforms to USP regulations on weight variation. Tablet 
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thickness and width were both tested on digital callipers, and weight was determined by 
weighing dusted tablets immediately after compression. Data is reported as the mean of 10 
tablets ± SD. 
 Investigation into the Incorporation of Biologically-Active Surfactants into Granule 2.5.
Coatings for the use in Directly Compressed ODTs 
 Preparation of Ibuprofen Granules via Wet Granulation 2.5.1.
Ibuprofen granule formulations were produced according to Table 2.1 to a 120 g batch size. 
This was then mixed with 25 mL of distilled water and the subsequent wet mass extrusion 
sieved through a 710 μm mesh. The granules were then spread evenly on a steel tray and 
dried at 60 oC for two hours in the oven until a moisture range of 5-7 % was achieved, 
measured using a Sartorius Thermo control infrared moisture balance. 
 
Table 2.1. Formulation composition of ODTs used in coating trials. 
 
 
 Preparation of Kollicoat IR Coating Solutions Containing Biologically-Active 2.5.2.
Excipients 
The Kollicoat IR (BASF) coatings were made according to Table 2.2 by dissolving the 
appropriate amount of excipient in 100 mL of distilled water using a magnetic stirrer. The 
ibuprofen granules were then coated in 20 g batches using the ERWEKA AR 403 DKE 
coating pan using a 2 mL min-1 spray rate at 200 rpm for 15 minutes with further conditions 
outlined in Table 2.3. The granules were then dried for an additional 5 minutes.  
 
Excipient Percentage Content (%) Mass (g) 
Starch 1500 8.68 10.42 
MCC 17.37 20.84 
Mannitol 28.95 34.74 
Crospovidone 4.50 5.40 
Magnesium stearate 0.50 0.60 
Ibuprofen 40.00 48.00 
Total 100.00 120 
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Table 2.2. Nomenclature of Kollicoat IR dispersions. 
 
 
 
 
 
 
Table 2.3. Specifications used during the coating process. 
 
 
 
 
 
 
 Preparation of ODTs from Surfactant-Coated Granules 2.5.3.
Magnesium stearate was then added to a total of 0.5 % (w/w) and thoroughly mixed. The 
granules were then made into 500 mg tablets using a Specac Atlas press at 1 ton for most 
formulations and 2 tons for some chosen batches, both with 6 seconds compression time. 
 Powder Characteristics Testing 2.5.4.
 Bulk and Tapped Density of the Granules 2.5.4.1.
Bulk and tapped density were measured using 10 g of granules slowly poured through a 
wide neck funnel into a 50 mL measuring cylinder attached to a Sotax TD2 tap density 
tester. The occupied volume was recorded as the bulk volume. Following 250 taps, a 
second reading was taken of the consolidated volume, recorded as the tapped density. 
Results were recorded in triplicate. Bulk and tapped density values were then used to 
calculate the compressibility and Hausner ratio according to Equation 2.1 and Equation 2.2, 
respectively: 
Coating dispersions Coating 
Uncoated C0 
10 % (w/v) Kollicoat IR C1 
10 % (w/v) Kollicoat IR + 2 % (w/v) PEG 2000 C2 
10 % (w/v) Kollicoat IR + 2 % (w/v) Poloxamer 407 C3 
10 % (w/v) Kollicoat IR + 2 % (w/v) Cremophor EL C4 
Batch size 20 g 
Pan speed 200 rpm 
Inlet air temperature  60 °C 
Outlet air temperature 40 – 45 °C 
Atomizing air pressure  2 - 3 bar 
Pattern air pressure  1–1.75 bar 
Distance Bed-Nozzle  20 cm 
Spraying rate  2mL min-1 
Processing time  15 min and 30 min 
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Equation 2.1. 
 
 
Equation 2.2. 
 
 
 Angle of Repose 2.5.4.2.
The angle of repose was calculated by draining 10g of granules through a funnel held 5cm 
above the platform. The radius (r) and height (h) of the resulting cone was measured order 
to calculate the angle of repose according to Equation 2.3: 
 
Equation 2.3. 
 
 
 Physical Properties of ODTs Made from Surfactant-Coated Granules 2.5.5.
Tablet hardness and disintegration testing was conducted as previously described in 
sections 2.4.4.1 and 2.4.4.2, respectively, conducted in triplicate. Friability was conducted as 
described in section 2.4.4.3. For uniformity of content, three tablets from each batch were 
chosen at random and crushed using a pestle and mortar. The resulting powder was 
transferred to 500 mL of accurately weighed phosphate buffer (pH 7.2). The solution was 
inverted several times until the crushed tablet completely dissolved, and 1 mL of solution 
was tested for absorbance in the UV spectrometer at 264 nm using phosphate buffer as a 
blank between readings. According to the United States Pharmacopeia (USP, 2011), all 10 
tested tablets must contain 85% - 115% of the drug content in comparison to the mean 
amount of Ibuprofen with an RSD below 6 % of the mean. 
 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑅𝑎𝑡𝑖𝑜 = (
𝑃𝑡𝑎𝑝𝑝𝑒𝑑
𝑃𝑏𝑢𝑙𝑘
) 
 
 
𝐶𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦 𝐼𝑛𝑑𝑒𝑥 = 100. (
𝑃𝑡𝑎𝑝𝑝𝑒𝑑 − 𝑃𝑏𝑢𝑙𝑘
𝑃𝑡𝑎𝑝𝑝𝑒𝑑
) 
 
 
𝐴𝑛𝑔𝑙𝑒 𝑜𝑓 𝑅𝑒𝑝𝑜𝑠𝑒 = 𝑡𝑎𝑛(𝛼) (
𝐻𝑒𝑖𝑔ℎ𝑡
0.5 𝐵𝑎𝑠𝑒
) 
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 Statistical Analysis 2.5.6.
All data sets were assessed for significance using analysis of variance (ANOVA) with a 
predetermined alpha value of 0.05 on GraphPad Prism software (version 6.0) with 
Dunnett’s or Tukey’s Multiple Comparison Post-test for one-way and two-way ANOVA. 
In all figures using statistics, the error bars depict standard deviation. 
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The Development and Validation of a High-Throughput Screening Assay for the 
Detection of Excipients with Efflux Modulation Characteristics 
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 3. The Development and Validation of a High-Throughput Screening Assay for the 
Detection of Excipients with Efflux Modulation Characteristics 
 Chapter Aim and Objectives 3.1.
Polarised and differentiated adenocarcinoma (Caco-2) cells are highly regarded as the in 
vitro ‘gold standard’ model for the small intestine, expressing microvilli and enzymatic 
components resembling those of the intestinal epithelium (Wilson et al., 1990). To the 
formulation scientist wishing to use the Caco-2 cell line, there are a number of options as to 
the precise nature of the model itself. Of the potential model choices, cells grown on 
Transwell® inserts are commonly used after 21 days growth time. This method is typically 
low-throughput owing to the lengthy growth time, and additional time is required for 
post-experiment HPLC analytics. High-throughput processing is becoming increasingly 
common as a method to produce data at a faster rate and lower cost, often utilising recent 
advances in fluorescent probes in order to maximise output and, therefore, data 
processing. The aim of this study was to establish a working Transwell® model and 
evaluate the transport of the key probe substrate indometacin (IND) and examine the 
transport of this compound in the presence of PEGylated excipients. PEGs, both as stand-
alone materials or as the hydrophilic chains of larger and more complex compounds, 
maintain an illustrious role in the pharmaceutical industry, and the biological effects of 
PEGylated excipients has been well studied since first appearing in the literature regarding 
the reversal multiple drug resistance (MDR) (Ueda et al., 1987). Moreover, this early phase 
of experimentation was used to evaluate whether throughput could be streamlined for 
screening excipients with the ability to inhibit efflux-mediated transport by evaluating 
other potential screening protocols. 
 The In Vitro Transwell® Model 3.2.
 Examination of Test Solution Concentrations: Drug and Excipient 3.2.1.
As IND concentrations as high as 500 μM has previously been shown to lead to consistent 
and reproducible damage to Caco-2 monolayer integrity (Tang et al., 1993), the drug 
concentration for all studies was kept below 100 μM. A drug stock solution was prepared 
overnight prior to experimentation, which was subsequently filtered and to which various 
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amounts of polymer were added to achieve the concentrations shown in Table 3.1. The 
PEG 8000 and POLYOX concentrations were selected on the assumption of a 350 mg oral 
dosage form with a polymer content up to 85 % (w/v), and taken with a 250 mL glass of 
water on an empty stomach. Whilst the concentration of PEG 400 used in liquid dosage 
forms is at least 17 % (v/v) (Strickley, 2004), such high concentrations were found to be 
toxic to the Transwell® inserts during initial studies, with TEER values dropping well 
below 400 Ω.cm2 (results not shown). Concentrations have been found in literature as high 
as 20% (v/v) for the closely related PEG 300; however, the osmotic pressure was stabilised 
in the in vitro model by using an equal concentration of PEG 300 on both sides of the 
membrane and the authors acknowledge that this is proof of principle rather than a true 
model of in vivo condition (Hugger et al., 2002a). As such, the maximum concentration of 
PEG 400 used was 0.5 % (v/v) (Table 3.1). Poloxamer 407 has been shown to be a 
satisfactory lubricant for tablets made by direct compression at 1 % (w/w) (Muzíková et al., 
2012), and has been used as high as 19 % in formulations designed for photodynamic 
therapy via the administration of a thermosetting gel for the putative treatment of Barrett’s 
oesophagus using an oral dosage form (Bourre et al., 2002). As such, this latter 
concentration was used for testing (Table 3.1). 
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Table 3.1. Typical PEG 400, PEG 8000, POLYOX N-10 and poloxamer 407 concentrations found in oral dosage 
forms. The resultant polymer concentrations used in the study assumes the oral dosage formulation is taken with a 
250 mL glass of water. 
 Percentage Polymer Polymer Quantity in Dosage Form Concentration used in Study 
     Control 0 0 0 
     
PEG 400 
6.8 0.7 mL 0.10 (% v/v)a 
10.2 1.0 mL 0.25 (% v/v)a 
13.6 1.4 mL  0.50 (% v/v)a 
17.0 1.7 mL 
      
PEG 8000 
28.3 99.1 mgb 0.40 mg mL-1 
56.6 198.1 mgb 0.79 mg mL-1 
85.0 297.5 mgb 1.19 mg mL-1 
     
POLYOX N-10 
28.3 99.1 mgb 0.40 mg mL-1 
56.6 198.1 mgb 0.79 mg mL-1 
85.0 297.5 mgb 1.19 mg mL-1 
     
Poloxamer 407 
6.3 0.63 mgc 0.63 mg mL-1 
12.7 1.27 mgc 0.91 mg mL-1 
19.0 1.90 mgc 1.90 mg mL-1 
          a Percentage (v/v) adjusted to lower toxicology; 
b Assumes 350 mg tablet; 
c Assumes 10 mL liquid dosage form. 
 
 
 Results of In Vitro Screening Using the Transwell® Model 3.2.2.
  The Impact of Indometacin on Tight junction Integrity 3.2.2.1.
The paracellular hypothesis describes the passive movement of the drug through the 
monolayer via intracellular tight junctions. The tight junction macromolecular complex 
provides this barrier function and is the rate-limiting structure. A major component of this 
structure is the Zonula occludens (ZO-1), which act by directly binding actin cytoplasmic 
filaments to the transmembrane protein occludens, and so form cell-cell interfaces. Here, 
they play a cardinal role in the exclusion of macromolecules by the paracellular route, 
effectively sealing the apical plasma membranes of the intestinal lumen (Van Itallie et al., 
2009). IND is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of 
chronic inflammatory diseases. Like all drugs of this category, IND may lead to the 
development of gastric mucosal injury, where a plethora of individual pathologies may 
develop. The loss of mucosal integrity, gastric mucosal bleeding, inhibition of cell renewal 
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and the loss of inherent antioxidant defence has for a long time been linked to the inherent 
ability of NSAIDs to inhibit cycolooxygenase (COX) (Rainsford and Willis, 1982). This 
enzyme is necessary for the production of a group of the lipid compounds known as 
prostaglandins, which have a role in the regulation of inflammation, and therefore are 
considered protective (Rainsford and Willis, 1982). Furthermore, oxidative stress, 
particularly mitochondrial oxidative stress (MOS), also plays a pivotal role in NSAID-
induced gastric damage (Mahmud et al., 1996). Here, the uncoupling of oxidative 
phosphorylation leads to a decrease in cellular ATP/ADP and a subsequent loss of 
membrane potential (Mahmud et al., 1996). The opening of permeability transition pores 
ultimately releases cytochromes from the intra-mitochondrial space and into the cytoplasm 
– a hallmark of apoptosis. Oxidative stress has also been shown to lead to the disassembly 
of tight junction proteins, particularly ZO-1 via tubulin oxidation (Banan et al., 2003). The 
depletion of ATP in MDCK cells was shown to alter the distribution of ZO-1, leading to the 
formation of insoluble complexes, which were unable to interact with the cytoskeletal 
proteins of the cytoplasm (Wagner et al., 2008). ATP depletion has also been shown to 
decrease in ZO-1 and occludin expression in Caco-2 cells (Carrasco-Pozo et al., 2013). 
It follows, therefore, that in order to use Caco-2 cells as a model for the permeability of 
drugs through the human intestine, a concentration of IND must be found which is both 
detectable at each time point by the chosen analytical method, whilst leaving membrane 
integrity intact. Epithelial integrity can be measured indirectly using transepithelial 
electrical resistance (TEER), that is, the resistance of an electrical current passed across the 
monolayer. By short-circuiting the membrane, interference of electrical current generated 
by ion transport is negligible and therefore follows that an increase in TEER correlated to 
monolayer integrity, and so a decrease in paracellular transport. By monitoring the value 
before and after the permeability study in fresh DMEM growth media (37 °C), TEER was 
measured as accurately as possible to ensure membrane integrity was held throughout the 
experiment. Over the range of IND tested (10-100 μM), TEER values were maintained over 
400 Ω.cm2, showing the ability of the membrane to maintain acceptable levels of barrier 
function in the presence of higher drug concentrations. Typical TEER values are presented 
in Table 3.2. Naturally, any disturbance to the monolayer, such as those conducted as part 
of the permeability study including twice washing with buffer and the absence of serum 
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for over 60 minutes, will lead to minor decreases in TEER. Although a decrease in the 
extent of TEER degradation is seen in the presence of the polymeric excipient, this is not 
significant (p > 0.05). 
Table 3.2. The change in transepithelial resistance over time in the presence of drug alone or with PEG 8000. 
TEER Before (Ω.cm2)  TEER After (Ω.cm2)  Percentage Decrease (%) 
Controla 
Drug and 
Excipientb  
Controla 
Drug and 
Excipientb  
Controla 
Drug and 
Excipientb 
531.0 ± 20.7 534.0 ± 22.5 
 
454.0 ± 43.1 508.7 ± 7.51 
 
14.6 ± 5.6 4.6 ± 5.27 
a10 μM IND 
    b10 μM IND with 1.19 mg mL-1 PEG 8000 
   
  Indometacin Concentration-Dependent Transport 3.2.2.2.
Based on the results shown in Table 3.2, in which the tight junction integrity was 
maintained, the next stage was to investigate the concentration-dependent uptake of IND 
in the apical to basolateral direction without the excipients being present. The percentage 
of drug recovered from the basolateral compartment over 60 minutes is shown in Figure 
3.1. After 60 minutes, the percentage recovery for 100 μM initial concentration of IND was 
significantly higher (p < 0.0001) than for 50 μM initial concentration, indicating that the 
efflux transporter has become saturated and can no longer efficiently transport the drug 
because the Km value has been reached or surpassed once the system has reached 
equilibrium. Although initial permeability studies in the presence of polymer were 
conducted using 10 μM, these results show that higher drug marker concentrations of up 
to 50 μM could be used. 
 
Figure 3.1. The apical to basolateral transport of IND at varying concentrations through 21-day old Caco-2 
monolayers. Data is presented as mean ± SD of triplicate values. Statistical significance was analysed using two-
way ANOVA followed by Dunnett’s post hoc test annotated as follows: **** (p < 0.0001). 
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Plotting the permeability coefficients of AP-BL direction against BL-AP can reveal the 
manner of transport through which a compound is able to move through a monolayer: if 
the coefficients are of equal value, paracellular transport is indicated; asymmetrically 
superior transport in the AP-BL direction suggests carrier mediated transport, whilst 
asymmetrically dominant in the BL-AP direction is indicative of carrier mediated efflux. 
Figure 3.2 shows the data from Figure 3.1 represented as apparent permeability plotted 
alongside the apparent permeability data conducted using the same concentrations 
measured in the BL to AP direction, and Table 3.3 shows the Papp values obtained as a ratio 
of the two pathways for 50 μM drug as a typical example. The results demonstrate that 
permeability is dominant in the BL-AP direction, indicating possible carrier-mediated 
efflux associated transport. The higher Papp values seen at higher concentrations of the drug 
at 100 μM in the AP-BL direction (2.2 x 10-5  cm s-1 after 60 minutes compared to 1.6 x 10-5 
cm s-1, 1.4 x 10-5 cm s-1 and 1.5 x 10-5 cm s-1 for 50, 25 and 10 μM, respectively) may be 
indicative of the drug concentration exceeding the functional capacity of the transporter in 
terms of efflux transporter saturation, supporting the data from Figure 3.1. 
As efflux proteins such as ABCB1 reside on the apical membranes of epithelial cells, the 
ratio of the AP-BL and BL-AP permeability coefficients shows to what extent these 
transporters influence drug absorption. The examination of the transport of IND (Figure 
3.2), indeed, shows that the apparent permeability is higher in the BL-AP direction, 
indicating that the travel in the absorptive direction is influenced by the action of efflux 
transporters. Despite this, the efflux ratio between these directions of travel does not 
exceed 2. As such, the efflux ratios that we obtained leave the transport of IND in a state of 
contention. Efflux ratio values above 1.2 or 1.5 indicate that the compound is a substrate of 
efflux transporters (Lentz et al., 2000, Polli et al., 2001). Additionally, the speed at which a 
compound transits the membrane must also be considered. Any rapidly-transiting 
compound can overcome the effects of efflux transporters by bypassing them (Polli et al., 
2001). Verapamil (VER) is a well-known substrate of ABCB1, but is able to traverse the cell 
membrane quickly that it is able to quickly saturate the transporter with a Papp value of 1.7 
x 10-5 measured on the Caco-2 monolayer (Westerhout et al., 2014). Naturally, not all 
compounds that transit so fast will become inhibitors. Over the course of the experiments 
examining the transport of IND through Caco-2 monolayers, Papp values between 2.18-2.59 
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x 10 -5 cm s-1 were recorded, in agreement with existing literature between 1.5 x 10-5 and 2.0 
x10-5 cm s-1 on the Caco-2 monolayer (ElShaer et al., 2014, Mandagere et al., 2002). Using the 
recently outlined definition of high-permeability as compounds with a Papp value of 1.6 x10-
5 cm s-1 and over (Kim et al., 2006), both our calculated IND value and the reported VER 
value consider both of these compounds highly permeable. In contrast, well-studied 
ABCB1 substrate compounds have much higher efflux ratios than those reported for IND 
on the Caco-2 cell line, such as digoxin between 15-18 (Hughes and Crowe, 2010, Stephens 
et al., 2001, Mease et al., 2012), paclitaxel between 23-391 (Mease et al., 2012, Hughes and 
Crowe, 2010) and rhodamine 123 with a value around 10 (Troutman and Thakker, 2003, 
Sachs-Barrable et al., 2007). In conclusion, IND could well be a substrate of ABCB1 with an 
already exceptional ability to cross membranes, rendering the action of efflux transporters 
redundant.  
 
 
Figure 3.2. Bidirectional apparent permeability coefficient data for AP-BL (clear) and BL-AP transport (blue), 
conducted over a range of IND concentrations, showing A) 10 μM, B) 25 μM, C) 50 μM and D) 100 μM. Data 
presented as ± SD (n = 3). BL-AP transport is broadly dominant to AP-BL, suggesting the latter is influenced by 
efflux transporters residing on the apical membrane. 
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Table 3.3. Typical absorption to secretion permeability coefficients for 50 µM IND through 21-day old Caco-2 
monolayers. The higher value of the former compared to the latter is suggestive of transporter mediated efflux, 
demonstrated by the asymmetrical transport. 
Time (minutes) 
Papp (cm s-1) x 10 -5  Efflux Ratio 
Papp AP -> BL  Papp BL -> AP  (Papp BL -> AP / Papp AP -> BL) 
5 2.87 ± 0.15  3.42 ± 0.50  1.19 
10 3.09 ± 0.74  3.94 ± 0.35  1.28 
20 2.13 ± 0.28  3.73 ± 0.29  1.75 
30 2.37 ± 0.34  3.36 ± 0.21  1.42 
60 1.82 ± 0.34  2.89 ± 0.24  1.59 
 
  Indometacin Permeability Across Caco-2 Monolayers in the Presence of PEG 400 3.2.2.3.
PEG 400 is the lowest molecular weight material tested during the Transwell® studies and 
comes as a liquid at room temperature. The results of the permeability studies of IND 
across the Caco-2 monolayer in the presence of PEG 400 are shown in Figure 3.3. At high 
concentrations of this excipient, a statistically significant (p < 0.01) increase in the 
percentage of IND recovered is observed at 0.5 % (v/v). When PEG 400 was used below this 
concentration the percentage recovery of IND decreased when compared to drug alone - 
this is of interest, as literature supports the paradigm of PEG 400 as a permeability 
enhancer (Shen et al., 2006), in addition to being able to inhibit the efflux of digoxin, a P-gp 
substrate, in vitro (Johnson et al., 2002a). Both of these studies were conducted using rat 
jejunal tissue, although previous studies have used PEG 300 at similar concentrations to 
those shown herein, also using the Caco-2 cell line (Hugger et al., 2002a). Therefore, it is 
possible that the formation of PEG 400 micelles is having an inhibitory effect. As a large 
compound, absorption of PEG 400 is less than 0.5 % in vivo (Hugger et al., 2002a), and any 
micelle formation may not only prevent cellular efflux of the drug, but prevent 
permeability from the AP-BL membrane. The CMC of PEG 400 in the transport media has 
yet to be experimentally determined, although decreasing the concentration range below 
0.5 % (v/v) did lead to a statistically significant (p > 0.05) decrease in uptake after 60 minutes 
for 0.5 % (v/v) PEG 400 (Figure 3.3). 
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Figure 3.3. The permeability of IND in the presence of PEG 400, showing A) the percentage transport and B) 
apparent permeability (Papp) for AP-BL transport of 50 µM IND across 21-day old Caco-2 monolayers either alone 
or with 0.1-0.5 % (v/v) PEG 400 in the apical compartment. All results are shown in triplicate. Data is presented 
as ± SD. Statistical significance was analysed using two-way ANOVA followed by Dunnett’s post hoc test annotated 
as follows: ** (p < 0.01). 
 
 Indometacin Permeability Across Caco-2 Monolayers in the Presence of PEG 8000 3.2.2.4.
PEG 8000 is the second lowest molecular weight material tested during the Transwell® 
transport studies and is a waxy material at room temperature. The results of the 
permeability studies of IND across the Caco-2 monolayer in the presence of PEG 8000 are 
shown in Figure 3.4. Both the percentage transport and apparent permeability of IND 
increased significantly (p < 0.0001) for all concentrations tested, although this only occurs 
after 60 minutes, the final time point tested in this study. PEG 8000 has been shown to 
increase ABCB1 substrate permeability using IND and Caco-2 monolayers (Khan et al., 
2011). This study showed a profound increase in IND transport with a 2.8-fold increase in 
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permeability in the presence of PEG 8000. During the study conducted herein, an 
enhancement in transport of IND in the highest concentration of PEG 8000 (1.19 mg mL-1) 
was only 1.33-fold after 60 minutes. 
 
Figure 3.4. The permeability of IND in the presence of PEG 8000, showing A) the percentage transport and B) 
apparent permeability (Papp) for AP-BL transport of 50 µM IND across 21-day old Caco-2 monolayers either alone 
or with 0.369-1.19 mg mL-1 PEG 8000 in the apical compartment. All results are shown in triplicate. Data is 
presented as ± SD. Statistical significance was analysed using two-way ANOVA followed by Dunnett’s post hoc test 
annotated as follows: **** (p < 0.0001). 
 
 Indometacin Permeability Across Caco-2 Monolayers in the Presence of POLYOX 3.2.2.5.
Higher molecular weight PEGs over 20,000 Da are known as polyethylene oxides (PEOs). 
POLYOX N-10 is a PEO with a molecular weight around 100,000 Da. This excipient was 
selected for study as a contrast to the smaller molecular weight PEGs. The results of the 
permeability studies of IND across the Caco-2 monolayer in the presence of POLYOX N-10 
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are shown in Figure 3.5. After 60 minutes, both the percentage transport and apparent 
permeability of IND increased significantly (p < 0.01) in the presence of POLYOX after only 
10 minutes, increasing in significance after 60 minutes (p < 0.0001), although this increase is 
once more observed at the higher concentrations used, indicating the low efficacy of 
POLYOX as permeability enhancer. 
 
 
Figure 3.5. The permeability of IND in the presence of POLYOX N-10, showing A) the percentage transport and 
B) apparent permeability (Papp) for AP-BL transport of 50 µM IND across 21-day old Caco-2 monolayers either 
alone or with 0.369- 1.19 mg mL-1 POLYOX in the apical compartment. All results are shown in triplicate. Data is 
presented as ± SD. Statistical significance was analysed using two-way ANOVA followed by Dunnett’s post hoc test 
annotated as follows: ** (p < 0.01); **** (p < 0.0001). 
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 Indometacin Permeability Across Caco-2 Monolayers in the Presence of 3.2.2.6.
Poloxamer 407 
Poloxamer 407 (P407) is an amphiphilic excipient commonly used as a surfactant with a 
HLB value of 22, and is a soft and waxy material at room temperature. The effects of P407 
on IND transport across the Caco-2 monolayer is presented in Figure 3.6. The presence of 
this material lead to a profound increase in the rate of transport of IND, becoming 
significant at the highest concentration (1.9 mg mL-1) after just 10 minutes (p < 0.05), 
becoming extremely significant after 30 minutes for all concentrations tested (p < 0.0001). 
The possible reasoning for such an increase could be attributed to the mode of action 
previously suggested for these two different polymers in their respective action against the 
efflux transporters. PEGs have been reported to lead to an increase in membrane fluidity, 
and so disrupting the sensitivity to P-gp substrates acting in the inner leaflet of the 
membrane. Kabanov et al conducted an extensive study on poloxamers of various 
molecular weights and hydrophilic-lipophilic balance values (Kabanov et al., 2002). In this 
study using bovine brain microvascular endothelial cells (BBMECs), lipophilic poloxamers 
with propylene oxide (PO) lengths of 30-60 units, coupled with a HLB < 20, were the most 
effective of the P-gp inhibitors. Poloxamer 407 has a HLB of 22, with a PO length around 
67, putting these parameters close to the ideal. The precise mechanism is multifaceted, and 
appears to be a combination of decreasing the affinity of P-gp for ATP, membrane 
fluidisation and endocytosis of P-gp substrates into the cell by micelle activity when used 
above the CMC (Kabanov et al., 2002). The efficacy of poloxamer 407 in inhibiting P-gp has 
been reported using the Caco-2 model and the rat gut sac (Guan et al., 2011). Moreover the 
potential of poloxamers, and surfactants in general, for high efficacy in terms of P-gp 
inhibition is highly intriguing, and warrants extensive investigation. 
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Figure 3.6. The permeability of IND in the presence of poloxamer 407 showing A) the percentage transport and 
B) apparent permeability (Papp) for AP-BL transport of 50 µM IND across 21-day old Caco-2 monolayers either 
alone or with 0.63-1.9 mg mL-1 poloxamer 407 in the apical compartment. All results are shown in triplicate. Data 
is presented as ± SD. Statistical significance was analysed using two-way ANOVA followed by Dunnett’s post hoc 
test annotated as follows: * (p < 0.01); **** (p < 0.0001). 
 
Interestingly, the Papp values vary considerably over the first 2 time points (5 and 10 
minutes) between 0.36 - 3.37 cm s-1, highlighting the difficulty in washing cells, adding test 
solutions before cells dry out, initiating the experiment and then sampling the first data 
points and replacing the subtracted media in the opening minutes of the experiment. More 
consistent values are obtained at 20 minutes, with Papp values between 2.18 - 2.59 x 10 -5 cm 
s-1 for control wells. 
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 Confirming the Increase in Indometacin Transport as Efflux Inhibition 3.2.2.7.
As the action of efflux transporters is contrary to that of the absorptive route, any 
movement of compounds arriving at the apical fascia from the basolateral compartment is 
unlikely to have its movement impeded by this mechanism. Whilst the mechanism of 
action of poloxamer 407 is well understood and the efflux inhibition properties of PEG 400 
not fully elucidated using the Transwell® model herein, the two compounds which 
demonstrated clear efficacy were chosen for further study: PEG 8000 and POLYOX N-10. 
The data presented in Figure 3.7 shows the BL-AP transport of IND with the presence of 
1.19 mg mL-1 of either PEG 8000 or POLYOX in the basolateral compartment. The results 
showed no significant (p > 0.05) difference between the percentages of drug transported 
when the polymers are present compared to drug transport alone. From this, it can be seen 
that the excipients only change the apparent permeability in the AP-BL direction of travel, 
indicating that the effects noted in Figure 3.4 and Figure 3.5 were isolated to the apical 
membrane and crucially to the fascia expressing the efflux transporters. It is by this process 
that the increase in IND transport can be attributed to apical efflux modulation and not by 
a non-specific mechanism such as tight junction modulation. 
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Figure 3.7. The basolateral to apical (BL-AP) transport of IND in the presence of PEG 8000 and POLYOX N-10, 
showing A) the percentage drug transported and B) the permeability coefficients. Error bars refer to standard 
deviation (n = 3). No statistically significant difference was observed using two-way ANOVA between all time 
points tested in the presence of the excipients and the control, ns (p > 0.05). 
 
 Membrane Integrity Studies: Lucifer Yellow Transport 3.2.2.8.
Lucifer yellow (LY) is a non-P-gp substrate and is poorly transported through monolayers, 
making it an ideal marker for loss of membrane integrity. Therefore the AP-BL flux of LY 
across the Caco-2 cell monolayer was determined in the absence or presence of the highest 
polymeric concentrations to test for possible modulation of the paracellular pathway (Table 
3.4). The results show that neither polymer had a statistically significant impact (p > 0.05) 
on LY transport, with total recovery between 0.1 and 0.4 % (Table 3.4) and, hence, do not 
alter this pathway in Caco-2 monolayers. In an in vivo study, the surfactant Labrasol was 
able to increase the transport of LY in rat ileum at 0.1 % (Lin et al., 2007). In a study of the 
Caco-2 cell line, a number of nanoparticulates based on trimethylchitosan (TMC) were 
found to increase the permeability of LY, therefore demonstrating their propensity to open 
tight junction complexes (Sandri et al., 2007). Both of these studies highlight the importance 
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of monitoring tight junction integrity as any increase in the paracellular route may give 
identical results to efflux transporter inhibition. 
 
Table 3.4. Percentage Lucifer yellow transported after 60 minutes through 21-day old Caco-2 monolayers grown in 
Transwell® inserts. Data shown as the mean of triplicate values ± SD, 
 
Lucifer Yellow Transport (%) 
Control 0.02 ± 0.02 
PEG 8000 0.36 ± 0.56 
POLYOX 0.13 ± 0.23 
IND 3.30 ± 4.32 
 
 Introduction to High-Throughput Screening 3.3.
Whilst the Transwell® model is an incredibly powerful tool for evaluating the transport of 
drugs through intestinal monolayers, the process suffers from slow growth rates, which 
can limit throughput. As such, the next stage was to use the same Caco-2 platform to 
develop a high-throughput screening (HTS) assay with the aim of reducing growth time to 
7 days or less and increase scalability in contrast to the cumbersome Transwell® model. The 
fluorescent dye rhodamine 123 (R-123) has been used extensively in methodologies as a 
high-affinity ABCB1-mediated dye (Tapiero et al., 1984). The experimental premise of the 
method follows that of the bioavailability equation (Equation 1.2). As a fluorescent entity, 
the amount of R-123 that is retained in the cell is a function of the activity of the ABCB1 
transporter and it follows that Fg, the fraction of R-123 in the cell, can be quantified as a 
measure of the efficacy of an efflux transporter inhibitor. Following method development 
and optimisation of conditions, the protocol was validated using two commonly used 
excipients, Tween 20 and Tween 80, both polyethylene derivatives commonly used in the 
pharmaceutical industry and have long been known as inhibitors of efflux mediated by P-
gp.  
 Evaluation of Rhodamine Concentration Range 3.3.1.
The fluorescent probe R-123 at various concentrations was investigated in order to find a 
concentration of R-123 that is easily detected using the fluorescent plate reader, yet is low 
enough not to overwhelm ABCB1-mediated efflux. To this end, the cellular uptake of R-123 
in concentrations between 1 - 250 µM was assessed over a 4-hour period (Figure 3.8). The 
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uptake of R-123 was linear over the range tested (r2 = 0.998). For method optimisation, 5 
µM R-123 was chosen as this concentration is below the reported Km value of the probe (7.2 
- 17.5 µM in ABCB1-expressing cells (Forster et al., 2012, Wang et al., 2006, Shapiro and 
Ling, 1997)). Moreover, this concentration is well within the detectability limit of the 
equipment. Above this concentration, the efflux transporter will quickly become saturated 
and any inhibition properties of the drug or excipient will be masked. 
Whilst the use of R-123 as an efflux substrate was the focus of the current study, at low 
concentrations the uptake of this probe has been shown to be a saturable process that can 
be inhibited by the substrates of Oat1a4 (orthologous to human OATP1A2) such as digoxin 
and quinine, amongst others, in the rat model (Annaert and Brouwer, 2005). At higher 
concentrations, the uptake of the probe is by passive diffusion. As an amphiphilic 
molecule, R-123 is able to traverse the lipid bilayer by rare inversions known as ‘flip flop’ 
events. R-123 excluded by ABCB1 is free to continuously re-enter the cell by a process in 
which the hydrophobic elements of the compound initially bind to the acidic head groups 
of the phospholipids (Eytan et al., 1997). Therefore, highest level screening sensitivity 
(signal to noise ratio) will occur during the lowest reasonably detectable concentration of 
the dye and much below the saturation limit of the efflux transporter.  
  
Figure 3.8. The concentration-dependent uptake of R-123 over a 4-hour period on the Caco-2 cell line. Cellular 
accumulation of R-123 was linear over the concentration range and time points used. Cells were incubated in 
DMEM-HEPES (pH 7.4) with a R-123 concentration between 1 and 250 µM to obtain the time points indicated. 
Error bars are shown as ± SD (data pooled from 10 wells). 
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 Inhibition of ABCB1-Mediated Efflux 3.3.2.
The efflux ability of ABCB1 in the presence of a potential inhibitor was assessed by the 
extent of accumulation of R-123 in the Caco-2 cells grown for 5-7 days on clear plastic 96-
well plates by incubating the cells with R-123 in the presence of varying concentrations of 
the ABCB1 inhibitor VER (Figure 3.9), which was selected due to the high frequency of 
citations making use of its inhibition properties (Aller et al., 2009, Profit et al., 1999, 
Yumoto et al., 1999, Varma and Panchagnula, 2005). The results in Figure 3.9A demonstrate 
that the addition of the inhibitor leads to a concentration-dependent increase in fluorescent 
signal consistent with that of increased R-123 accumulation in accordance with previous 
studies on the Caco-2 cell line (Perloff et al., 2003, Wang et al., 2006, Shapiro and Ling, 
1997). The introduction of the efflux inhibitor leads to a statistically significant increase in 
accumulation R-123 as low as 1 µM of VER (p < 0.05). Further evidence supporting the 
blockade of the ABCB1 efflux transporter was observed visually using fluorescence 
microscopy, with increased intensity in the presence of VER indicative of increased R-123 
accumulation compared to control wells (Figure 3.10).  
The efflux of R-123 by ABCB1 is mediated by pairs of the probe binding simultaneously to 
the protein. The efflux inhibition by VER is non-competitive, suggesting that ABCB1 has 
separate binding sites for R-123 and VER, and further elucidating the broad-specificity of 
this transporter (Wang et al., 2006). Although the multidrug resistance protein 1 (MRP1) 
has been suggested to have a role in R-123 transport (Daoud et al., 2000), expression of this 
efflux transporter is low on the Caco-2 cell line (Prime-Chapman et al., 2004), suggesting a 
negligible contribution of the transporter in this model. Indeed, no significant increase was 
observed in the accumulation of R-123 in the presence of the MRP inhibitor IND at low 
concentrations (Figure 3.9B), although becoming statistically significant at 100 µM. This is 
most likely attributed to IND as a low-affinity substrate of ABCB1 as established during the 
Transwell® model experiments at this exact concentration (Figure 3.1). Therefore, 100 µM of 
VER was chosen to be incorporated into the screening model as an excipient-free positive 
control due to the high degree of statistical significance versus non-treated controls, and 
shown to be approaching the maximum levels of inhibition of the ABCB1 transporter on 
the Caco-2 cell line (Burton et al., 1993). Further kinetic data could not be obtained for VER 
beyond 100 µM at this stage due to the limitations of the MTT toxicology study currently 
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employed. As an efflux inhibitor, VER may increase the uptake of MTT in the same manner 
to which it increases R-123 uptake, an artefact which has previously been reported 
(Vellonen et al., 2004). 
 
    
Figure 3.9. The effects of VER and IND on R-123 accumulation. Uptake of R-123 was increased in the presence 
of 1-100 µM of the ABCB1 efflux protein inhibitor VER in a concentration-dependent manner after 4 hours 
incubation (A) but not in the presence of the MRP family inhibitor IND until a concentration of 100 µM (B). Data 
is presented as ± SD (data pooled from 10 wells), with R-123-only control normalised to 100 %. Statistical 
significance was analysed using one-way ANOVA followed by Dunnett’s post hoc test annotated as follows: * (p < 
0.05); **** (p < 0.0001). 
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Figure 3.10. The increase in the ABCB1 substrate accumulation was confirmed using fluorescence microscopy 
showing 10 µM R-123 alone (A) and with 10 µM or 100 µM VER (B and C respectively), leading to a 
concentration-dependent blockade of the ABCB1 efflux mechanism shown schematically above each image. 
Images are representative of cells imaged under identical conditions using 40x magnification using Caco-2 
monolayers grown for 7 days in 6-well plates.  
 
 Method Optimisation 3.3.3.
 Effects of Growth Time on the Cellular Accumulation of R-123 3.3.3.1.
The optimisation of growth conditions is crucial in order to support reproducible R-123 
uptake over a short time frame for true HTS conditions. For this purpose, cellular uptake of 
R-123 was tested periodically post seeding on Caco-2 cells grown for 5-7 days on clear 
plastic 96-well plates by incubating the cells. Dome structures, indicative of solute 
transport accumulation underneath a monolayer of cells grown on smooth plastic, were 
used as a guide to the degree of confluence, which first appear between day 4-5 and were 
present up to day 14 (Figure 3.11). The results of inter-day testing of the uptake of R-123 in 
the presence/absence of 100 µM VER showed no statistical significance between days 5 and 
day 7 (p > 0.05), with ABCB1 inhibition increasing intracellular R-123 accumulation 
between 134 to 147% (Figure 3.12). These results confirmed that studies could be 
undertaken reproducibly within this 3-day window. Caco-2 cells are well known to fully 
differentiate after 21 days growth post seeding, although this requires the presence of a 
porous material, such as the apical fascia of a Transwell® insert. When grown on the 
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smooth plastic of the 96-well plate, membrane becomes weak during washing steps for 
monolayers over 8 days old, presumably due to the high proliferation rates of the cell line 
resulting in net reduction in monolayer adhesion to the limited surface of the smooth 
plastic. 
 
 
Figure 3.11. Visual indication of confluence seen under light microscopy observation. Complete confluence is 
observed on day 3 (A), with early dome formation observed on day 4 (B). By day 14 (C), numerous domes appear 
with well-defined established borders although monolayers appear less smooth. Images taken on 10x 
magnification. 
 
 
Figure 3.12. The effects of growth time on the uptake of R-123 in the presence of 100 µM VER, tested on day 5 
(clear bars) and day 7 (blue bars). The increase in R-123 accumulation remains consistent following the appearance 
of dome structures on the monolayers on around day 5 post-seeding following treatment with 100 µM VER. Data 
is shown as the percentage increase from inhibitor-free control wells ± SD (intraday data pooled from 3 plates, n = 
30 wells total). Statistical significance was analysed using one-way ANOVA followed by Tukey’s post hoc test 
annotated as follows: ns (p > 0.05). 
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 Effects of Incubation Time on the Cellular Accumulation of R-123 3.3.3.2.
Pre-incubation of inhibitors prior to the addition of the transporter functionality probe, 
fluorescent or otherwise, is highly recommended as a means of blockading the transporter 
system and so increasing the sensitivity of the assay for time-dependent inhibition (TDI) 
assays (Huang et al., 2007). In 2009, 47 % of companies screening for inhibition pre-
incubated inhibitors before conducting IC50 values (Grimm et al., 2009). Therefore, the 
optimal incubation time the ABCB1 modulator VER was tested over 60 minutes (Figure 
3.13). From these studies, it is shown that VER is able to traverse the cell membrane 
quickly, and has a Papp value of 12.6 x 10-6 cm s-1 (Pauli-Magnus et al., 2000). A statistically 
significant ABCB1 blockade is observed after only 10 minutes pre-incubation (p < 0.0001), 
leading to an increase R-123 accumulation to 146 % of the control value via transporter 
inhibition (Figure 3.13). No statistical difference was observed in the increase in 
accumulation of R-123 following further pre-incubation up to 60 minutes (p > 0.05). As 
such, the membrane-permeable VER is able to quickly saturate the efflux transporter on 
opposing binding sites to R-123. As it is unable to exclude this concentration of VER, the 
inhibited ABCB1 transporter is further unable to efflux R-123 out of the cell, leading to an 
increase in fluorescent signal consistent with increased cellular accumulation of the 
fluorescent probe compared to non-treated control. 
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Figure 3.13. The effects of pre-incubation time of VER on the cellular accumulation of R-123. Full ABCB1 
blockade is achieved in less than 10 minutes pre-incubation with 100 µM VER. Data is shown as the percentage 
increase from inhibitor-free control after 60 minutes uptake ± SD (data pooled from 3 plates, n = 30 wells total). 
Statistical significance was analysed using one-way ANOVA followed by Dunnett’s post hoc test annotated as 
follows: ns (p > 0.05); **** (p < 0.0001). 
 
 The Effects of Media Composition on the Cellular Viability 3.3.3.3.
The binding of drugs to plasma proteins, such as albumin, is known to alter drug 
disposition; moreover, it is the concentration of unbound drug rather than the total 
concentration of drug that is responsible for its effects (Benet et al., 1996). For this reason, 
initial short-term R-123 uptake studies (≤ 4 hours) excluded serum from the DMEM 
composition. To evaluate the true inhibition properties of certain excipients, extended 
studies (4 ≥ hours) may be necessary in order to measure subtle biological effects that 
would be masked using short-term studies. To this end, the MTT toxicology assay was 
employed to test the effects of media composition on cellular viability over a 24-hour 
period. The MTT assay is the established method for evaluating mitochondrial 
dehydrogenase activity by the conversion of MTT to the insoluble formazan, which is a 
strong indicator of the overall viability of a cellular population. HBSS alone had a dramatic 
impact on the monolayers, which came off during final processing after 4 hours and so was 
excluded from further studies. As such, the composition of DMEM as a transport media 
with or without serum became the focus of investigation, and the results are presented in 
Figure 3.14. Interestingly, apparent mitochondrial activity increased significantly in serum-
free DMEM to 190 % formazan production (compared to serum treated controls set to 100 
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% viability) after only 10 minutes incubation (p < 0.0001). Over a 24-hour period, this trend 
continues (Figure 3.14)  
Whilst de novo synthesis of elements essential to cellular activity such as cholesterol from 
acetyl-CoA (Garcia-Ruiz et al., 2009) in lieu of readily available proteins present in the 
media containing serum may account for the differences in mitochondrial activity over 24 
hours, the difference in viability over a 10 minute period suggests this explanation to be 
unlikely. Moreover, the differences observed in relative viability in the presence or absence 
of serum is most likely attributed to protein binding by MTT itself, which limits the 
availability to the cells. In a previous study, it was observed that 10 % serum was enough 
to reduce MTT absorbance readings by as much as 50 %, similar to the present study 
(Huang et al., 2004). This is supported by the statistical difference between cells treated 
with MTT after 10 minutes versus those treated after 4 hours (p < 0.01) and after 24 hours (p 
< 0.0001), at which point the composition of the media was likely to have changed due to 
partial serum depletion by the time MTT was added to initiate the assay (Figure 3.14). In 
the absence of serum, the adhesion of the monolayers to the smooth plastic was observed 
to be weaker (data not shown). 
The data presented in Figure 3.14 indicates that this platform can, if necessary, be extended 
for uptake over a 24-hour period when stabilised in serum-containing media. However, in 
addition to extending the time of the assay, the physiological implications of a 24-hour 
study are difficult to justify in the context of enhancing drug delivery. If they are able to 
escape metabolism and excretion by the body, a systemically circulating compound in vivo 
may last for extended periods of time in which to have a biological effect against efflux 
transporters. Although oral formulations are typically dosed to a steady state, and so 
repeated exposure to the same excipient is to be expected, only the active ingredient of the 
formulation is likely to be absorbed through the intestinal membrane to reach systemic 
stability when drug clearance is accounted for, with the pharmaceutical excipient unlikely 
to last more than 4 hours in transit in the gastrointestinal tract. This would suggest that any 
biological effects must become apparent within the first few hours of contact when the 
excipient is in contact with the intestinal membrane where the efflux transporters reside. 
Indeed, the uptake of radiolabelled molecules such as PEG 400 has been used to 
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demonstrate that the paracellular permeability of compounds with a molecular weight 
above 500 is limited in both Caco-2 monolayers and rat ileum (Artursson et al., 1993a). This 
molecular weight is much below the weight of many of the putative excipients being 
considered for testing. Therefore, whilst the possibility of a serum-stabilised extended 
study over a 24-hour period is achievable, a more time-efficient 4-hour assay time was 
selected for the R-123 screening assay. 
 
Figure 3.14. The effects of serum on the cellular viability of monolayers of Caco-2 cells. MTT cell viability assays 
measured the mitochondrial activity of the cells with serum (clear bars) and without (blue bars), over a 24 hour 
period. Data is shown standardised against serum-containing media as 100 % ± SD (data pooled from 3 plates for 
a total of 30 wells). Statistical significance was analysed using two-way ANOVA followed by Dunnett’s post hoc test 
annotated as follows: ** (p < 0.01); **** (p < 0.001). 
 
 Effects of Media Composition on the Cellular Accumulation of R-123 3.3.3.4.
Having established cellular viability over a 4-hour period in media both with and without 
serum, the impact of serum on the transport of R-123 alone and in the presence of 100 µM 
VER was examined. The results are presented in (Figure 3.15). At the 4-hour time point, the 
cellular uptake of R-123 alone in serum-containing and serum-free media showed no 
significant (p > 0.05) difference between the two, with the cell lysate showing relative 
fluorescent unit (RFU) values of 41 and 39 respectively (Figure 3.15). This suggests the 
propensity of the amphiphilic R-123 to interact with the serum proteins is limited and an 
almost identical amount of probe reaches the cells under both conditions. In the presence of 
100 µM VER, statistically significant differences were seen in R-123 cellular uptake between 
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the serum-containing and serum-free media (p < 0.0001) from 97 RFU to 118 RFU, 
respectively (Figure 3.15), attributed to the high degree of protein binding of this drug. An 
in vivo human study has suggested around 90 % of circulating VER is bound to plasma 
proteins (Keefe et al., 1981), possibly accounting for the reduced bioavailability in the 
model and so decreased percentage of inhibition of the ABCB1 protein. At the site of drug 
delivery in the small intestines, a similar effect will be apparent due to the presence of bile 
and dietary proteins. Despite this, the increase in R-123 accumulation in the presence of 
VER in serum-containing media was still significant in the context of serum-containing 
controls, so this variable was chosen to stabilise cultures up to 4 hours. A summary of 
further assay conditions for the HTS away protocol and the rationale behind them are 
displayed in Table 3.5. 
 
Figure 3.15. The effects of media composition on R-123 accumulation. Cellular uptake of R-123 alone was found 
to be unaffected by the presence of serum in the media composition over a 4 hour period. In the presence of 
serum (clear bars), the relative increase in R-123 accumulation by the action of 100 µM VER was reduced 
compared to serum-free media (blue bars). Data is shown as raw relative fluorescence units (RFU) for direct 
comparison of uptakes ± SD (data pooled from 3 plates, n = 30). Statistical significance was analysed using one-
way ANOVA followed by Tukey’s post hoc test annotated as follows: ns (p > 0.05); **** (p < 0.001).  
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Table 3.5. Optimised conditions for HTS protocol.  
Variable Options Chosen Rationale 
    
Culture Plate 96-well plate 
12-well plate 
6-well plate 
96-well plates  Low cost 
 Increased well number for higher concentration variation and 
increased chance of positive hit, higher n number for increased 
significance 
    
Inhibitor concentration 1 - 100 µM 100 µM  Most statistically significant concentration against non-treated control 
(p < 0.001) (Figure 3.9) 
    
Cell growth time 2-14 days 7 days  Excellent differentiation between positive and negative controls 
between days 5-7 (Figure 3.12) 
 Cells require 21-day growth period on filters for complete 
differentiation (Wilson et al., 1990) 
 Monolayers became fragile to washing step after 7 days 
 
R-123 concentration 1 - 250 µM 5 µM  Excellent detectability below reported Km of ABCB1 (Forster et al., 2012, 
Wang et al., 2006, Shapiro and Ling, 1997) 
    
Inhibitor Preincubation time 10-60 minutes 10 minutes  No significant difference (p > 0.05) between amount of R-123 increase 
over 10-60 minutes (Figure 3.13) 
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Transport Buffer ± Serum + Serum  Maintains cellular viability over extended periods 
 Significant (p < 0.0001) increase in R-123 uptake using 100 µM VER 
(Figure 3.14 and Figure 3.15) 
    
 
 
Lysis buffer HBSS 
PBS 
dH2O 
dH2O  No expense on buffer 
 No autofluorescence (data not shown) 
    
Lysis time 15 minutes – 
24 hours 
15 minutes  Faster turnaround time for truly HTS condition 
 Less chance of R-123 degradation by lysate components 
    
Lysis conditions Fridge (4-5 ˚C) 
Bench top (16 ˚ 
C) 
Orbital shaker 
(ambient) 
Orbital shaker  Evaluation of various lysis conditions demonstrated the superiority 
orbital shaker for reduced evaporation and quicker monolayer 
destruction 
 Plates left overnight in the fridge were found to have intact monolayers 
(data not shown) 
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 The Validation of the HTS Method by Evaluating the Impact of Tween 20 and 3.3.4.
Tween 80 on Caco-2 Monolayers 
 Cytotoxicity 3.3.4.1.
As the Caco-2 monolayer is utilised as a model for the human intestine, treatment 
concentrations have to be scaled appropriately. As such, MTT toxicology studies are 
commonly used to indicate the non-toxic parameters of test solutions by monitoring 
mitochondrial activity. The conversion of MTT to formazan produces an insoluble product 
that can be measured and quantified in relation to non-treated cells. The main toxic effects 
of drugs tend to be mitochondrial damage (Chresta et al., 1996). However, Tweens, as 
surfactants, will have an additional high propensity to interact with the lipid membranes of 
the cells of the monolayer, and in doing so may impart cellular toxicity. The cellular 
viability of the Caco-2 monolayers in the presence of different concentrations of Tween 20 
and Tween 80 over 4 hours is presented in Figure 3.16. Both Tween 20 and Tween 80 
showed a statistically significant reduction in cell viability on the Caco-2 cells at 1 % (v/v) 
(p < 0.01) with reductions to 26 % and 89 % viability, respectively. For this reason, a 
concentration range between 0.01 - 0.1 % (v/v) was chosen for uptake studies in the 
presence of R-123, as this concentration range showed no significant change in cellular 
viability (p > 0.05). 
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Figure 3.16. The toxicological effects of the Tweens on Caco-2 monolayers. MTT assays were performed on Caco-
2 monolayers incubated with varying concentrations of Tween 80 (A) and Tween 20 (B) for 4 hours. Data 
expressed as the mean of percentage cell viability relative to untreated controls ± SD (n = 20 from 2 passage 
numbers). Statistical significance was analysed using one-way ANOVA followed by Dunnett’s post hoc test 
annotated as follows: ** (p < 0.01); **** (p < 0.0001). Triton-X was used as a positive control at 0.05 % (v/v). 
 
 The Biological Effects of Tween 20 and Tween 80 on ABCB1 Activity 3.3.4.2.
In order to validate the developed HTS platform, the well-known inhibitors of ABCB1-
mediated transport, Tween 20 and Tween 80, were tested for their ability to inhibit ABCB1-
mediated efflux of R-123. The results are presented in Figure 3.17. Over 4 hours, all 
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treatments showed statistically significant increases in the accumulation of R-123 (p < 0.05). 
At the lowest concentration of Tween 20 and 80 (0.01 % v/v), statistical significance is 
observed after 120 minutes (p < 0.0001), and 60 minutes (p < 0.001) respectively. At 0.05 % 
and 0.1 % (v/v), Tween 20 increases R-123 accumulation rapidly, becoming statistically 
significant after 10 minutes (p < 0.001 and 0.0001 respectively). Tween 20 has the most 
dramatic overall impact on the increase in accumulation: after 4 hours, the uptake in the 
presence of Tween 20 reached 522.7 ± 98.7 % of non-treated control, whereas Tween 80 
increased uptake by 264.8 ± 48 % (Figure 3.17). 
As a high-affinity substrate of the ABCB1 transporter system, any increase in the 
accumulation of R-123 can be attributed to the decrease in ABCB1-mediated efflux. As the 
activity of this efflux transporter decreases, the R-123 that enters the cell remains, leading 
to a rise in fluorescent signal compared to that of non-treated controls. Surfactants such as 
Tweens have been well studied for their ability to modulate ABCB1 through the altered 
fluidity of the lipid membrane, and so were chosen to validate the screening protocol, and 
the ability of a surfactant molecule to alter membrane fluidity is dependent upon the 
hydrophilic to lipophilic balance (HLB) (Buckingham et al., 1995). The large differences in 
the inhibition properties of the two Tweens cannot be explained in terms of the HLB values 
of the compounds, both of which are similar (16.7 and 15 for Tweens 20 and 80, 
respectively (Wade and Weller, 1994)). This suggests that their propensity for interacting 
with the lipid bilayer, and so disrupt the microviscosity of the membrane through their 
respective hydrophobic regions, is not only similar, but optimal (Lo, 2003). Structurally, the 
two Tweens have a large degree of homogeneity, and differ only in the side chain length: 
Tween 80 has a larger oleic acid side chain, whereas Tween 20 has a smaller lauric acid side 
chain. This is reflected in the molecular weights of the two compounds (1310 gmol-1 for 
Tween 80 versus 1228 gmol-1 for Tween 20), and may explain why Tween 20 may have 
better lipid association by having less steric hindrance, and so resulting in enhanced 
membrane disruption when compared to Tween 80. Tweens may use several other 
mechanisms to modulate ABCB1, such as inhibiting protein kinase C (PKC) activity, 
thereby reducing the phosphorylation of the protein and resulting in a modulating effect 
(Komarov et al., 1996). Additionally, Tween 80 has been shown to non-competitively 
inhibit substrate binding to ABCB1 (Yamazaki et al., 2000). The degree of efflux inhibition 
Pollard J 
125 
 
may suggest that the Tweens mode of action is multi-factorial, involving a number of 
mechanisms for the blockade of ABCB1. Both Tween 20 and Tween 80 appear in the 
literature multiple times as P-gp inhibitors (Hugger et al., 2002b, Lo, 2003, Shono et al., 
2004, Li et al., 2011b), validating the dose-dependent increase in R-123 in the presence of 
these excipients as inhibition of ABCB1-mediated efflux. 
  
Figure 3.17. The biological effects of the Tweens on ABCB1 activity, showing (A) Tween 80 and (B) Tween 20 
after 4 hours of incubation in the presence of R-123. Data is shown as the percentage increase in cellular R-123 
accumulation in the presence of the Tweens versus excipient-free control wells, presented as the mean from n = 
10 wells ± SD. Statistical significance was analysed using two-way ANOVA followed by Dunnett’s post hoc test 
annotated as follows: ns (p > 0.05); ** (p < 0.01); *** (p < 0.001); **** (p < 0.0001). 
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 Testing the Biological Effects of MCC, HPMC, Starch 1500 and PVAP on ABCB1-3.3.5.
Mediated Transport 
Once the assay was established and validated, the next stage was to test previously 
uncharacterised excipients. In order to boost throughput, the cellular accumulation of 5 µM 
R-123 was examined over a 2-hour assay time. The excipients of choice were 
microcrystalline cellulose (MCC), Starch 1500, polyvinyl acetate phthalate (PVAP) and 
hydroxypropyl methylcellulose (HPMC) (Table 3.6). Although these excipients are not 
PEGylated, literature contains examples of compounds which have shown activity against 
transporters without having this moiety, such as lipid excipients which decrease 
expression of ABCB1 (Sachs-Barrable et al., 2007), and polycarbophil which is believed to 
increase oral bioavailability of paclitaxel by inhibition of this protein (Föger et al., 2008). 
Both MCC and HPMC are cellulose derived, whereas Starch 1500 is a polymer of amylose 
and branched amylopectin and PVAP consists of various repeating units of acetyl and 
phthalyl. Of these, only HPMC was soluble under ambient conditions at 10 mg mL-1. All 
other excipients tested produced suspensions at pH 7.4 (the physiological enteric pH used 
for in vitro studies), and test solutions were prepared as such. Co-solvents were not used 
due to concerns regarding cellular viability. As the only soluble excipient with a well-
known lack of toxicity, HPMC was used to a final concentration of 10 mg mL-1, whereas all 
other excipients were used at 2.5 mg mL-1 in order to minimise the amount of precipitate 
present in each of the wells.  
The results of the efflux studies (Figure 3.18) demonstrate that MCC had no significant 
impact on efflux (p > 0.05). However, PVAP significantly decreased uptake of R-123 (p < 
0.0001) between 65-59 % of the control wells in a concentration-dependent manner. Starch 
1500 showed an increase in a concentration-dependent manner between 111-212 % of the 
control wells. Likewise, HPMC showed a concentration-dependent increase over the range 
tested (p < 0.001) between 117 – 148 % of the control wells. The increase seen for Starch 1500 
and HPMC is most likely not attributed to the inhibition of ABCB1 (Figure 3.18b and 
Figure 3.18d). HPMC is a well-known mucoadhesive, and at higher concentrations HPMC 
films could be seen covering the cells within each well (data not shown). During the wash 
phase of the experiments, this film could not be removed without prior removal of cell 
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monolayer, an issue likely compounded by the ice-cold wash increasing the viscosity of the 
excipient. Likewise, Starch 1500 particles were also visible on the cell monolayer surface 
which again could not be removed. Such factors are a limitation to the model, and 
highlight the need for increasing the diversity of the concentration ranges used over 
logarithmic dilution range in order to overcome such issues. The significant decrease in 
cellular R-123 accumulation seen by PVAP (Figure 3.18a) is most likely attributed to the 
decrease in pH observed over the course of the 4-hour experiment as individual particles of 
PVAP underwent dissolution, notably decreasing the pH of the transport media beyond 
the buffering capacity of the HEPES, and effectively reversing the pH gradient of the assay. 
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Table 3.6. Purpose and structural formula of excipients tested (* source Handbook of Pharmaceutical Excipients, 6th Edition)  
Excipient Purpose 
Appearance upon dissolution in PBS 
(pH 7.4) 
Structural Formula* 
Microcrystalline cellulose (MCC) Disintegrant Suspension 
 
 
 
 
 
Starch 1500 Binder/Disintegrant Suspension 
 
 
Polyvinyl Acetate Phthalate (PVAP) Enteric release coating polymer Suspension 
 
 
Hydroxypropyl methylcellulose (HPMC) Extended release polymer Clear viscous liquid 
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Figure 3.18. The percentage increase in cellular accumulation of R-123 in the presence of 100 μM VER or the excipients of choice of 4 hours, showing A) PVAP, B) HPMC, C) 
MCC and D) Starch 1500. Data is presented as ± SD (data pooled from 8 wells), with R-123-only control normalised to 100 %. Statistical significance was analysed using one-way 
ANOVA followed by Dunnett’s post hoc test annotated as follows: ns (p > 0.05); * (p < 0.05); *** (p < 0.001); **** (p < 0.0001).  
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 Conclusions of In Vitro Method Development and Model Selection 3.3.6.
Using an optimised protocol, the non-ionic excipients Tween 20 and Tween 80 were tested 
for their biological effect against the ABCB1 transporter below their cytotoxic 
concentrations. The results of this study validate the HTS platform against existing 
literature examining the biological effects of surfactants. Of course, every model has 
positive and negative attributes and a fair criticism of both types evaluated are displayed 
in Table 3.7. Owing to the multi-purpose nature of the 96-well plate format, the reduction 
in the time and resources necessary to obtain data, and the high-throughput potential of 
the platform, this method was chosen for future development over the Transwell® model. 
The final HTS protocol is outlined in Figure 3.19. 
During the platform development, literature searches showed the existence of a fluorescent 
probe of the MRP2 transporter: 5(6)-carboxy-2′,7′-dichlorofluorescein. This probe is unable 
to cross membranes of cells, so is added to transport media in diacetate form which is able 
to freely diffuse to the cytoplasm where it gets converted to the fluorescent species. 
Although ABCC2 is a well-characterised efflux protein, little is known about the effects of 
excipients against its function. The addition of this new fluorescent entity to the HTS 
protocol presented in this chapter had the potential to address this.  
Finally, a critical evaluation of the HTS platform in its current form also highlights the lack 
of quantification of the inhibition data. From data obtained on excipients as inhibitors of 
efflux transports in this chapter, no reference point can be used to link the materials in 
order of efficacy, or the quantity required to elicit appropriate efflux inhibition in vivo. This 
data is of critical value if the information is to be utilised in order to enhance oral dosage 
formulations, as it indicates the minimal quantity of material required in a potential dosage 
form. As such, the following chapter will focus on the kinetic analysis of excipients by 
highlighting the amount required to reduce transporter activity by 50 % - the IC50 value. 
 
 
  
 
 
Table 3.7. A critique of the aspects of both models tested in this chapter. Media consumption per plate is based on renewal every 48 hours and includes seeding media.  
Model Positives Negatives 
6-Well Transwell®  
 Considered the 'gold standard' of in vitro drug 
transport assays 
 Full differentiation 
 Established tight junctions 
 Polarised transport can be explored 
 Drug transport can be used to estimate human 
absorption 
 Slow 21-day growth time 
 Slow time to analyse data 
 Transporter probe substrate requires careful 
evaluation 
 264 mL media to get a single 6-well plate to 
maturation 
 Low n number 
 High unit cost 
   
96-Well Plate 
 77 mL to get one 96-well plate to maturation 
 Probe specificity can easily be established 
 High-throughput, fast analysis 
 Multi-purpose platform, can easily be used for 
fluorescent probe uptake as well as MTT or 
morphological studies etc. without 
modification 
 High n number possible 
 Data easily manipulated to gain PK data 
 Low unit cost 
 Poor estimation of mode of transport due to 
2D monolayer, e.g. does not account for 
paracellular route 
 Only partial differentiation 
 Only absorptive (apical to intracellular) 
transport can be observed 
 Monolayer fragility over time 
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Figure 3.19. Schematic diagram of HTS protocol. Cells are grown for 5-7 days, at which point MTT is conducted on 
the test excipient to determine the non-toxic concentrations used. Next, a separate 96-well plate is prepared for the 
uptake study by carefully washing out the well, incubating with the excipient(s) before the addition of the fluorescent 
probe. Cells are then incubated for 2 hours prior to careful washing, lysing, and fluorescence quantification using 
black 96 well plates. 
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Chapter 4 
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 4. A Kinetic Study on the Effects of Excipients against ABCB1- and ABCC2-Mediated 
Transport 
 Chapter Aim and Objectives 4.1.
Intestinal efflux transporters are of pharmacodynamic and pharmacokinetic interest for 
anticipating drug behaviour in vivo. The existing literature on this subject reveals an 
extensive list of excipients that elicit effects against ABC efflux transporters — most 
notably ABCB1. However, such information is rarely quantified in pharmacokinetic terms, 
thereby making the process of optimising oral formulations for increasing efflux prone 
drug bioavailability challenging. Therefore, the aim of the work presented in this chapter 
was to identify excipients of high efficacy which are inhibitors of the ABCB1 and ABCC2 
efflux transporter systems, and quantify this data in a way that can be pragmatic from the 
formulation perspective. In order to do this, a number of objectives needed to be met: 
 The first objective was to obtain kinetic data relating to the established ABCB1 
inhibitors verapamil (VER) and ciclosporin (CsA) and the ABCC2 inhibitors 
indometacin (IND) and probenecid (PBD), in order to assess the function of these 
transporters on the cell line within the framework of existing literature and also to 
act as a reference point for the efficacy of excipients found to be inhibitors.  
 
 As the overall aim of the project was to produce an oral dosage form capable of 
enhanced delivery, the second objective was to screen a plethora of excipients using 
the HTS assay that could be used as tablet components. These excipients were 
coating agents, polymeric carriers and a broad range of surfactants. 
 
 The final objective was to identify and delineate any non-specific effects of the 
excipients that are not mechanisms related to transporter inhibition, such as 
membrane damage and toxicology, which may otherwise give false inhibition data.  
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In order to rank the ability of the excipients to inhibit the ABCB1 and ABCC2 efflux 
transporters, the data were presented in a pharmacokinetic format by elucidating the 
amount of excipient required to reduce the transporter activity by 50 %, the IC50 value. This 
approach allowed the excipients to be directly compared in terms of their efficacy, as well 
as a direct comparison to the established inhibitors of efflux.  
 An Examination of Inhibitors of the ABCB1 and ABCC2 Efflux Transporter Systems 4.2.
In order to initially establish the functional activity of the transporters, established 
inhibitors of the efflux transporters were tested in conjunction with the fluorescent probes 
in order to obtain their IC50 values, as outlined in the materials and methods section 
(Section 2.3). The results shown in Figure 4.1 demonstrate that the inhibitors of both 
ABCB1 (VER and CsA) and ABCC2 (IND and PBD) follow a dose-dependent response 
(non-linear regression curves), allowing IC50 values to 95 % confidence to be calculated 
(Table 4.1). The ABCB1 inhibitors VER and CsA give IC50 values of 4.08 and 1.16 μM, 
respectively, with the ABCC2 inhibitors IND and PBD giving IC50 values of 38.08 and 68.08 
μM, respectively. Compared to established literature (Table 4.1), the derived IC50 data for 
the ABCB1 inhibitors aligns well with the published range. For the inhibitors of ABCC2, 
the derived IC50 value for IND also aligns well with published literature, although the 
derived value for PBD is an order of magnitude lower than the published values (Table 
4.1). However, comparative literature IC50 values for IND and PBD as inhibitors of ABCC2-
mediated efflux are limited, despite their prevalence in the literature as common 
modulators of this transporter. In this respect, the study by Heridi-Szabo et al was used to 
derive two further IC50 values from the Ki values given (Heredi-Szabo et al., 2008). These Ki 
values were converted to IC50 values using the Cheng-Prusoff equation (Yung-Chi and 
Prusoff, 1973) shown in Equation 4.1, 
 
Equation 4.1 
 
where Ki is the inhibitor affinity, the IC50 is the concentration of inhibitor that inhibits 50% 
of the transport, [S] is the concentration of the substrate, and Km is the substrate affinity.  
Ki = 
𝐼𝐶50
1+ 
[𝑆]
𝐾𝑚
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From the published values collected in Table 4.1 (Rautio et al., 2006, Wang et al., 2001, 
Perloff et al., 2002, Tamai and Safa, 1991, Colombo et al., 2012, El-Sheikh et al., 2007, Dahan 
and Amidon, 2010, Heredi-Szabo et al., 2008, Förster et al., 2008), it is apparent that the 
variation in the cell line or vesicle type used to determine the IC50 has minimal impact upon 
the IC50 value obtained, as each inhibitor falls within a tight range of values. Moreover, the 
type of probe used has a notable impact: Rautio et al used the Caco-2 platform in the 
Transwell® format, and evaluated the IC50 values of VER using multiple probe substrates 
(Rautio et al., 2006). The inhibition IC50 value of VER was found to be below 11 μM when 
digoxin and prazosin were used as probe substrates, between 17 μM and 34 μM when 
colchicine and vinblastine were used as probe substrates, and 60.9 μM when calcein-AM 
was used as a probe substrate (Rautio et al., 2006). As P-gp has known multiple binding 
sites (Shapiro et al., 1999, Wang et al., 2001), Rautio et al attributed the broad range of 
inhibition IC50 values to the different inhibitors exerting their effects on different binding 
sites within the transporter (Rautio et al., 2006). Taken together, the data present in Figure 
4.1 and Table 4.1 confirm the functionally of the ABCB1 and ABCC2 transporter systems on 
the cell line by using the combination of specific fluorescent probes with established 
inhibitors, subsequently validating the method and providing a foundation for translating 
this work on drug-drug interactions (DDIs) to excipient-drug interactions (EDIs). 
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Figure 4.1. The IC50 curves of inhibitors of efflux proteins, showing activity against A) ABCB1 and B) ABCC2. 
Caco-2 cells were grown for 5-7 days on 96-well plates prior to experimentation. Data presented as each of a 
minimum of 4 replicates from 2.5 μM initial extracellular concentration of either R-123 or CDFDA as probes of 
ABCB1 and ABCC2 activity, respectively. 
  
 
Table 4.1. Literature IC50 values of the inhibitors against those obtained from Caco-2 cells grown for 5-7 days on 96-well plates. Data of determined IC50 values shows the outcome 
of the kinetic modelling using GraphPad Prism presented in Figure 4.1 extrapolated for 50 % transporter inhibition using the sigmoidal curve.  
Drug Structure Transporter Action Reported IC50 (µM) 
Mean 
Determined 
Value (µM) 
Determined 
Upper Value 
(µM) 
Determined 
Lower Value 
(µM) 
      
 
  
    
Verapamil 
 
ABCB1/P-gp 1.18 - 60.9 (Rautio et al., 2006)a 4.08 7.44 2.36 
  4.2 (Wang et al., 2001)b    
  6.5 (Perloff et al., 2002)c    
       
Ciclosporin 
 
ABCB1/P-gp 0.5 (Tamai and Safa, 1991)d 1.16 1.936 0.72 
 
 1.4 (Wang et al., 2001)b    
  0.74-2.22 (Rautio et al., 2006)a    
       
Indometacin 
 
ABCC2/MRP2 25 (Colombo et al., 2012)e 38.99 41.4 36.31 
  46 (El-Sheikh et al., 2007)e    
  75.1 (Dahan and Amidon, 2010)c    
 99  (Heredi-Szabo et al., 2008)e    
       
Probenecid 
 
ABCC2/MRP2 130 (Colombo et al., 2012)e 68.08 77.27 60 
 812 (Heredi-Szabo et al., 2008)e    
 814.8 (Förster et al., 2008)f    
aMDCKII-MDR1 
bMDR1-NIH3T3-G185 
cCaco-2 
dVincristine-resistant Chinese Hamster Lung Cells 
eMRP2 Membrane Vesicles 
fMDCK-ABCC2 
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 An Examination of the Effects of Low Viscosity HPMCs on ABCB1- and ABCC2- 4.3.
Mediated Transport 
Having achieved the first of objectives of this chapter by establishing the functionality of 
the ABCB1 and ABCC2 transporter systems, the next stage was to utilise this assay to 
common excipients which are efflux inhibitors, and to model these in a pharmacokinetic 
manner. To undertake this, hydroxypropyl methylcellulose (HPMC) was selected in the 
first stage of the studies. HPMC is a semi-synthetic polymer system consisting of partly O-
methylated cellulose (Figure 4.2). High-viscosity HPMCs are frequently used in the tablet 
binder role, film coating and as an extended release matrix, whereas the low-viscosity 
HPMCs are favoured for coatings. As one known limitation of this high-throughput 
screening assay is viscosity, especially in those excipients that are able to impart 
mucoadhesion to the cell surface, the HPMCs chosen for evaluation were of the 
METHOCEL LV (low viscosity) type, outlined in Table 4.2. Of these, METHOCEL “E” 
grades are favoured for all coatings, whereas the “K” grades are recommended only for 
sugar coating (DOW, 2002). METHOCEL K grades have poorer flow properties compared 
to E grades with a higher degree of long, fibrous particles than the METHOCEL “E” grades 
(DOW, 2000). 
 
 
Figure 4.2. The general structure of HPMCs, with the degree of substitution of methoxyl or hydroxypropyl (x) 
specific to the grade. 
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Table 4.2. Degree of substitution and viscosity of the METHOCEL LV grade HPMCs. 
HPMC Grade Methoxyl Content (%) Hydroxypropyl Content (%) Viscosity (mPa.s) 
METHOCEL E3 LV 28-30 7-12 2.4-3.6 
METHOCEL E6 LV 28-30 7-12 5-7 
METHOCEL E15 LV 28-30 7-12 12-18 
METHOCEL K3 LV 19-24 7-12 2.4-3.6 
 
 The Effects of Low Viscosity HPMCs on Cellular Viability 4.3.1.
In order to evaluate the toxicological impact of the HPMCs against the Caco-2 cell line, the 
MTT assay was used to probe the mitochondrial vitality under a range of polymer 
concentrations. The results of the toxicological screening are presented in Figure 4.3. These 
materials were well tolerated in the in vitro cell model at concentrations as high as 0.01 % 
(w/v). At higher HPMC concentrations, a small but significant (p < 0.05) reduction in 
apparent viability of approximately 10 to 20 % was observed (Figure 4.3). This apparent 
reduction in the viability of the monolayer may be attributed to residual mucoadhesion of 
these grades masking MTT ingress into the cells, as visual examination confirmed 
monolayer integrity was otherwise uninterrupted (results not shown).  
On the Caco-2 cell line, HPMC K4M and HPMC K100 have been shown to have IC50 
toxicology values of 7.69 and 13.57 mg mL-1, respectively, with the toxicology found to be 
related to molecular weight, with the higher molecular weight (HPMC K4M) showing 
significantly (p < 0.05) higher toxicity (Li et al., 2013a). The viscosity of HPMC has been 
shown to be connected to molecular weight (DOW, 2000), with K100 and K4M having 
viscosities of 100, 000 mPa·s and 4000 mPa·s respectively at 2 % (w/v). The HPMCs tested 
in the present study have much lower molecular weight values (Table 4.2) and 
consequently would be expected to impart much lower toxicities. HPMCs are regarded as 
safe excipients (Burdock, 2007) and have been used up to 20 mg mL-1 on both the HepG2 
and Fa2N4 cell lines (Tompkins et al., 2010). As such, 0.1 % (w/v) was selected as an upper 
limit for efflux probe uptake studies, similar to a concentration used previously on the 
Caco-2 cell line grown in the Transwell® format (Rege et al., 2001). 
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Figure 4.3. The effects of HPMCs on cellular viability using the MTT toxicology assay, showing A) METHOCEL 
E3, B) METHOCEL E6, C) METHOCEL E15 and D) METHOCEL K3. Caco-2 cells were grown for 5-7 days 
on 96-well plates prior to experimentation. Data presented as the mean value of 6 replicates ± SD. Statistical 
significance was analysed using one-way ANOVA followed by Dunnett’s post hoc test annotated as follows: ** (p < 
0.01); **** (p < 0.0001). 
 
 The Effects of Low Viscosity HPMCs on ABCB1- and ABCC2-Mediated 4.3.2.
Transport 
Having established that the low-viscosity HPMCs are non-toxic to the Caco-2 cell line at or 
below 0.1 % (w/v), the next stage of investigation was to examine the impact of these 
excipients on ABCB1- and ABCC2-mediated efflux. The results of the screening study are 
presented in Figure 4.4. Over the concentrations tested, no significant (p > 0.05) impact 
upon either transporter activity could be seen, and fluorescent signal remained stable for 
each test solution relative to control (Figure 4.4). Therefore, the data does not fit the non-
linear sigmoidal regression line shown in Figure 4.1. Although the other materials in this 
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study have much lower viscosity than the HPMCs, and therefore less likely to alter the 
diffusional path of the tracer probes used, the wide concentration range used in this study 
should have negated the possibility of such interference on probe uptake. Therefore, it can 
be concluded that the low viscosity HPMCs have no efflux modulating capacity. 
 
HPMC is frequently used as a matrix excipient in a number of formulation studies, and has 
been examined individually as an inhibitor of P-gp. Similar to the findings in Fig 4.4, using 
the Caco-2 Transwell® model, 0.012 % (w/v) HPMC E5 Premium LV has been shown to 
have no significant impact upon the apical to basolateral transport of the three P-gp 
substrate drugs atenolol, ranitidine and acyclovir (Rege et al., 2001). During the testing of a 
binary solid dispersion (SD) containing Solutol HS-15 and HPMC 2910, analogous to 
HPMC METHOCEL ‘E’ grade, the latter material individually showed no significant (p > 
0.05) impact upon the uptake of R-123 in ovarian NCI/ADR-RES cells overexpressing P-gp 
(Han and Lee, 2011). Furthermore, as part of a wider screening of a number of excipients 
on the rat everted gut sac model, HPMC had no significant (p > 0.05) impact upon the 
transport of the P-gp substrate domperidone (Al-Mohizea et al., 2014). During the 
development of a hot-melt formulation of propranolol contained in a HPMC-Gelucire® 
44/14, 0.0128 % (w/v) HPMC Premium K100 was excluded as a P-gp inhibitor whilst 
Gelucire was shown to have inhibitory properties on the Caco-2 Transwell® model 
(Mehuys et al., 2005). Indeed, the HPMCs do not contain the structure expected of an 
inhibitor of efflux, such as a hydrophobic core and hydrophilic extensions. Therefore, the 
data presented herein are in agreement with existing literature. 
  
  
Figure 4.4. The effects of HPMCs on the uptake of the ABCB1 and ABCC2 specific probes R-123 and CDF (CDFDA) respectively, showing A) METHOCEL E3, B) 
METHOCEL E6, C) METHOCEL E15 and D) METHOCEL K3. Caco-2 cells were grown for 5-7 days on 96-well plates prior to experimentation. Data presented as each 
replicate from a minimum of four data values as a function of overall R-123 or CDF (CDFDA) uptake for ABCB1 and ABCC2 respectively with initial conditions of 2.5 µM 
extracellular tracer dye per well, with excipient-free control wells set to 100 % transporter activity. 
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 An Examination of the Effects of Polyethylene Glycols Against ABCB1- and ABCC2-4.4.
Mediated Transport 
In Chapter 3, PEG 8000 and POLYOX N-10, a PEO, were shown to increase the rate of IND 
transport through Caco-2 monolayers grown in the Transwell® format (Figure 3.4 and 
Figure 3.5). In order to examine the impact of polymeric molecular weight on the efflux 
inhibition, the PEGs were re-examined using the HTS assay. Polyethylene glycols (PEGs), 
both as stand-alone materials and as the hydrophilic chains of larger and more complex 
compounds, are ubiquitous within the pharmaceutical industry, and the biological effects 
of PEGylated excipients were amongst the first to be implicated in the reversal of multiple 
drug resistance (MDR) (Ueda et al., 1987). PEGs are linear hydrophilic polymers consisting 
of repeating monomer units (Figure 4.5). They are generally well tolerated in vivo, used as 
an excipient in a variety of roles from water-miscible plasticisers, solvents to suspension 
agents (Rowe et al., 2009). PEGs over 20 kDa are known as polyethylene oxides. 
 
 
 
Figure 4.5. The general structure of a PEG monomer, where n is the average number of repeat units, with the 
name of the polymer based on its average molecular weight. 
 
 
 The Effects of PEGs on Cellular Viability 4.4.1.
PEGs as excipients are well known for their low toxicity, regardless of their route of 
administration (Rowe et al., 2009). However, in order to assess the level of toxicity of the 
PEGs to the Caco-2 cell line, the MTT assay was used to measure mitochondrial activity. 
The results are presented in Figure 4.6. Apparent viability decreased with increasing PEG 
concentrations with the exception of PEG 400. For the remaining PEGs, apparent viability 
decreased significantly (p < 0.0001) at 10 % (w/v), with additional decreases seen at 1 % 
(w/v) PEG 8000 and POLYOX (p < 0.01). Even at 10 % (w/v) for all the PEGs tested, 
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monolayer integrity was confirmed using light microscopy (results not shown). Therefore, 
the decrease in apparent viability is most likely attributed to the reduction in 
thermodynamic activity in the extracellular space owing to the increased viscosity at higher 
PEG concentrations, thereby limiting the availability of MTT. A similar effect has been 
noted in a study examining the permeability of carbamazepine through rabbit intestine 
(Riad and Sawchuk, 1991). In this study, the permeability of the drug was found to 
decrease proportionally to the concentration of PEG 400 used as a cosolvent, essentially 
limiting the bioavailability of the drug (Riad and Sawchuk, 1991). 
PEGs 400, and 20000 have been used as high as 20 % (w/v) on the rat model (Shen et al., 
2006), and PEG 300 as high as 20 % (v/v) on the Caco-2 Transwell® model without loss of 
TEER (Hugger et al., 2002a, Hugger et al., 2002b), albeit present on both sides of the 
monolayer to equilibrate osmolality. In order to comply with the Transwell® study using 
IND presented in Chapter 3 (Figure 3.3-3.5), 1 % (w/v) was chosen as an upper 
concentration limit to encompass the previous inhibition range. 
  
 
Figure 4.6. The effects of PEGs on cellular viability using the MTT toxicology assay, showing A) PEG 400, B) PEG 4000, C) PEG 8000, D) PEG 12000, E) PEG 20000 and F) 
POLYOX N-10. Caco-2 cells were grown for 5-7 days on 96-well plates prior to experimentation. Data presented as the mean value of 6 replicates ± SD. Statistical significance was 
analysed using one-way ANOVA followed by Dunnett’s post hoc test annotated as follows: ** (p < 0.01); **** (p < 0.0001).  
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 The Effects of PEGs on ABCB1- and ABCC2-Mediated Transport 4.4.2.
Using the HTS protocol developed in Chapter 3, PEGs of various molecular weights were 
examined for their effects against ABCB1- and ABCC2-mediated efflux. The results are 
presented in Figure 4.7. Over the concentration range tested, none of the PEGs had a 
significant (p > 0.05) impact upon the intracellular accumulation of either of the fluorescent 
probes, and do not fit the non-linear sigmoidal regression line shown by the established 
inhibitors in Figure 4.1. The PEG concentration range was chosen to exceed the previous 
concentration used in the Transwell® study in order to anticipate the lower plateau of an 
IC50 curve. In Chapter 3, PEG 8000 and POLYOX N-10, a PEO, were shown to increase the 
rate of IND transport in the apical to basolateral direction of transport at 0.0119 % (w/v) 
(Figure 3.4 and Figure 3.5), but not in the basolateral to apical direction (Figure 3.7). This is 
indicative of efflux transporter modulation, either directly through membrane fluidisation 
or by bypassing the transporter by the opening of tight junctions and enhancing the 
paracellular route. In the present study, concentrations of up to 1 % (w/v) were unable to 
generate an IC50 curve. At concentrations above this, the viscosity began to impact probe 
mobility (Riad and Sawchuk, 1991) (Figure 4.6). 
PEGs were amongst the first excipients identified as inhibitors of efflux, and have been 
studied extensively. In an extended in vitro and in situ study, Qi Shen et al examined the 
effects of PEG 400, 2000 and 20000 (Shen et al., 2006). The excipients and concentrations 
chosen herein encompassed this range intentionally, albeit with a different outcome. In the 
study by Shen et al, R-123 was also used as a P-gp substrate using the rat model, and the 
PEGs were used at concentrations up to 20 % (w/v) with the majority of inhibition (p < 0.01) 
occurring below 1 % (w/v) for PEG 400 and PEG 20000 (Shen et al., 2006). Whilst specific, 
R-123 is well known as an intracellular marker – actually a mitochondrial stain – and has 
poor passive diffusional capability through monolayers (Störmer et al., 2001). The increase 
in uptake seen with these PEGs could well be attributed to increased drug transport via 
another route such as passive diffusion via tight junctions.  
In a separate series of studies, Hugger et al was able to demonstrate the efficacy of PEG 300 
on the Caco-2 Transwell® model, but only at higher concentrations up to 20 % (v/v), a 
concentration affected by viscosity on our study (Hugger et al., 2002a, Hugger et al., 
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2002b). Another study has concluded no significant (p > 0.05) efficacy of PEG 1000 as stand-
alone inhibitor of P-gp at the same concentration that TPGS 1000 was able to elicit an effect 
(0.005 % % (w/v) (Collnot et al., 2006). Although low in toxicity, PEGs are high in viscosity 
in higher concentrations, making them difficult materials to work with for the HTS assay. 
Higher concentrations of PEGs will no doubt impact upon the speed of delivery with 
concentrations of the PEGs at or over 0.1 % (w/v) decreased the cellular uptake of the dyes 
compared to the non-treated controls, most probably attributed to altered diffusional paths 
of the probes by the increased viscosity of the polymers at these concentrations and so 
reduction in thermodynamic activity (Riad and Sawchuk, 1991). A study using the Caco-2 
Transwell® model has shown that PEG 400 was able to decrease the permeability of the P-
gp substrates atenolol, ranitidine and acyclovir at 1.5 % (w/v), similar to the concentration 
used herein, interpreted as the immobilisation of the drugs by high viscosity (Rege et al., 
2001). In the study herein, the focus of the assay was direct efflux inhibition since the 
modulation of the paracellular route cannot be detected and this strength of the HTS model 
is also its weakness: any material which is high in viscosity may slow down dye ingress by 
altering the diffusional path and/or creating a mucoadhesive gel that favours retention of 
the dye into the extracellular space. Therefore, the most intriguing detail between the data 
presented herein and that of the literature is the exact format of the model used. Whilst the 
Caco-2 platform is a well-established model of intestinal absorption, most work on the 
inhibition properties of PEGs focuses on the Transwell® format where the 3-dimensional 
aspect of the model may work in the favour of proponents of PEGs as efflux inhibitors. In 
the HTS protocol designed and validated in the previous chapter, only intracellular 
accumulation of dye by direct inhibition of efflux can be detected, whereas the Transwell® 
format allows the possibility of other modes of efflux avoidance, such as the opening of 
tight junctions, and so allowing the bypass of efflux entirely. However, most groups 
working on this would establish that tight junctions remain intact during the experiments, 
either by measuring membrane resistance or using a poor paracellular marker such as 
mannitol to assess monolayer integrity. These methods are a good guide to monolayer 
integrity, but by no means infallible. Our previous work on Transwell® model 
demonstrated the difficulty in obtaining stable TEER values before and after 
experimentation. Even the effects of the buffer in use played a role in the value, as well as 
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temperature and the age of the media (results not shown). In our previous studies, fresh 
serum-containing media was always used to measure TEER before and after each study, 
requiring cells to be washed and refilled after each experiment. Modulation to the 
paracellular route by the opening of tight junction has been shown to be transient on the 
Caco-2 cell line (Anderberg et al., 1992, Lindhardt and Bechgaard, 2003). Therefore, the 
interpretation of the data is that the permeability enhancing effects of PEGs appears model-
dependent. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. The effects of PEGs on the uptake of the ABCB1 and ABCC2 specific probes R-123 and CDF (CDFDA) respectively, showing A) PEG 400, B) PEG 4000, C) PEG 
8000, D) PEG 12000, E) PEG 20000 and F) POLYOX N-10. Caco-2 cells were grown for 5-7 days on 96-well plates prior to experimentation. Data presented as each replicate 
value from a minimum of triplicate data values. 
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 An Examination of the Effects of Poloxamers and Tweens on ABCB1- and ABCC2-4.5.
Mediated Transport 
The screening of PEGs over a range of molecular weights showed a lack of inhibition 
properties against the ABCB1 and ABCC2 transporter systems. PEGs are hydrophilic 
polymers, which may have a limited propensity to interact with cell membranes where the 
efflux transporters are expressed. As such, excipients of a more complex composition were 
examined which have a higher propensity for interacting with the membranes of cells. 
Poloxamers and Tweens are non-ionic amphiphilic surfactants commonly used as 
excipients (Figure 4.8). Poloxamers are triblock copolymers consisting of a hydrophobic 
core of poly(propylene oxide)(PPO) flanked on either side by hydrophilic chains of 
poly(ethylene oxide) (PEO). These molecules can be precisely customised to give rise to a 
plethora of hydrophilic-lipophilic balance (HLB) values and molecular weights by 
optimising the precise PPO to PEO chain length. Due to the broad specificity of poloxamers 
of various types, they are used as emulsifiers, gelling agents, tablet coatings and wetting 
agents (Rowe et al., 2009). Tweens, also known as polysorbates, consist of sorbitan core 
from which chains of PE and a lipophilic chain emanate. The most common Tweens used 
as excipients are Tween 20 and Tween 80, containing lauric and oleic lipophilic groups, 
respectively. Both of these Tweens contain 20 units of PEO, making them favourably 
hydrophilic and suitable for emulsification, solubilisation and wetting agents. (Rowe et al., 
2009). As these excipients present a broad range of HLB values, molecular weights and 
structures (Table 4.3), the poloxamers and Tweens were chosen for HTS for activity against 
the ABCB1 and ABCC2 transporter system. 
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Figure 4.8. The general structures of A) Poloxamers and B) Tweens. Poloxamers consist of a hydrophobic 
poly(propylene oxide) (PPO) core (y) flanked by poly(ethylene oxide) (PEO) chains (x and z), the precise 
composition of which give rise to the HLB of the polymer. Tweens consist of ethoxylated sorbitan esterified with 
fatty acids. The Tween shown is Tween 20 with a lauric acid lipophilic group, whereas Tween 80 contains an oleic 
acid group. 
 
Table 4.3. The range of surfactants selected for initial HTS according to the hydrophilic-lipophilic balance values. 
Excipient HLB Molecular Weight State 
Poloxamer 182 7.0 2500 Liquid 
Poloxamer 184 13.0 2900 Liquid 
Tween 80 15.0 1310 Liquid 
Tween 20 16.7 1128 Liquid 
Poloxamer 335 18.0 6500 Solid 
Poloxamer 407 22.0 12500 Solid 
Poloxamer 188 29.0 8400 Solid 
 
 
 The Effects of Poloxamers and Tweens on Cellular Viability 4.5.1.
Surfactants have a high propensity to interact with a lipid bilayer, and in doing can 
eventually breach the cell membrane and cause loss of cellular viability. As such, the first 
investigation into the biological effect of excipients must be to delineate direct efflux 
inhibition from toxic and/or non-specific mechanisms. Therefore, the MTT assay was used 
in order to assess the cellular viability in relation to non-treated control cells (Figure 4.9). 
Most materials tested for toxicology using the MTT assay will display a ‘step down’ profile 
e.g. the cellular viability decreases as a function of concentration of test excipient, resulting 
in a reduction in formazan production and, therefore, a reduction in percentage viability in 
relation to the non-treated control. Interestingly, an artefact possibly unique to the Caco-2 
cell line was noticed during the MTT assays. Some materials gave statistically significant (p 
Pollard J 
153 
 
< 0.05) increases in apparent cellular viability owing to intense bands of formazan formed 
in cells treated by higher concentrations of certain excipients (Figure 4.9). Poloxamers 184, 
335 and 407 all displayed these increases (Figure A.1k, Figure A.1w, and Figure A.1y of the 
appendix, respectively). Poloxamer 182 also displayed stronger purple bands of formazan 
in higher concentrations but these crystals dislodged during draining of the MTT prior to 
the addition of the isopropanol solvent, and so these bands are not represented on the 
graph (Figure 1.Ae of the appendix). This information is difficult to interpret and the effects 
were observed over two independent passage numbers. This is most likely attributed to the 
efflux inhibition properties of these compounds – MTT as a classic ‘toxin’ may well be an 
apparent efflux substrate, most likely of ABCB1 or another undetermined transporter 
cascade. Whilst the interference to the MTT assay by other endotoxins has been noted 
before with regards to certain drugs which are known inhibitors of efflux transporters 
(Vellonen et al., 2004), this is the first time this phenomenon has been observed in relation 
to excipients. Moreover, this effect serves as an early indication as to the efficacy of the 
materials for efflux inhibition. As such, the MTT toxicology assay cannot be taken at prima 
facie, and must be used in concert with a working knowledge of the novel aspects of the 
Caco-2 cell line and its associated morphology over different experimental conditions. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Typical (A) and atypical (B) MTT profiles presented after incubation with various concentrations of A) Poloxamer 188 and B) Poloxamer 407. Caco-2 cells were grown 
for 7 days on the smooth plastic of 96-well plates before 4 hour exposure to the excipients and 3 hours incubation with MTT. Note the increase in formazan production for wells 
containing higher concentrations of poloxamer 407 shown by the increase in the purple intensity despite the same initial concentrations of MTT. Also note that the bands of the 
highest intensity, poloxamer 407 at 10 % (w/v), do not correspond to the highest bar on the chart. Formazan production was of such intensity that crystals typically dislodge during 
draining of the MTT solution prior to isopropanol addition, and so do not have a representative bar on the chart. Morphological examination of the cells under such concentrations 
using light microscopy clearly showed cells in distress. Data shown as mean ± SD from a minimum of 8 replicates over 2 passage numbers. Statistical significance was analysed 
using one-way ANOVA followed by Dunnett’s post hoc test annotated as follows: ** (p < 0.01); **** (p < 0.0001). 
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 The Effects of Poloxamers and Tweens on ABCB1- and ABCC2-Mediated 4.5.2.
Transport 
Using the HTS method, poloxamers and Tweens were tested for activity against ABCB1- 
and ABCC2-mediated transport. Contrary to PEGs, the biological effects of the poloxamers 
and Tweens were on the whole profound. Both of the Tweens and 4 out of the 5 
poloxamers tested yielded data from which IC50 values could be determined for ABCB1 
inhibition with over 95 % confidence (Figure 4.10). Particularly with the use of surfactants 
such as poloxamers and Tweens, no single unifying mechanism of inhibition appears to 
exist and is most likely a multi-faceted process. Membrane fluidisation is thought to be the 
cardinal mechanism for inhibition (Sinicrope et al., 1992). During this study, we have taken 
care to eliminate the effects of interference of membrane damage within the limits of 
viability, so we are able to exclude the possibility of severe loss of integrity as a major form 
of probe ingress. It has long been known that membrane fluidisation is a fundamental 
factor in efflux inhibition due to the sensitivity of ABC transporters such as P-gp to their 
microenvironment (Sinicrope et al., 1992), in particular P-gp ATPase activity (Regev et al., 
1999). A comparable study examined Pluronic L85 (poloxamer 235), similar in HLB to 
poloxamer 184 and 335 used in this study, as an efflux inhibitor of P-gp, MRP1 and MRP2 
(Batrakova et al., 2004). Using porcine kidney epithelial cells overexpressing these 
transporters, the degree of ATPase inhibition was observed in the order MRP1 < MRP2 << 
P-gp, attributed to conformation changes of the transporter via membrane fluidisation 
and/or steric hindrance of drug-binding sites by P85 side chains. This difference in the 
degree of inhibition is similar to the results in Figure 4.10. Whilst Batrakova et al suggest 
that MRP structures may be more robust and resilient to alterations in fluidisation, they 
also suggest that the differences in the overall structures between P-gp and the MRP 
isoforms may also play a significant role by having a binding site which is inaccessible to 
the long side chains of poloxamers. This could explain why none of our excipients yielded 
sufficient inhibition data to give an IC50 value for ABCC2 inhibition (Figure 4.10). 
The differences in the biological effects of the PEGs and poloxamers may give us some 
insight into the structure/function relationship of efflux inhibitors. PEGs constitute the 
hydrophilic elements of the poloxamers, which are found flanking the hydrophobic core. 
From our data, it would be apparent that membrane interaction and subsequent 
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fluidisation requires the prerequisite of both hydrophilic and hydrophobic elements. More 
intriguingly, closer examination of our current data set would identify a trend in the 
efficacy of the poloxamers as ABCB1 inhibitors. This trend appears to show that not only is 
the hydrophobic and lipophilic composition necessary, there is also an optimum. PEGs are 
entirely hydrophilic and gave no IC50 data in this model (Figure 4.7). Likewise, poloxamer 
188, with a HLB of 29, had no significant impact either (Figure 4.10). Clearly more 
information would be needed to examine this trend, but it is entirely plausible that a 
compound should possess hydrophilic and lipophilic elements in the correct composition 
in order to impart specific levels of fluidisation upon the cell membrane. Hydrophilic 
compounds may not interact with cell membranes at all, whereas a highly lipophilic 
compound may in fact lead to membrane reinforcement and a subsequent increase in 
membrane rigidity (Batrakova et al., 2003). The relationship between these two properties 
may not be linear, but parabolic in nature, and warrants further exploration over a greater 
range of compounds. 
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Figure 4.10. ABCB1 and ABCC2 modulation of the poloxamers and Tweens, showing A) Poloxamer 182, B) 
Poloxamer 184, C) Poloxamer 407, D) Poloxamer 335, E) Poloxamer 188, F) Tween 80 and G) Tween 20. Data 
presented as a function of overall R-123 uptake with initial conditions of 2.5 µM extracellular tracer dye, with non-
treated controls set to 100 % transporter activity. Data shown pooled from a minimum of 5 replicates per 
concentration ± SD. 
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 The Effects of Poloxamers and Tweens on Caco-2 Membrane Integrity 4.5.3.
As mentioned, surfactants by their nature are able to interact with cell membranes, and it is 
through this mechanism that potential damage could occur by which extracellular R-123 
may enter the cell, bypassing efflux. Therefore to assess the level of membrane damage, the 
cells were incubated at 37 oC for 1 hour in the presence of the excipients and without tracer 
dye. The plate was then removed and placed at 4 oC. R-123 was then added to the cells. The 
results are presented in Figure 4.11. At this temperature, all ATP-driven processes, 
including efflux, should be inhibited and drug entry into the cells is a result of the cell 
membrane damage.  
From these results in Figure 4.11, it is shown that for all 7 surfactants tested at 
concentrations below 0.01 % (w/v), no significant (p > 0.05) increase in R-123 uptake was 
observed. This confirms that the increase in probe uptake seen in Figure 4.10 is connected 
to an ATP-driven process and not the result of surfactant-induced membrane damage. The 
central objective of this chapter was to screen for excipients that inhibit efflux transporters, 
and this required delineation on non-transporter related mechanisms of the excipients 
which could impact the accuracy of screening assay. Surfactant-induced damage could 
increase the ‘leakiness’ of the cell membrane and provide additional route of tracer dye 
ingress, which did occur at concentrations above 0.01 % (w/v). Above these concentrations, 
the surfactants promoted membrane damage, leading to a rise in fluorescent signal, as 
more R-123 was able to achieve cellular ingress, and/or severe morphological damage 
(Figure 4.11). 
Surfactant-induced toxicity is dependent upon the ability to partition the cell membrane 
and the aqueous phase. The rate-limiting step in surfactant membrane partitioning is the 
formation of a free area in the membrane surface with sufficient room for amphiphile 
addition (Sampaio et al., 2005). Confluent epithelial cells, such as the polarised Caco-2 cell 
line, have a highly ordered membrane with defined tight junctions, making them less 
prone to surfactant-induced cell damage than non-polarised cells, such as the HeLa cell 
line, which have less ordered membrane structures (Inácio et al., 2011). 
In order to delineate the effects of surfactant-induced membrane damage from inhibition of 
efflux transport, Bogman et al used two otherwise identical cell lines (P388), one which 
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expressed P-gp and the other which had no P-gp expression (Bogman et al., 2003). At lower 
concentrations, the surfactants were able to increase the uptake of R-123 only for cells 
expressing P-gp which the authors attributed to efflux inhibition, but at higher surfactant 
concentrations, the cellular uptake of R-123 was also increased for the cells which did not 
express P-gp which the authors attributed to membrane damage (Bogman et al., 2003). In 
another investigation examining the role of Tweens as permeability enhancers using the 
Caco-2 cell line, it was found that higher surfactants concentrations above the critical 
micelle concentration (CMC) were able to solubilise membrane components rather than the 
membrane itself, with severe damage occurring at higher concentrations similar to those 
seen in Figure 4.11 (Dimitrijevic et al., 2000). Indeed, Tween 80 has been shown to damage 
cell membranes at higher concentrations (Ujhelyi et al., 2012, Roohinejad et al., 2014). Using 
both MTT in addition to measuring the activity of the cytoplasmic enzyme lactate 
dehydrogenase (LDH) in the extracellular medium as an evaluation of membrane integrity, 
it was observed that concentrations of non-ionic surfactants close to the CMC cause acute 
toxicity in Caco-2 cells (Inácio et al., 2011). Below the CMC, no toxicity was recorded 
suggesting membrane destruction as the mode of toxicity (Inácio et al., 2011). However, 
cationic surfactants were able to impart toxicity well below their CMC values (Inácio et al., 
2011). 
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Figure 4.11. The uptake of R-123 in the absence of ATP synthesis, showing A) Poloxamer 182, B) Poloxamer 184, 
C) Poloxamer 407, D) Poloxamer 335, E) Poloxamer 188, F) Tween 80 and G) Tween 20. Cells were incubated in 
the presence of surfactants for 1 hour at 37 oC, then rinsed in ice cold KH buffer (pH 7.4) and incubated at 4 oC in 
the dark in the presence of 100 nM R-123. Data shown ± SD from data pooled from 5 replicates in relation to the 
surfactant-free control (KH buffer only) replicates. Statistical significance was analysed using one-way ANOVA 
followed by Dunnett’s post hoc test annotated as follows: ns (p > 0.05); * (p < 0.05); ** (p < 0.01); **** (p < 0.0001). 
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 The Effects of Poloxamers and Tweens on Micelle Encapsulation of the Tracer 4.5.4.
Dye R-123 
Alongside toxicity, the role of quenching was also examined to remove the possibility of 
contrived inhibition data via the encapsulation of dye into micelles and/or implicate a 
method of bypassing efflux transporters by delivering the tracer probe safely through the 
cell membrane by endocytosis. As such, the poloxamers and Tweens were examined for 
encapsulation by studying the phenomenon of quenching using R-123 as the tracer probe 
in the absence of cells. The results are presented in Figure 4.12. 
Poloxamers had no significant (p > 0.05) influence on the fluorescence intensity of R-123 up 
to 10 % (w/v) at or above their reported CMC values, and the data best fits linear regression 
(Figure 4.12). In contrast, the Tween 20 and Tween 80 both showed a decrease in 
fluorescence intensity, becoming significant (p < 0.01) at 0.1 % (w/v) and 0.5 % (w/v) 
respectively in relation to the control wells containing only KH buffer (Figure 4.12). This 
reduction is most likely attributed to micelle formation, since this reduction in fluorescence 
intensity only occurs at concentrations above the CMC (Figure 4.12). 
In a similar study to the present one, Bogman et al tested the ability of various surfactants 
to quench the fluorescent probes R-123 and CDF (Bogman et al., 2003). It was found that 
poloxamer 188 did not quench either fluorescent marker, but Tween 80 was able to quench 
both, but only above its CMC (Bogman et al., 2003) similar to the data presented in Figure 
4.12. Interestingly, it was noticed that the apparent CMC of Tween 80 was about 10-fold 
higher in the presence of cells, attributed to the defection of Tween monomers to cell 
membrane partitioning, and so reducing the free monomers in the supernatant (Bogman et 
al., 2003). This could suggest that many of the published CMC values may be 
underestimates when cells are factored into the assay. 
It is interesting to note that this quenching effect occurs much beyond the CMC values 
reported in literature. The values obtained from published literature are generally 
conducted at a lower temperature than those in present study, where biological conditions 
were simulated by using an incubator at 5 % CO2 at 37oC, except for the study by 
Alexandridis et al who used a higher temperature to induce poloxamer 188 CMC formation 
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(Alexandridis et al., 1994). It would be expected that the elevated temperature used in this 
study would aid the formation of the micelles of non-ionic surfactants, although this may 
be offset by the ‘shift’ in the CMC owing to loss of monomer to membrane partitioning 
(Bogman et al., 2003). Furthermore, the CMC values quoted within the literature are 
conducted in distilled water, whilst the data obtained herein used KH buffer to replicate as 
closely as possible the conditions of the uptake assay. As all of the surfactants used are 
non-ionic, the presence of electrolytes such as sodium chloride in solution should not 
impact CMC formation (Acharya et al., 1997). The quenching of R-123 at higher 
concentrations of Tweens was only around 10 % in relation to non-treated controls at the 
highest concentrations of surfactant (Figure 4.12). In general, given that the amphiphilic 
marker R-123 appears to have poor micelle association suggests their contribution to the 
fluorescent probe transport is negligible in this assay (Figure 4.12).  
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Figure 4.12. Rhodamine 123 (50 nM) was incubated for 2 hours at 37 o C in the presence of various concentrations 
of poloxamers and Tweens in the absence of cells in order to assess the contribution of the excipients to tracer dye 
quenching, showing A) Poloxamer 182, B) Poloxamer 184, C) Poloxamer 407, D) Poloxamer 335, E) Poloxamer 
188, F) Tween 80 and G) Tween 20. Data presented in relation to the surfactant-free control (KH buffer only) 
wells ± SD from at least 6 individual replicates. CMCs (dashed line) obtained from literature (P182 from (Tiberg et 
al., 1991), measured at 23 oC, P407, P335 and P184 measured at 30 oC and P188 measured at 40 oC (Alexandridis 
et al., 1994), Tween 80 and Tween 20 from (Patist et al., 2000) measured at 22 oC). Statistical significance was 
analysed using one-way ANOVA followed by Dunnett’s post hoc test annotated as follows: ** (p < 0.01). 
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 An Examination of the Effects of Surfactants on ABCB1- and ABCC2-Mediated 4.6.
Transport 
In the previous section, a small cross section of surfactants was examined for their efflux 
inhibition properties. This screening found 5 inhibitors of the ABCB1 efflux transporter. 
Surfactants are often categorised according to their use (Table 4.4), ranging from water-oil 
emulsifying agents at low HLB values to solubilising agents in the higher HLB range 
(Griffin, 1946). In order to expand on the study of poloxamers and Tweens, additional 
surfactants were obtained incorporating a wider range of HLB values from lipophilic 
molecules with a HLB of 4.5 to hydrophilic molecules with a HLB of 29 (Table 4.5). These 
excipients were specifically chosen for variations in structure and molecular weights, and 
were evaluated for their impact on ABCB1- and ABCC2-mediated transport. 
 
Table 4.4. The utilisation of surfactants based on their HLB values (Griffin, 1946). 
HLB Use 
4-7 Water-oil 
emulsifiers 7-9 Wetting agents 
8-18 Oil-water 
emulsifiers 13-15 Detergents 
15-18 Solubilising agents 
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Table 4.5. The range of surfactants selected for HTS according to the hydrophilic-lipophilic balance values. 
Excipient HLB 
Capmul PG-12 5.0 
Capmul MCM 5.5 
Capmul MCM C8 5.5 
Capmul PG-8 6.0 
Poloxamer 182 7.0 
Span 20 8.6 
Arlatone TV 9.0 
Crovol A-70 10.0 
Etocas 29 11.7 
Brij S-10 12.4 
Poloxamer 184 13.0 
Etocas 40 13.0 
Brij CS-12 13.4 
Acconon C-44 13.5 
NatraGem S140 14.0 
Acconon MC8-2 14.5 
Tween 80 15.0 
Cetomacrogol 1000 15.7 
Tween 20 16.7 
Myrj S-40 16.7 
Poloxamer 335 18.0 
Myrj S-100 18.8 
Poloxamer 407 22.0 
Poloxamer 188 29.0 
 
 Effects of Surfactants on Cellular Viability 4.6.1.
In order to find acceptable doses of the surfactants to use on the cells, the mitochondrial 
activity of the Caco-2 monolayer was probed using the MTT assay. As all of the materials 
chosen for investigation are surfactants, they have a high propensity to interact with lipid 
membranes and therefore impart specific toxicities. Some materials such as the Etocas were 
tolerated well, at least as high as 0.1 % (w/v), whereas others were found to be toxic as low 
as 0.0001 % (w/v) for Brij CS-12, S-10 and Cetomacrogol 1000 (Figure A.1 of the Appendix). 
Despite the differences in nomenclature, the latter three compounds are closely related as 
PEGylated stearyl/cetostearyl ethers with varying lengths of the hydrophilic regions, and 
collectively these form the most toxic of the series tested. Morphological examination using 
light microscopy revealed that the cause of toxicity as damage ranged from altered cellular 
morphology, to monolayer fragmentation and, in the higher concentrations of some 
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excipients, complete removal of the monolayer (results not shown). Of the materials tested, 
Arlatone TV, Myrj S40, NatraGem S-140, Acconon C44 and Span 20 displayed distinctive 
‘step up’ signature in a concentration dependent manner, indicating an apparent 
propagation in mitochondrial activity, previously attributed to efflux inhibition, 
presumably ABCB1, which results in higher intracellular accumulation of MTT and 
subsequent increase in formazan production in the mitochondria of the treated cells. 
However, these upward inflections were often able to mask certain toxicities and are 
therefore difficult to interpret, and monolayers were fragile during screening of some 
excipients in higher doses indicated to be non-toxic by MTT. Once more, the MTT 
toxicology assay was supplemented with visual confirmation of monolayer integrity using 
a working knowledge of the cell line. 
 Effects of the Surfactants on ABCB1- and ABCC2-Mediated Efflux 4.6.2.
In order to examine the underlying structural relationship between surfactants and efflux 
inhibition, a broad range of compounds encompassing different HLB values, molecular 
weights and structural composition were screened. The results are presented in Figure 4.13. 
Of the 24 tested, 12 yielded data from which IC50 values could be determined for ABCB1 
inhibition with over 95 % confidence (Figure 4.13) with the remaining excipients 
correlating with linear regression and therefore showing no efflux activity (data not 
shown). Only Etocas 29 and 40 gave confident inhibition against ABCC2 (16.2 µM and 12.9 
µM). Against ABCB1, the excipients gave the rank order poloxamer 335, poloxamer 407, 
Myrj S-40, Crovol A-70, poloxamer 184, poloxamer 182, Etocas 40, Tween 20, Etocas 29, 
Tween 80, Acconon C-44 and Span 20. Of all the excipients, Span gave by far the highest 
IC50, with an unprecedented value of 7.7 mM (Table 4.6). This IC50 curve is very steep, 
occurring within the higher concentrations that were toxic to most materials. Excluding 
Span 20, the remaining excipients had IC50 values of 26.5 μM or below. The excipients with 
the lowest values, poloxamers 335 and 407, showed IC50 values of 0.63 and 0.71 μM (Table 
4.6), exceeding that of VER (4.08 μM) and CsA (1.16 μM) (Table 4.1). Of the materials to 
give the ‘step up’ MTT signature, only Arlatone TV and NatraGem S140 failed to give 
corresponding IC50 curves against ABCB1, possibly due to the higher levels of toxicity of 
these materials occurring before inhibition could occur. 
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Figure 4.13. Percentage inhibition curves of various surfactants against ABCB1 showing A) Poloxamer 182, B) 
Span 20, C) Crovol A70, D) Etocas 29, E) Poloxamer 184, F) Etocas 40, G) Acconon C44, H) Tween 80, I) 
Tween 20, J) Myrj S40, K) Poloxamer 407 and L) Poloxamer 335. Sigmoidal curves were constructed from 4 
different passage numbers on confluent Caco-2 monolayers grown on 96 well plates for 5-7 days and are shown 
pooled from a minimum of 4 replicates per concentration. Data presented as a function of overall R-123 or CDF 
(CDFDA) uptake for ABCB1 and ABCC2 respectively with initial conditions of 2.5 µM extracellular tracer dye per 
well, with excipient-free control wells set to 100 % transporter activity. 
 
Despite the inherent biological effects of excipients being well established, supporting 
kinetic data in the literature is difficult to find. Tween 80 has been shown to have an IC50 of 
152 µM for inhibition against P-gp using MDR1 overexpressing mouse lymphocytes 
(P388/mdr) using R-123 as a substrate (Bogman et al., 2003). The results of the present 
study, 12.67 µM (Table 4.6), is much lower than the previously reported value and may be 
attributed to the low membrane partitioning of P388/mdr cells by Tween 80 which could be 
cell type specific. However, the same study also gave the IC50 value for poloxamer 181, 
with a HLB of 3, as 0.01 % (w/v). The lowest HLB value of a poloxamer that we tested, 
P182, has a HLB of 7, and we determined an IC50 of 0.00219 % (w/v), which is within this 
range. As in our study, the group raised no significance modulation in the presence of P188 
to either ABCB1 or ABCC2. 
The mechanism of action of these materials against ABCB1 is most likely a multi-faceted 
process involving, amongst others, ATP depletion by the inhibition of ATPase (Batrakova 
et al., 2001, Batrakova and Kabanov, 2008) and/or membrane fluidisation (Hugger et al., 
2002a, Lo, 2003). Membrane fluidisation is a fundamental factor in efflux inhibition due to 
the sensitivity of ABC transporters to their microenvironment (Sinicrope et al., 1992), in 
particular P-gp ATPase activity (Regev et al., 1999). Using porcine kidney epithelial cells 
overexpressing P-gp, MRP1 and MRP2, a similar study has examined Pluronic P85, similar 
in HLB to poloxamers 184 and 335 used in our study, as an efflux inhibitor (Batrakova et 
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al., 2004). The degree of ATPase inhibition was observed in the order MRP1 < MRP2 << P-
gp, attributed to conformation changes of the transporter via membrane fluidisation and/or 
steric hindrance of drug-binding sites by P85 side chains. Batrakova et al suggest that MRP 
structures may be more robust and resilient to alterations in fluidisation, and also that the 
differences in the overall structures between P-gp and the MRP isoforms may also play a 
significant role by having a binding site which is inaccessible to the long side chains of the 
poloxamers (Batrakova et al., 2004). Evers et al could not find any correlation between P-gp 
and MRP inhibition using Pluronic L61 on MDCKII transfected cell lines (Evers et al., 
2000). If this structural explanation is correct for transporter-specific excipient inhibition, it 
could explain why only two of our excipients yielded sufficient inhibition data to give an 
IC50 value, the castor oil derivatives. 
Previous literature has also noted the efficacy of the polyethoxylated castor oils against 
ABCC2. Cremophor EL and Cremophor RH (equivalent to Etocas 35 and Etocas 40, 
respectively) has been shown to decrease ABCC2-mediated transport on MDCKII-ABCC2 
cells (Hanke et al., 2010). The same study also showed that Tween 80 also interrupted 
ABCC2 transport, but only at higher concentrations, and only after 5 hours of assay time 
(Hanke et al., 2010). In another study using SF9 membrane vesicles overexpressing MRP2, 
Cremophor EL and Cremophor RH was able to inhibit MRP2-mediated transport of 
scutellarin (Li et al., 2013a). In contrast to the study conducted herein, the study by Li et al 
also found that poloxamer 188, poloxamer 407 and Capmul MCM also inhibited ABCC2-
mediated transport, but only after 4 hours incubation (Li et al., 2013a). A subsequent study 
found that the inhibition of ABCC2 by the polyethoxylated castor oils has been shown to be 
concentration-dependent (Li et al., 2014a). However, the distinction between excipients 
which inhibit ABCB1 and those which inhibit ABCC2 remains unclear. 
  
 
Table 4.6. Physical properties and IC50 values of the tested excipients. Molecular weight values were either obtained from the manufacturer or estimated from the structures, as 
given in the parentheses below. All other values were determined experimentally.  
Excipient 
 Physical Properties IC50 (µM)  
HLB• MW State Average Upper Lower  
Capmul PG-12 Propylene Glycol Monolaurate 5 246§ Liquid - - -  
Capmul MCM Medium Chain Mono- and Diglycerides 5.5 218§ Liquid - - -  
Capmul MCM C8 Glyceryl Monocaprylate 5.5 202§ Liquid - - -  
Capmul PG-8 Propylene Glycol Monocaprylate 6 258§ Liquid - - -  
Poloxamer 182 Poly(ethylene) Poly(propylene) Glycol 7.0 2500• Liquid 8.57 10.62 7.35 (Fig. 4.13a) 
Span 20 Sorbitan Monolaurate 8.6 346• Liquid 7725.45 9793.18 6250.69 (Fig. 4.13b) 
Arlatone TV PEG 40 Sorbitan Peroleate 9.0 3508§ Liquid - - -  
Crovol A-70 PEG 60 Almond Glyceride 10.0 3251§ Liquid 2.56 3.51 1.92 (Fig. 4.13c) 
Etocas 29 PEG 29 Castor Oil 11.7 2202§ Liquid 12.00 17.87 8.84 (Fig. 4.13d) 
Brij S-10 PEG 10 Stearyl Ether 12.4 710§ Waxy - - -  
Poloxamer 184 Poly(ethylene) Poly(propylene) Glycol 13.0 2900• Liquid 7.64 10.11 5.95 (Fig. 4.13e) 
Etocas 40 PEG 40 Castor Oil 13.0 2686§ Liquid 9.55 14.45 6.62 (Fig. 4.13f) 
Brij CS-12 PEG 12 Cetostearyl Ether 13.4 770§ Waxy - - -  
Acconon C-44 Lauroyl Macrogoglycerides 13.5 1500• Waxy 26.54 32.88 21.62 (Fig. 4.13g) 
NatraGem S140 Polyglyceryl-4 Laurate/Sebacate 14.0 664/532§ Liquid - - -  
Acconon MC8-2 PEG 8 Caprylic/Capric Glycerides 14.5 350• Waxy - - -  
Tween 80 PEG 80 Sorbitan Monolaurate 15.0 1310• Liquid 12.24 19.89 7.44 (Fig. 4.13h) 
Cetomacrogol 1000 PEG 20 Cetostearyl Ether 15.7 1122§ Waxy - - -  
Tween 20 PEG 20 Sorbitan Monolaurate 16.7 1128• Liquid 9.65 12.76 7.41 (Fig. 4.13i) 
Myrj S-40 PEG 40 Stearate 16.7 2044§ Solid 6.13 8.84 4.62 (Fig. 4.13j) 
Poloxamer 335 Poly(ethylene) Poly(propylene) Glycol 18.0 6500• Solid 0.63 0.75 0.53 (Fig. 4.13k) 
Myrj S-100 PEG 100 Stearate 18.8 4684§ Solid - - -  
Poloxamer 407 Poly(ethylene) Poly(propylene) Glycol 22.0 12500• Solid 0.71 0.77 0.70 (Fig. 4.13l) 
Poloxamer 188 Poly(ethylene) Poly(propylene) Glycol 29.0 8400• Solid - - -  
 •Determined by manufacturer 
 §Estimated from molecular weight 
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 The Effects of Surfactant Structure on Inhibition of ABCB1-Mediated Efflux 4.6.3.
Using the HTS screening assay, 24 surfactants were screened for activity against the ABCB1 
and ABCC2 efflux transporter systems, identifying 12 excipients as inhibitors of ABCB1. In 
order to elucidate the structure/function relationship between excipients and their efficacy, 
the molecular structures were examined in closer detail. It has previously been noted that 
the inhibitory effects of poloxamers against ABCB1 is heavily dependent upon the HLB of 
the molecules. In an comprehensive study, the block copolymers with intermediate 
propylene oxide blocks (30-60 units) with HLB values below 20 gave the optimum 
inhibition against P-gp in bovine brain microvessel endothelial cells (BBMECs) by 
increasing microviscosity of the lipid membrane and P-gp ATPase inhibition (Batrakova et 
al., 2003). Indeed, our findings are in agreement. Of the 5 poloxamers tested, only P188 
showed no pharmacological activity against ABCB1 and was more hydrophilic than the 
other poloxamers with a HLB of 29. Yet, closer examination of Table 4.6 reveals substantial 
gaps in the list that cannot be explained using HLB alone. 
Of the materials tested, the lowest molecular weight to be seen is Span 20, which has a 
comparatively high IC50 value. Tween 20, with a molecular weight of 1128 Da, has an IC50 
value of 9.7 µM, yet has a very similar molecular weight to Cetomacrogol 1000 (1122 Da) 
which had no effect on ABCB1-mediated efflux. For these materials, the separating factor 
appears to be the structural geometry. Tweens have central ring structure from which 
PEGylated moieties emanate, divided over 3 branches. For Cetomacrogol, the molecule is 
essentially split in two distinct regions, the hydrophobic part and the hydrophilic part in a 
linear fashion. As membrane interaction and subsequent fluidisation is the generally 
accepted mechanism of action, it can be expected that polarised linear chains represent a 
larger degree of steric hindrance during lipid partitioning compared to the compact 
geometry of Tween 20, through which membrane interactions can pivot around the 
hydrophobic ring system. Closely related to Cetomacrogol 1000, Brij CS-12 and Brij S-10 
suffer the same fate. Myrj S-40 is also a linear chain, but appears to be able to interact with 
the membrane, and therefore inhibit, because of its more compact geometry with PEG 40 
forming the hydrophilic element. In contrast, Myrj S-100 has no biological effect, most 
likely attributed to the extension of the linear chain by PEG 100 as the hydrophilic segment. 
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Interestingly, Arlatone TV has no inhibitory effect, yet possesses 6 branches structure 
emanating from a sorbitol backbone. In this case, the distribution of the PEGylation 
appears inadequate (an average of 6.6 repeat units per branch) to counter the bulk of the 
molecule. 
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 Conclusions of In Vitro Kinetic Screening using the HTS Method 4.6.4.
The central aim of this chapter was to identify a number of excipients that could be 
incorporated into an oral dosage formulation. In order to do this, the following objectives 
were met: 
 Kinetic data relating to the established inhibitors of the ABCB1 and ABCC2 efflux 
transporter systems was obtained in order to establish the functionality of these 
transporters on the Caco-2 cell line. 
 
 A broad range of excipients were screened using the HTS assay for activity against 
ABCB1- and ABCC2-mediated transport, with a number of inhibitors found that 
could be used in oral dosage formulations. 
 
 Non-specific mechanisms not related to efflux inhibition were carefully considered 
and excluded from the data, such as membrane damage and toxicology. 
Using the HTS assay developed in the previous chapter, the established inhibitors of the 
efflux transporters gave IC50 values that were similar to that of published values, 
confirming the functional activity of the ABCB1 and ABCC2 transporters on the Caco-2 cell 
line and establishing the assay within the framework of existing literature. A large and 
diverse number of excipients were then screened for inhibition activity against the ABCB1 
and ABCC2 transporter systems. This identified 12 excipients that are inhibitors of ABCB1 
and 2 that are inhibitors of ABCC2. Care and attention was taken to identify mechanisms 
that were not transporter related such as toxicology, excipient-induced membrane damage 
and fluorescent probe quenching by surfactant encapsulation. 
Of all of the excipients screened, surfactants with intermediate HLB values that were small 
and linear or larger and branched showed high efficacy. It is of interest to note that the data 
presented in this study puts a number of IC50 values for the excipients within the 
micromolar range. In this respect, Crovol A70, poloxamer 335 and poloxamer 407 have 
efficacy that exceeds VER (IC50 4.08), whilst P335 and P407 exceed that of CsA (IC50 1.16). 
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In terms of physiological relevance, these data need to be examined in the context of oral 
dosage forms. Poloxamers are typically not used to the high concentrations seen by binders 
or disintegrants for example, and their role is typically as coatings or emulsifiers. However, 
according to the Excipient Handbook, poloxamers may appear up to 10 % of a tablet (Rowe 
et al., 2009). Assuming a 500 mg tablet taken with accepted 250 mL of water, the materials 
with the lowest IC50 values in our dataset, the poloxamers 335 and 407, would only need to 
be present as 1.0 and 2.2 mg, respectively, if taken on an empty stomach. As such, the data 
obtained in this chapter offers a selection of materials that can be incorporated into oral 
dosage formulations for potential efflux inhibition in vivo. 
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 5. The Design and Manufacture of Orally Disintegrating Tablets with Enhanced 
Delivery Capability 
 Chapter Aim and Objectives 5.1.
The work presented in Chapter 4 characterised a diverse range of excipients in order to 
elucidate their biological effects against the ABCB1 and ABCC2 efflux transporter systems. 
This provides a working toolbox for the design and production of tablets with the potential 
to realise enhanced delivery of drugs which are prone to efflux. Therefore, the aim of the 
following work was to produce two orally disintegrating tablet (ODT) formulations with 
disintegration times conforming to United States Pharmacopoeia at or below 30 seconds 
(McLaughlin et al., 2009), utilising the excipient kinetic data obtained using the HTS 
screening assay of the previous chapter in order to achieve the potential for enhanced oral 
bioavailability. The work presented in the following chapter was conducted entirely during 
industrial placement at the Colorcon Dartford facility. 
 Tablet Design Overview 5.2.
The ODTs chosen for formulation were a 295 mg ‘low-dose’ formulation, and a 793 mg 
‘high-dose’ formulation. The high-throughput screening assay produced two clear lead 
candidate excipients, poloxamer 335 and poloxamer 407 with IC50 values of 4.12 x 10-4 % 
(w/v) and 8.85 x 10 -4 % (w/v), respectively. Poloxamer 407 was chosen as the material for 
incorporation into the ODTs as a micronised version of the same polymer previously used 
in the high-throughput screening assay in the previous chapter. 
This tablet development phase required two assumptions. The first is that the tablet must 
contain an excessive quantity of biologically active material. As such, the content of each 
tablet was chosen to be 10 % (w/w) as a surplus quantity to ensure a good drug: excipient 
ratio in the final diluted solution for in vitro uptake studies, delivering 28.6 mg and 79.3 mg 
of poloxamer 407 respectively for low-dose and high-dose tablets, both in excess of the 2.2 
mg theoretical amount required. 
The second assumption in the tablet design was a drug substitution. For this 
developmental phase, paracetamol (acetaminophen, APAP) was chosen as the active 
pharmaceutical ingredient (API) as a relatively non-toxic model drug. Fundamentally, one 
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of the objectives in the project was to produce a tablet with enhanced delivery, requiring 
not just biologically active excipients to exploit, but also a drug with poor uptake such that 
there is ample potential for improvement. APAP is neither an ABCB1 or ABCC2 substrate, 
and is able to traverse the cell membrane rapidly (Papp 23.7-100 x 10-6 cm s-1 (Irvine et al., 
1999, Yamashita et al., 2000)), meaning that the impact of efflux transporters is likely to be 
negligible. Furthermore, APAP has 80 % fraction absorbed in humans (Irvine et al., 1999). 
The inclusion of APAP was entirely as a model compound to represent high-dose drug and 
to determine the impact of inclusion of P407 on the formulation of high-dose ODTs. The 
second model compound to be tested was atorvastatin (ATV). This drug has an efflux ratio 
of seven on the Caco-2 model (Wu et al., 2000), indicating excess efflux transport primarily 
by P-gp (Wu et al., 2000, Hochman et al., 2004, Li et al., 2011a), but with lesser contributions 
from the MRP2 and BCRP transporter systems (Li et al., 2011a). ATV tablets typically have 
10, 20, 40 or 80 mg loading. Based on the differences in the typical dosage of the two model 
APIs, the high-dose formulation was intended to closely resemble a typical APAP tablet 
with ~ 40 % drug loading. The second formulation, the low-dose, was chosen as a typical 
sized ATV tablet to be converted at the advanced phase of the tablet development. The 
remaining excipients and the grades chosen are presented in Table 5.1.  
Table 5.1. List of excipient selected for ODT development.  
Tablet Constituent Type Chosen Purpose 
Granulated Paracetamol CompapTM PVP3 API 
Ethyl Cellulose Ethocel™ 7 FP Binder 
Microcrystalline Cellulose Avicel® PH102 Disintegrant 
Mannitol Mannogem® 2028 Dilutant/Sweetener 
Crospovidone Kollidon® CL-F Superdisintegrant 
Efflux Modifier Poloxamer 407 ABCB1 Inhibitor 
Partially Pregelatinised Maize Starch Starch 1500® Multipurpose Binder/Filler 
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 Design of Experiments: Screening Round 1 5.3.
In order to explore the response of different combinations of the excipients MCC, mannitol 
and Starch 1500, a design of experiments approach was taken to design a set of 
experiments with varying concentrations of each material for both high and low-dose 
materials, with 40 % and 70 % excipient content, respectively. The JMP 12 DoE software 
proposed 10 formulations out of a potential 225 (Table 5.2). These formulations were then 
made into tablets by direct compression at 1 metric ton. 
Table 5.2. Low-dose and high-dose formulation compositions indicated by the first round of DoE mapping using 
JMP 12 DoE software to optimise MCC, Starch 1500 and mannitol content within the ODT formulation. 
Low-dose - 11 % Drug – 295 mg 
70% MCC/Starch 1500/Mannitol 
Excipient 
Composition, % (w/w) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Starch 1500 0.0 30.0 25.0 10.0 30.0 30.0 20.0 0.0 25.0 20.0 
MCC 30.0 30.0 25.0 25.0 0.0 30.0 20.0 30.0 10.0 20.0 
Mannitol 40.0 10.0 20.0 35.0 40.0 10.0 30.0 40.0 35.0 30.0 
Ethocel 7 FP Premium 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Poloxamer 407 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
Crospovidone 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Glycerol Behenate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
APAP 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 
Total 100.0          
 
High-dose - 41 % Drug – 795 mg 
40% MCC/Starch 1500/Mannitol 
Excipient 
Composition, % (w/w) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Starch 1500 20.0 2.5 16.7 9.2 19.0 2.5 15.8 19.0 17.4 15.8 
MCC 0.0 15.0 4.4 11.9 15.0 15.0 8.8 15.0 11.9 8.8 
Mannitol 20.0 22.5 19.0 19.0 6.0 22.5 15.4 6.0 10.7 15.4 
Ethocel 7 FP Premium 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Poloxamer 407 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
Crospovidone 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Glycerol Behenate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
APAP 41.0 41.0 41.0 41.0 41.0 41.0 41.0 41.0 41.0 41.0 
Total 100.0          
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 Tablet Description 5.3.1.
Low-dose tablets were made to 295 mg in a 10 mm die to normal convex geometry. High-
dose tablets were made to 793 mg flat-faced 13 mm die in order to accommodate the larger 
powder volume. Both tablet types appeared smooth and glossy. 
 Physical Characterisation 5.3.2.
The hardness and disintegration information for both tablet formulations is presented in 
Figure 5.1. For the low-dose formulations, hardness was 5.9- 11.2 kp and disintegration 
times were 103-291 s (Figure 5.1a). For high-dose tablets, hardness was greater than the 
low-dose at 11.3 – 17.3 kp with disintegration times of 88-150 s (Figure 5.1b). Paracetamol is 
known for its poor compressibility, which results in poor hardness and a tendency to cap, a 
process that results in the separation of the crown from the tablet (Krycer et al., 1982), 
owing to the monoclinic crystal structure, which results in reduced plastic deformation. As 
such, unprocessed paracetamol is not used for direct compression, which limits its 
usefulness. An effective strategy to address this is to mix the paracetamol with 
polyvinylpyrolidone (PVP), a binder which is able to undergo plastic deformation 
(Ayenew et al., 2012). When paracetamol is processed with PVP, this additive is able to 
influence the crystal habit of paracetamol. The action of PVP in habit modification is 
twofold; first, PVP interacts with paracetamol in the aqueous solution via hydrogen 
bonding (Horn and Ditter, 1982, Garekani et al., 2003), secondly, PVP is a strong inhibitor 
of crystal growth by direct adsorption onto the surface of the growing crystal (Ziller and 
Rupprecht, 1988). In a study examining the different grades of PVP, it was found that the 
effectiveness of additives, judged by the change in paracetamol crystal habit and the delay 
in crystal formation, was found to follow the molecular weight in the order PVP 50000 > 
PVP 10000 > PVP 2000 (Garekani et al., 2000b). Used in direct compression, the paracetamol 
particles produced by crystallisation in the presence of 0.5 % PVP 10, 000 or PVP 50, 000 
produced hard tablets without capping (Garekani et al., 2000a). These particles consisted of 
multiple agglomerated microcrystals, which could fragment under pressure, allowing the 
opportunity for multiple fresh surfaces for enhanced interparticulate bonding. Indeed, the 
compacts produced in the presence of PVP exhibited lower elastic recoveries compared to 
untreated paracetamol (Garekani et al., 2000a). The APAP used in the current study is 
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CompapTM PVP3 which has been coprocessed with 3 % (w/w) PVP to aid compressibility. 
As such, both the low-dose and high-dose tablet formulations have good hardness. 
Plastic disk inserts, permitted for use with disintegrating equipment according to the USP, 
were found to stick to the tablets high in Starch 1500, and they were subsequently omitted. 
Of all of the low-dose formulations tested, F1, F4, F5, F8, F9 and F10 had disintegration 
times conforming to the European Pharmacopeia limit of 180 seconds for uncoated tablets 
(European Pharmacopeia, 2009), but no formulations displayed disintegration times 
conforming to the United States Pharmacopeia limit of 30 seconds (McLaughlin et al., 2009). 
Interestingly, the fastest disintegration time was seen for low-dose F5, which contained 
high Starch 1500 and no MCC. This formulation also had the lowest hardness (5.9 kp). A 
strong correlation between hardness and disintegration has been demonstrated using 
uncoated caffeine tablets, whereby hardness was able to govern the all stages of drug 
dissolution (Kitazawa et al., 1975). Moreover, at low hardness, a larger pore network is 
likely to exist within the tablet to aid water ingress, which has an important impact upon 
disintegration time (Shangraw et al., 1980). Therefore, the lower hardness of F5 is likely a 
contributing factor in this faster disintegration time due to the higher degree of porosity of 
the tablets, coupled with the ability of Starch 1500 to swell as a mechanism of 
disintegration. All high-dose tablets conformed to the European Pharmacopeia limits 
independent of the excipient composition (European Pharmacopeia, 2009). 
In order to test the robustness of the tablet formulations, friability testing was conducted 
according to the United States Pharmacopeia (USP, 2013). Low-dose tablet friability (Table 
5.3) was found to be negligible for all low-dose formulations (≤ 0.044 %) and well within 
the 1 % limit recommended by the United States Pharmacopeia (USP, 2013). Friability for the 
high-dose tablets was higher than low-dose tablets, but no greater than 0.7 % (Table 5.3) 
and also conforms to the 1 % limit recommended by the United States Pharmacopeia (USP, 
2013). For both low-dose and high-dose formulations, width, thickness and weight 
variation were found to be negligible (Table 5.3). Moreover, the results of the initial study 
give room for improvement for both low-dose and high-dose formulations.  
  
 
 
 
 
Figure 5.1. The results of the DoE screening approach, showing tablet hardness (clear bars) and disintegration time (blue bars) for A) low-dose and B) high-dose tablets. Whilst 
some low-dose formulations and all high-dose formulations were able to disintegrate in less than 3 minutes in accordance with the EP, no formulations conformed to the USP limit 
of 30 seconds. Data presented as mean ± SD from n = 10 tablets for hardness and 6 tablets for disintegration time. 
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Table 5.3. Remaining physical data from both high and low-dose APAP tablet. For all datasets, n = 10 tablets.  
Formulation Friability (%) 
 
Width (mm) 
 
Thickness (mm) 
 
Weight (mg) 
Low-dose 
1 0.017 
 
10.032 ± 0.023 
 
4.076 ± 0.013 
 
296.810 ± 0.737 
2 0.007 
 
10.039 ± 0.009 
 
4.181 ± 0.023 
 
296.700 ± 0.799 
3 0.024 
 
10.036 ± 0.007 
 
4.172 ± 0.018 
 
296.330 ± 0.738 
4 0.010 
 
10.028 ± 0.004 
 
4.120 ± 0.018 
 
296.640 ± 1.125 
5 0.037 
 
10.061 ± 0.009 
 
4.207 ± 0.027 
 
296.600 ± 0.720 
6 0.040 
 
10.042 ± 0.018 
 
4.183 ± 0.015 
 
296.840 ± 0.570 
7 0.044 
 
10.045 ± 0.012 
 
4.159 ± 0.007 
 
295.890 ± 0.713 
8 0.041 
 
10.023 ± 0.007 
 
4.068 ± 0.014 
 
295.840 ± 0.560 
9 0.027 
 
10.043 ± 0.008 
 
4.178 ± 0.009 
 
295.880 ± 0.661 
10 0.030 
 
10.034 ± 0.005 
 
4.155 ± 0.012 
 
295.830 ± 0.499 
               
High-dose 
1 0.746 
 
13.038 ± 0.021 
 
5.362 ± 0.021 
 
795.080 ± 0.975 
2 0.273 
 
13.009 ± 0.007 
 
5.268 ± 0.015 
 
794.930 ± 1.608 
3 0.484 
 
13.015 ± 0.005 
 
5.315 ± 0.021 
 
794.080 ± 0.588 
4 0.295 
 
13.007 ± 0.009 
 
5.318 ± 0.019 
 
794.420 ± 1.030 
5 0.447 
 
13.022 ± 0.004 
 
5.374 ± 0.026 
 
794.710 ± 1.007 
6 0.311 
 
13.006 ± 0.007 
 
5.280 ± 0.011 
 
794.140 ± 0.961 
7 0.515 
 
13.019 ± 0.006 
 
5.348 ± 0.011 
 
793.770 ± 0.860 
8 0.381 
 
13.021 ± 0.009 
 
5.381 ± 0.029 
 
795.560 ± 0.977 
9 0.474 
 
13.019 ± 0.012 
 
5.378 ± 0.026 
 
794.850 ± 0.546 
10 0.314 
 
13.023 ± 0.015 
 
5.340 ± 0.012 
 
794.270 ± 0.589 
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 Design of Experiments Interpretation of Excipient Composition 5.3.3.
Using JMP 12 DoE software, the impact of Starch 1500, MCC and mannitol was examined 
in further detail using bivariate analysis. The data are presented in Figure 5.2 and Figure 
5.3 for low-dose and high-dose formulations respectively. For the low-dose formulations, 
Starch 1500 decreased tablet strength, mannitol had little impact and MCC was able to 
improve tablet strength (Figure 5.2a). Of these, Starch 1500 and MCC correlated well, with 
r2 values of 0.60 and 0.80 respectively, moreover both of these excipients had a significant 
(p < 0.01) impact upon tablet hardness (Table 5.4). For disintegration, Starch 1500 and MCC 
increased disintegration time whereas mannitol was able to decrease it (Figure 5.2b). The 
impact of mannitol had good correlation with the model (r2 = 0.85); furthermore mannitol 
was the only material to have a significant (p < 0.001) impact upon disintegration for the 
low-dose formulations (Table 5.4). In agreement with the impact upon the low-dose 
formulations, Starch 1500 also decreased tablet strength of the high-dose formulations, 
mannitol had little impact and MCC was able to improve tablet strength (Figure 5.3a). Of 
these, Starch 1500 and MCC correlated well, with r2 values of 0.75 and 0.71 respectively, 
moreover both of these excipients had a significant (p < 0.01) impact upon tablet strength 
(Table 5.5). Starch 1500 increased disintegration time, MCC had little impact whereas 
mannitol was able to decrease it (Figure 5.3b). Both Starch 1500 and mannitol correlated 
well in this model (r2 = 0.77 and 0.79 respectively), and the impact of both was significant (p 
< 0.001) (Table 5.5). 
Tablet hardness for both high and low formulations was shown to correlate well to an 
increase in MCC content (Figure 5.2a and Figure 5.3a). MCC is known to undergo a unique 
plastic deformation during compression that occurs through enhanced hydrogen bonding 
to adjacent MCC particles (Al-Khattawi and Mohammed, 2013), as opposed to 
conventional plastic deformation that occurs when compression is able to overcome the 
intermolecular forces of the material (Hess, 1978). This conglomerate hypothesis has been 
observed by measuring large amorphous regions in MCC by XRD and DSC (Al-Khattawi 
et al., 2014). In addition to increasing hardness, the low-dose tablets showed an increase in 
disintegration time with an increased level of MCC (Figure 5.2b), most likely attributed to 
the difficulty faced by the disintegrants in overcoming the binding forces of the tablet with 
increased strength. For the high-dose formulations, the impact of MCC on disintegration 
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was minimal (r2 = 0), suggesting the dominant role of the compressible form of APAP in 
determining the rate of disintegration (Figure 5.3b). Indeed, a common limitation of the 
compressible forms of paracetamol is poorer disintegration (Martinello et al., 2006). 
For both high and low-dose APAP formulations, high Starch 1500 corresponded to poor 
tablet strength. Whilst the overall compressibility of Starch 1500 is good, the strength of the 
subsequent compacts is low. The reason for this is twofold: plastic deformation of Starch 
1500 is a slow process, meaning quick compression is insufficient in producing strong 
interparticle bonds during plastic deformation, additionally the deformation is largely 
elastic (Rees and Rue, 1978). Furthermore, the disintegration time increased with the 
increased levels of Starch 1500, most likely attributed to the gel forming properties of the 
material. However, Starch 1500 is not intended as a stand-alone disintegrant and is 
recommended as part mixture of different excipients to complement disintegration by 
relying on the mechanism of swelling for its disintegration properties (Rojas and Kumar, 
2012). Despite the absence of MCC in low-dose F5 (Table 5.2), Starch 1500 as the lone 
disintegrant gave the fastest disintegration time of the batch at 103 s (Figure 5.1), implying 
that the swelling mechanism was able to overcome the binding properties imparted by this 
tablet composition. Mannitol had no impact upon hardness for either formulation (Figure 
5.2a and Figure 5.3a, r2 > 0.05). For both high and low formulations, increasing mannitol 
content led to a significant (p < 0.05) decrease in disintegration time (Figure 5.2b and Figure 
5.3b) likely attributed to the good wetting properties which facilitate the ingress of water to 
the crospovidone and so decreasing the disintegration time (Kubo and Mizobe, 1997). 
 
Figure 5.2. Design of experiments trace plots for low-dose formulations showing A) hardness and B) 
disintegration, showing the impact of Starch 1500 (red), MCC (blue) and mannitol (black). 
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Table 5.4. Summary of the model statistics on the impact of the test excipients on hardness and disintegration on 
the low-dose formulations from the first round of DoE screening. 
Factor r2 F ratio Prob > F 
Hardness 
Starch 1500 0.61 12.29 0.0080 
MCC 0.80 32.11 0.0005 
Mannitol 0.00 0.00 0.9742 
     
Disintegration 
Starch 1500 0.20 2.03 0.1925 
MCC 0.30 3.47 0.0996 
Mannitol 0.85 44.40 0.0002 
 
 
 
Figure 5.3. Design of experiments trace plots for high-dose formulations showing A) hardness and B) 
disintegration, showing the impact of Starch 1500 (red), MCC (blue) and mannitol (black). 
 
 
Table 5.5. Summary of the model statistics on the impact of the test excipients on hardness and disintegration on 
the high-dose formulations from the first round of DoE screening. 
Factor r2 F ratio Prob > F 
Hardness 
Starch 1500 0.75 23.13 0.0012 
MCC 0.71 19.17 0.0024 
Mannitol 0.05 0.46 0.5161 
  
      
Disintegration 
Starch 1500 0.77 26.23 0.0009 
MCC 0.00 0.03 0.8697 
Mannitol 0.79 30.72 0.0005 
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 Formulation Refinement 5.4.
Having completed the first phase of tablet evaluation by evaluating the impact of filler 
composition, the other excipients were evaluated in order to improve disintegration time. 
From the DoE data presented Figure 5.1, the formulations with the fastest and slowest 
disintegration times (F5 and F6 for low-dose respectively, F6 and F5 for high-dose 
respectively) were selected as test platforms in order to examine the impact of the 
poloxamer 407, crospovidone and ethylcellulose content, as well as the grade of 
crospovidone used and finally the type of multi-purpose excipient. 
 Effects of Poloxamer 407 Content on Hardness and Disintegration 5.4.1.
Poloxamer 407 was incorporated in excessive quantities from the start in order to 
understand the upper payload limits of biologically active material that each delivery 
vehicle can accommodate. However, the inadequate disintegration times above 30 seconds 
meant that this value needed to be revised. Therefore, the percentage poloxamer content 
was evaluated at 0-10 % of the tablet weight, with the results presented in (Figure 5.4). 
Increasing the poloxamer concentration from 0 % to 10 % weight within the tablets resulted 
in a general increase in hardness and disintegration time. For the low-dose F5 tablets, both 
hardness and disintegration increased as a function of P407 content in relation to the 
poloxamer-free control, with hardness becoming significant between 2 % and 10 % (p < 
0.0001) with an increase from 4.8 kp to 5.2 and 5.9 kp respectively. Disintegration times also 
increased from 56s to 103s for low-dose F5 over the concentration range tested, becoming 
significant (p < 0.0001) at 10 % poloxamer content. For low-dose F6, a small but significant 
(p < 0.0001) increase was seen in hardness when P407 was increased from 0 % to 2 % from 
9.0 to 9.6 kp respectively, but this became non-significant (p > 0.05) by 10 % poloxamer 
content indicating that this could be attributed to batch to batch variation. However, a 
massive increase in disintegration time was observed from 50s to 290s over the range 
tested, becoming significant (p < 0.0001) at between 2% and 10 % poloxamer content. For 
the high-dose F5 formulation, hardness increased over the range tested from 10.4 kp at 0 % 
to 14.6 kp at 10 %, becoming significant (p < 0.0001) at 2 % poloxamer content. Hardness 
also increased marginally, becoming significant (p < 0.05) at 10 % poloxamer weight. For 
high-dose F6, the hardness increase became significant (p < 0.0001) at 2 % poloxamer 
content, increasing from 12.2s to 17.2s over the range tested. Likewise, disintegration times 
Pollard J 
187 
 
also increased from 39.2s to 88s over the range tested, becoming significant (p < 0.0001) at 2 
% poloxamer content. 
Poloxamer 407 has previously been used in directly compressed tablets as a lubricant at 2 
% (w/w) or less. In a study comparing micronised P407 to magnesium stearate, P407 gave 
similar ejection force data to that of magnesium stearate without decreasing tablet strength 
(Desai et al., 2007). In another study looking at the lubricant properties of 1-2 % P407, this 
material showed ejection forces less than that of magnesium stearate, but also increased 
disintegration times when used in conjunction with MCC as a binder and decreased 
slightly at 2 % P407 (Muzikova et al., 2012). Hardness followed a similar pattern; although 
this was not observed when spray dried lactose (Flowlac 100) was used as a binder 
instead of MCC. The results presented in Figure 5.4 are different, as no significant (p > 0.05) 
increase in hardness was observed between formulations with no P407 and those with 2 %. 
In an additional study using the surfactant poloxamer 188 (similar in hydrophilicity to 
P407) in immediate release tablets, multivariate analysis revealed this excipient was able to 
act as a binder either directly or by increasing intragranular cohesion (Kaul et al., 2011). 
The increase in dissolution time seen for the immediate release tablets was attributed to the 
increase in hydrophilicity of the tablet retarding the wicking action of the disintegrant 
crospovidone, in addition to the overall binding effects of the poloxamer. Indeed, 
exchanging the crospovidone with croscarmellose sodium, a disintegrant with a higher 
swelling capacity than crospovidone, was able to counter the decrease in dissolution (Kaul 
et al., 2011). As crospovidone is dependent upon wicking for its action (Kornblum and 
Stoopak, 1973), this could explain how the addition of a hydrophilic material, P407, is able 
to significantly (p < 0.05) increase the disintegration times of the tablets at 10 % (Figure 5.4). 
Furthermore, MCC is also a wicking agent (Al-Khattawi et al., 2014), and the same 
mechanism may explain the dramatic decrease in disintegration time from 290 s to 54 s for 
low-dose F6 containing 30 % (w/w) MCC when 10 % poloxamer is reduced to 2 % (Figure 
5.4b). In contrast, low-dose F5 contains no MCC, but does have 30 % Starch 1500 (Table 
5.2), which relies on swelling for its disintegration properties (Rojas and Kumar, 2012), and 
has a comparatively smaller reduction in disintegration time when P407 is reduced from 10 
% to 2 % to 103 s to 61 s respectively (Figure 5.4a). Even at 2 % (w/w), the 295 mg low-dose 
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tablet delivers 5.9 mg of poloxamer 407, well in excess of the 2.2 mg required to exceed the 
IC50 value outlined in the previous chapter. Therefore, because of the improvement in 
disintegration time, 2 % P407 was chosen for the second round of DoE. 
  
 
Figure 5.4. The impact of poloxamer 407 on A) low-dose F5, B) low-dose F6, C) high-dose F5 and D) high-dose F6, showing hardness (clear bars) and disintegration times (blue 
bars). Data presented as mean ± SD from n = 10 tablets for hardness and 6 tablets for disintegration time. Statistical significance was analysed using one-way ANOVA followed by 
Dunnett’s post hoc test annotated as follows: ns (p > 0.05); * (p < 0.05); **** (p < 0.0001).  
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 Effects of Kollidon® Crospovidone Type on Hardness and Disintegration 5.4.2.
Crospovidone is an insoluble polymer typically used as a superdisintegrant in ODT 
formulations (Figure 5.5). The manufacturer, BASF, offers a range of particle sizes to their 
product and these were evaluated for their impact on the tablet disintegration times. 
Kollidon® CL-F, with a particle size of 20-40 μm, was initially selected for evaluation for the 
first round of DoE screening as an intermediate particle size that should display low levels 
of grittiness, thereby maintaining the aesthetics of a potentially marketable product. 
Kollidon® CL (particle size 110-130 μm), Kollidon® CL-SF (10-30 μm) and Kollidon® CL-M 
(3-10 μm) were also sourced as samples from BASF for evaluation. 
 
Figure 5.5. The structural schematic of crospovidone. 
 
The results of the superdisintegrant testing are presented in Figure 5.6. For both low-dose 
formulations, the CL-F, CL-SF and CL-M grades significantly increased hardness for all 
formulations (p < 0.001) compared to the CL grade, most likely attributed to the higher 
compressibility of the smaller particle sizes. However, hardness appeared to plateau after 
the addition of the CL-F grade, and CL-F, CL-SF and CL-M all had similar hardness (p > 
0.05). The CL-F and grade had a significant (p < 0.01) reduction in disintegration time 
compared to the CL grade for low-dose F6, but had no significant (p > 0.05) impact upon 
the disintegration times of low-dose F5 or both high-dose formulations compared to the CL 
grade. The CL-SF grade only showed a significant (p < 0.01) decrease in disintegration time 
compared to CL for low-dose F6 and high-dose F6. The most profound impact upon 
disintegration time for all formulations was seen for tablets incorporating CL-M, with some 
formulations pushing over 10 minutes (Figure 5.6b and Figure 5.6c).  
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Crospovidone is more likely to allow water ingress via capillary action, known as wicking, 
by providing pores within the tablet network rather than swelling (Kornblum and Stoopak, 
1973). By this action, the particle size of crospovidone is likely not the rate limiting factor in 
disintegration times as a smaller particle size is more likely to result in a better distribution 
within the tablet to offset the smaller particle sizes. However, the smaller particle size will 
lead to an increased compressibility, as seen in the significant (p < 0.0001) increase in 
hardness of both low-dose tablets (Figure 5.6a and Figure 5.6b). However, the smaller 
particles of crospovidone do not have a consistent impact upon the high-dose 
formulations, indicating that the compressibility of the APAP at 70 % (w/w) is the 
dominant factor in these formulations (Figure 5.6c and Figure 5.6d). 
In the development of ODTs containing sumatriptan succinate, Kollidon® CL-SF was 
chosen as the optimised formulation as it gave faster disintegration than Kollidon® CL as 
well as harder tablet at 5 % (w/w) (Sheshala et al., 2011). In a study comparing Kollidon® 
CL and Kollidon® CL-F in directly compressed tablets, the CL grade gave the shortest 
disintegration times, although the SF grade gave harder tablets (Zimmer et al., 2015). In 
another recent study, Kollidon® CL-SF and CL-F were compared in the development of 
orally disintegrating loratadine formulations, with no difference observed in disintegration 
times, although the CL-F grade gave harder tablets, in agreement with the data presented 
in Figure 5.6 (Amelian et al., 2015). 
Due to the increase in hardness, a reduction or no change to disintegration times, coupled 
with the reduced grittiness of the grade owing to the smaller particle size, the CL-F grade 
was chosen for incorporation in all subsequent formulations. Further analysis of comparing 
CL-SF versus CL-F using high-dose F5 in later studies demonstrated a reduction in 
disintegration times (118 s and 134 s, respectively), and was the only formulation to display 
this reduction in disintegration time. However, CL-F was still carried forward in order to 
maintain commonality amongst the formulations as well as the aforementioned increase in 
hardness. 
  
 
 
Figure 5.6. The impact changing the superdisintegrant type on A) low-dose F5, B) low-dose F6, C) high-dose F5 and D) high-dose F6, showing hardness (clear bars) and 
disintegration times (blue bars). Hardness and disintegration data shown as the mean from an n of 10 and 6 tablets respectively ± SD. Statistical significance was analysed using one-
way ANOVA followed by Dunnett’s post hoc test annotated as follows: ns (p > 0.05); ** (p < 0.01); **** (p < 0.0001).  
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 Effects of Kollidon® Crospovidone Concentration on Hardness and 5.4.3.
Disintegration 
In addition to evaluating the type of crospovidone, the concentration of crospovidone was 
also examined up to 11 %, and the results are presented in Figure 5.7. In general, both low-
dose F5 and F6 displayed both an increase in hardness and a decrease in disintegration 
time. For low-dose F5, a small but significant (p < 0.01) decrease in hardness is observed at 
8 % CL-F content, but this appears to be a product of batch-to-batch variation, becoming 
non-significant (p > 0.05) again at 11 % CL-F content. Furthermore, low-dose F5 showed a 
small but significant decrease in disintegration time from 77 s to 61 s was observed at 8 % 
crospovidone content and above (p < 0.01), although this does not appear to be dose 
dependent. For low-dose F6, hardness was increased, becoming significant (p < 0.0001) at 
11 % crospovidone. Only low-dose F6 responded well in terms of disintegration times, 
dropping significantly (p < 0.01) from 198 s at 5 % crospovidone, to 137 s (at 8 %) and 92.5 
(at 11 %). Both high-dose formulations responded little to increased crospovidone content, 
and neither exhibited a significant (p > 0.05) impact upon disintegration, although high-
dose F6 showed a significant (p < 0.0001) decrease in hardness over the range tested (17.8 
kp at 8 % crospovidone to 16.5 kp at 11% crospovidone content). 
The decrease in disintegration time with increased crospovidone content is in general 
agreement with a previous study in which crospovidone was increased from 4 to 12 % 
without affecting disintegration time (Okuda et al., 2012). Only the low-dose F6 responded 
in a dose-dependent manner to increased superdisintegrant, which would supplement the 
poor tablet disintegration properties associated with a high MCC content indicated by the 
previous DoE study (Figure 5.2). Even with the decrease in disintegration time for low-
dose F6 at 11 % crospovidone, this is still a much larger decrease in disintegration time 
than the equivalent low-dose F5 which did show a significant (p < 0.01) decrease in 
disintegration time, but this did not appear dose dependent. For direct compression, 
crospovidone has been used at 2.5-8 % (w/w) (Okuda et al., 2012), 5 % (w/w) (Mishra et al., 
2006) and 7 % (w/w) (Shu et al., 2002). As this material is expensive and takes up potential 
room within the tablet, other means were explored in order to bring disintegration times 
down to acceptable levels. Moreover, the poor disintegration is more likely attributed to 
the 10 % P407 blocking the wicking action of the crospovidone and MCC. 
  
 
Figure 5.7. The impact changing concentration of the superdisintegrant, Kollidon CL-F, on A) low-dose F5, B) low-dose F6, C) high-dose F5 and D) high-dose F6, showing 
hardness (clear bars) and disintegration times (blue bars). Hardness and disintegration data shown as the mean from an n of 10 and 6 tablets respectively ± SD. Statistical 
significance was analysed using one-way ANOVA followed by Dunnett’s post hoc test annotated as follows: ns (p > 0.05); ** (p < 0.01); ****, (p < 0.0001).  
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 Effects of Ethylcellulose Concentration on Hardness and Disintegration 5.4.4.
Ethylcellulose is a hydrophobic polymer used in the role as a binder/filler (Figure 5.8). The 
role of this excipient has been evaluated in controlled release formulations of indometacin 
and theophylline, where the lower viscosity grades were able to produce harder tablets 
(Upadrashta et al., 1993). DOW produces ethylcellulose under the trade name 
ETHOCEL™, in grades 7 FP, 10 FP and 100 FP Premium corresponding to particle sizes 9.7, 
6.1 and 41 µm. To maintain good compressibility, ETHOCEL 7 FP was chosen for 
incorporation as a binder for initial screening at 2.5 %, (w/w). 
 
Figure 5.8. The schematic structure of ethylcellulose. 
 
Due to poor disintegration times for both low-dose and high-dose formulations, the 
content of ethylcellulose was revaluated for optimisation at 0-7.5 %, with the results 
presented in Figure 5.9. For all tablet formulations tested, a general increase in both 
hardness and disintegration time was observed. For both low-dose F5, an increase in 
hardness was seen over the range tested from 5.9 to 9.1 kp, becoming significant (p < 
0.0001) at 2.5 % ethylcellulose content versus the 0 % control, with a corresponding increase 
in disintegration time over the range tested from 48 s to 131 s, becoming significant at 2.5 % 
ethylcellulose content (Figure 5.9a). For low-dose F6, hardness increased from 9.3 to 12.7 kp 
over the range tested, becoming significant (p < 0.05) at 2.5 % ethylcellulose content (Figure 
5.9b). For high-dose F5, hardness increased over the range tested from 12.3 to 19.5 kp, 
becoming significant (p < 0.0001) at 2.5 % ethylcellulose content, with disintegration 
increasing from 114 s to 180 s, becoming significant at 5 % ethylcellulose content (Figure 
5.9c). Likewise, high-dose F5 showed an increase in hardness from 15.8 kp at 0 % 
ethylcellulose content to 19.7 kp at 10 %, becoming significant (p < 0.0001) at 2.5 % 
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ethylcellulose content, with an increase in disintegration time over the range tested from 66 
s to 119 s, becoming significant (p < 0.05) at 2.5 % ethylcellulose content (Figure 5.9d).  
Micronised ethylcellulose (particle size 5-10 µm, roughly equivalent to 7 FP and 10 FP 
grades) has been used in orally disintegrating tablet formulations from 2.5-7.5 % (w/w), 
leading to a corresponding increase in hardness with a decrease in friability (Okuda et al., 
2012) attributed to the increase in contact area between granules. Ethyl cellulose has been 
evaluated in controlled release formulation, where the lower viscosity grades were able to 
produce harder tablets (Upadrashta et al., 1993, Katikaneni et al., 1995b), indicating the 
better compressibility of the lower viscosity polymers. The mechanism of action of 
ethylcellulose compaction has been shown to be plastic deformation with a minor 
component of elasticity (Katikaneni et al., 1995a). However, the lower particle sizes have 
also been shown to lead to lower porosity (Upadrashta et al., 1994). Coupled with the 
insoluble nature of the polymer, this decrease in porosity is also likely to lead to a 
restriction in the access of water to the disintegrants, extending disintegration time. The 
results of testing ethylcellulose content in the present study are in agreement, as higher 
ethylcellulose content led to an increase in tablet hardness but also corresponded to an 
increase in disintegration time. Despite the advantages offered in hardness, the tablets 
appear to have adequate hardness without the addition of this excipient since 
disintegration is the primary focus. Therefore, this material was removed for the second 
round of DoE. 
  
 
  
Figure 5.9 The impact of ETHOCEL 7 FP concentration on A) low-dose F5, B) low-dose F6, C) high-dose F5 and D) high-dose F6, showing hardness (clear bars) and 
disintegration times (blue bars). Hardness and disintegration data shown as the mean of n = 10 and 6 tablets respectively ± SD. Statistical significance was analysed using one-way 
ANOVA followed by Dunnett’s post hoc test annotated as follows: ns (p > 0.05); * (p < 0.05); *** (p < 0.001); **** (p < 0.0001).  
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 Effects of Binder Type and Further Optimisation 5.4.5.
Having evaluated the composition of Starch 1500, MCC and mannitol, a second 
multipurpose excipient was evaluated as a replacement for Starch 1500 in the test 
formulations F5 and F6. Both Starch 1500 and StarCap 1500 are modified starches, but 
StarCap 1500 is a co-processed mixture of native starch and pregelatinised starch, which 
allows enhanced disintegration properties over Starch 1500. StarCap 1500 was therefore 
chosen for evaluation in order to address the poor disintegration times of the ODTs by 
utilising these superior disintegrating properties. The results of the evaluation are 
presented in Figure 5.10. Maintaining the 10 % P407 to make the results directly 
comparable to the previous Starch 1500 formulations, both low-dose formulations 
exhibited hardness that was significantly higher (p < 0.0001), and disintegration times that 
were significantly lower (p < 0.001) (Figure 5.10a and b). For both high-dose formulations, 
no significant (p > 0.05) impact upon hardness was observed, although a decrease in 
disintegration time was observed for both formulations from 134 s to 82 s for high-dose F5 
(p < 0.001) and 91 s to 78 s for high-dose F6 (p > 0.05) (Figure 5.10c and d). As such, StarCap 
1500 was carried forward for subsequent formulations.  
In order to explain the overall decrease in disintegration times and increased hardness 
using StarCap 1500, the differences between this material and Starch 1500 needs to be 
examined. Both StarCap 1500 and Starch 1500 have similar particle sizes (65 and 90 μm 
respectively) so this cannot be used to explain the differences in hardness observed when 
StarCap 1500 is used. In terms of structural composition, native starch has poor binding 
properties but is an excellent disintegrant owing to the high amylose content, which is 
insoluble but swells upon contact with water. Conversely, fully gelatinised maize starch 
has excellent binding properties provided by the water-soluble amylopectin, but acts as a 
poor disintegrant. Starch 1500 is partially pregelatinised maize starch, combining 
intermediate properties of native and fully gelatinised maize starch. However, StarCap 
1500 is a co-processed mixture of pregelatinised starch (essentially Starch 1500) and native 
starch, retaining more of the disintegrating properties of the latter. Additionally, Starch 
1500 appears gel forming upon hydration, which most likely contradicts the wicking action 
of the superdisintegrant by impeding access of water. It is this reason that disks could not 
be used in conjunction with the disintegration testing equipment, as the tablets with high 
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Starch 1500 content ended up sticking. StarCap 1500 is a relatively new product to market 
so comparative data is difficult to find. When compared to Starch 1500, StarCap 1500 was 
shown to have quicker disintegration and tablet hardness in agreement with our study, 
with the additional advantage of having higher lubricant sensitivity (Mužíková and 
Eimerová, 2011).  
Earlier data had shown that a P407 content of 2 % led to disintegration times comparable to 
0 % P407 content (Figure 5.4). Initial screening was conducted at 10 % as an initial value, 
but this was always surplus to requirements and likely to change during later formulation 
development. StarCap 1500 in combination with 2 % P407 was examined and this led to a 
further reduction in disintegration time for all formulations (Figure 5.10) to 34 s and 30 s, 
respectively, for low-dose F5 and F6, and 61 s and 50 s for high-dose F5 and F6, 
significantly lower than the formulations containing Starch 1500 and 2 % P407 (p < 0.01). 
Interestingly, low-dose F6 became the fastest low-dose formulation, despite previously the 
slowest. This change is also observed at 2 % P407 using Starch 1500 as a binder (Figure 
5.10), indicating that the hydrophilic 10 % poloxamer was able to mask the properties of 
the disintegrants/superdisintegrants, as outlined in section 5.4. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Summary of optimisation steps for A) low-dose F5, B) low-dose F6, C) high-dose F5 and D) high-dose F6, showing the conversion of the multipurpose binder, Starch 
1500, to StarCap 1500, showing hardness (clear bars) and disintegration times (blue bars), in addition to optimising P407 to 2 %. Hardness and disintegration data shown as the 
mean of n of 10 and 6 tablets respectively ± SD with disintegration times annotated for clarity. Statistical significance was conducted by one-way ANOVA followed by Tukey’s post 
hoc test. Statistical significance is annotated as follows: ns (p > 0.05); ** (p < 0.01); **** (p < 0.0001).  
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 Design of Experiments: Screening Round 2 5.5.
The removal of ethylcellulose completely, coupled with the reduction in poloxamer content, 
produced ODTs with disintegration times of 16 and 45 seconds for the lead low-dose and 
high-dose tablets, respectively (Figure 5.10) As such, a second round of DoE screening was 
utilised to further refine the tablet composition by examining the impact of mannitol, MCC 
and StarCap 1500 on the ODT characteristics, with the latter taking the place of Starch 1500. 
For the low-dose, these materials now occupied 50.5 % of the tablet by weight, and the 
screening was set up in order to test 0-42 % of each excipient. From the previous round of 
DoE screening, it was found that mannitol was the only excipient to significantly (p < 0.05) 
decrease disintegration time for both formulations (Table 5.4 and Table 5.5). For low-dose, 
disintegration time was less of a concern as the tablets were now disintegrating in less than 
30 seconds. For the high-dose formulations, mannitol was screened using a higher 
percentage upper limit of 0-30 % (w/w), whereas MCC was examined at 0-20 % (w/w). As the 
impact of StarCap 1500 was unknown, it was tested in a slightly higher range of 0-23 % 
(w/w). From the screening outlined by JMP DoE software, 15 low-dose formulations and 14 
high-dose formulations were suggested (Table 5.6). 
 Physical Characterisation 5.5.1.
Hardness and disintegration data for the second round of the DoE screening is presented in 
Figure 5.11. The low-dose formulations produced tablets with a hardness value of 4.4- 11.9 
kp, with disintegration times all of the low-dose formulations produced tablets with 
disintegration times of 16-29 s (Figure 5.11a). The high-dose formulations produced tablets 
with hardness values of 6.8-11.7 kp, although disintegration times were higher than low-dose 
at 36-78 s (Figure 5.11b). As such, all low-dose tablets conformed to both the European 
Pharmacopeia limit of 180 seconds for uncoated tablets (European Pharmacopeia, 2009) and to 
the United States Pharmacopeia limit of 30 seconds (McLaughlin et al., 2009). However, the 
high-dose tablets only conformed to the former and the 30-second target was never reached 
for these formulations (Figure 5.11b), with the lead high-dose formulations disintegrating at 
37-38 s and 36 s seconds for F7/F8 and F13, respectively (formulations F7 and F8 are identical 
repeats). 
  
 
 
Table 5.6. Low-dose and high-dose formulation compositions indicated by the second round of DoE mapping using JMP 12 DoE software to optimise MCC, Starch 1500 and 
mannitol content (indicating the key variables in red) within the ODT formulation. 
Low-dose - 11 % Drug – 295 mg 
     80.5% MCC/StarCap 1500/Mannitol 
Excipient Composition, % (w/w) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 
Mannitol 40.25 0.00 0.00 38.50 38.50 32.67 42.00 38.50 26.83 32.67 38.50 0.00 42.00 26.83 40.25 
MCC 0.00 40.25 42.00 42.00 0.00 34.42 38.50 0.00 26.83 13.42 42.00 38.50 0.00 26.83 40.25 
StarCap 1500 40.25 40.25 38.50 0.00 42.00 13.41 0.00 42.00 26.84 34.41 0.00 42.00 38.50 26.84 0.00 
Poloxamer 407 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
Crospovidone 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 
Glycerol Behenate 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 
APAP 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 
Total 100.00 
             
                High-dose - 41 % Drug – 795 mg 
     50.5% MCC/StarCap 1500/Mannitol 
Excipient Composition, % (w/w)  
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
 Mannitol 30.00 28.75 27.50 30.00 23.75 17.50 30.00 30.00 23.75 26.88 15.63 7.50 18.75 7.50 
 MCC 10.00 0.00 0.00 0.00 10.00 10.00 20.00 20.00 10.00 15.00 15.00 20.00 20.00 20.00 
 StarCap 1500 10.50 21.75 23.00 20.50 16.75 23.00 0.50 0.50 16.75 8.62 19.87 23.00 11.75 23.00 
 Poloxamer 407 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 10.00 
 Crospovidone 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 
 Glycerol Behenate 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 
 APAP 41.00 41.00 41.00 41.00 41.00 41.00 41.00 41.00 41.00 41.00 41.00 41.00 41.00 41.00 
 Total 100.00 
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Figure 5.11. The results of the second round of DoE screening, showing tablet hardness (clear bars) and disintegration time (blue bars) for A) low-dose and B) high-dose tablets. 
Data presented as the mean of n = 10 tablets for hardness and n = 6 tablets for disintegration time ± SD. 
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In order to test the robustness of the tablet formulations, friability testing was conducted 
according to the United States Pharmacopeia (USP, 2013), and the results are presented in 
Table 5.7. Low-dose tablet friability was found to be negligible for all low-dose 
formulations at 100 rotations (< 0.15 %) and well with the 1 % limit recommended by the 
United States Pharmacopeia (USP, 2013). Even using accelerated friability conditions of 500 
revolutions, friability never exceeded 0.65 % for all low-dose formulations. High-dose 
friability was higher than low-dose tablets (Table 5.7) and only formulations F7, F8, F10, 
F12 and F14 conformed to the recommended 1 % limit recommended by the United States 
Pharmacopeia (USP, 2013).  
Table 5.7. Results of friability testing of the low-dose and high-dose formulations following the second round of 
DoE screening, showing the percentage loss of tablet mass after 100 rotations and 400 rotations. 
Formulation 
Friability (%) 
100 rpm 500 rpm 
Low-dose 
1 0.10 0.54 
2 0.00 0.09 
3 0.06 0.16 
4 0.07 0.10 
5 0.08 0.40 
6 0.06 0.09 
7 0.05 0.10 
8 0.09 0.35 
9 0.08 0.21 
10 0.02 0.23 
11 0.15 0.16 
12 0.00 0.17 
13 0.13 0.65 
14 0.08 0.42 
15 0.07 0.10 
    
High-dose 
1 1.35 5.30 
2 1.82 6.66 
3 1.96 7.54 
4 1.75 6.51 
5 1.36 5.38 
6 1.32 4.99 
7 0.86 4.09 
8 0.86 3.45 
9 1.44 5.65 
10 1.04 3.99 
11 1.28 5.10 
12 0.91 2.78 
13 1.10 4.89 
14 1.06 4.18 
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 Design of Experiments Interpretation of Data 5.5.2.
With the formulations part optimised by the reduction in poloxamer content and the 
removal of ethylcellulose, a second round of screening was conducted in order to refine the 
tablets further, with the examination of StarCap 1500 in place of Starch 1500. The bivariate 
analysis of the second round of screening is presented in Figure 5.12 and Figure 5.13. 
For the low-dose formulations, StarCap 1500 and mannitol decreased tablet strength whilst 
MCC was able to improve it (Figure 5.12a). Furthermore, MCC had almost perfect 
correlation with tablet strength (r2 = 0.98) (Table 5.8). For disintegration, higher StarCap 
1500 content increased disintegration time, whereas MCC decreased it (Figure 5.12b). These 
effects were both significant (p < 0.05), but the impact of mannitol was insignificant (p > 
0.05) on tablet disintegration (Table 5.8). For the high-dose formulations, StarCap 1500 and 
MCC led to a significant (p < 0.05) decrease and increase respectively in tablet strength 
(Figure 5.13b), with MCC showing a particularly good fit to the model with r2 = 0.98 (Table 
5.9). The impact of mannitol on high-dose hardness was insignificant (p > 0.05). For high-
dose formulations, higher StarCap 1500 content increased disintegration time, whereas 
MCC decreased it (Figure 5.13b), with r2 values of 0.55 and 0.75 respectively (Table 5.9). 
Mannitol once more correlated extremely poorly with disintegration time (r2 = 0.01), and 
neither was the impact significant (p > 0.05). 
For both formulations, the increased quantity of MCC led to an increase in hardness most 
likely attributed to its ability to undergo a unique plastic deformation during compression 
that occurs through enhanced hydrogen bonding to adjacent MCC particles (Al-Khattawi 
and Mohammed, 2013), as was also apparent for the first round of DoE screening (Figure 
5.2a and Figure 5.3a). During the first round of DoE, MCC had no correlation with 
disintegration times with r2 values of 0.3 and 0.0 respectively for low-dose and high-dose 
formulations (Table 5.4 and Table 5.5). For the second round of DoE, MCC now correlated 
well for both formulations (r2 ≥ 0.85), with decreasing disintegration times confirming the 
data presented in Figure 5.6 that poloxamer 407 was able to block the wicking action of the 
disintegrants when used at 10 % (w/w) (Kaul et al., 2011), allowing the wicking action of 
MCC to become a dominant factor. For both formulations, StarCap 1500 led to a decrease in 
hardness and an increase in disintegration time (Figure 5.12b and Figure 5.13b). Although 
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an improvement over Starch 1500, the plastic deformation of starch is a slow process 
meaning quick compression is insufficient in producing strong interparticle bonds during 
plastic deformation, and the deformation is largely elastic (Rees and Rue, 1978). The 
increased disintegration time associated with this material most likely corresponds to gel 
forming of the material upon hydration. Mannitol had no impact upon hardness for either 
formulation (Figure 5.12a and Figure 5.13a, r2 > 0.05). For both low-dose and high-dose 
formulations, increasing mannitol content had no impact (p < 0.05) upon disintegration 
time (Figure 5.12b and Figure 5.13b). This is unlike the first round of DoE where mannitol 
significantly (p < 0.05) decreased disintegration times for both formulations (Figure 5.2a 
and Figure 5.3a). As this was attributed to the wetting properties of the material (Kubo and 
Mizobe, 1997), removing the ethylcellulose and decreasing the poloxamer content down to 
2 % (w/w) has likely achieved optimum wettability beyond that which mannitol is capable 
of achieving.  
 
 
Figure 5.12. Design of experiments trace plots for low-dose formulations showing A) hardness and B) 
disintegration, showing the impact of StarCap 1500 (red), MCC (blue) and mannitol (black). 
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Table 5.8. Summary of the model statistics on the impact of the test excipients on hardness and disintegration on 
the low-dose formulations from the second round of DoE screening. 
Factor r2 F ratio Prob > F 
Hardness 
StarCap 1500 0.43 9.87 0.0078 
MCC 0.98 544.34 0.0001 
Mannitol 0.14 2.08 0.1725 
     
Disintegration 
Starch 1500 0.53 14.46 0.0022 
MCC 0.85 71.97 0.0001 
Mannitol 0.0.5 0.65 0.4342 
 
 
Figure 5.13. Design of experiments trace plots for high-dose formulations showing A) hardness and B) 
disintegration, showing the impact of StarCap 1500 (red), MCC (blue) and mannitol (black). 
 
Table 5.9. Summary of the model statistics on the impact of the test excipients on hardness and disintegration on 
the high-dose formulations from the second round of DoE screening. 
Factor r2 F ratio Prob > F 
Hardness 
StarCap 1500 0.51 12.38 0.0042 
MCC 0.87 79.46 0.0001 
Mannitol 0.03 0.43 0.5264 
  
      
Disintegration 
StarCap 1500 0.55 14.51 0.0025 
MCC 0.75 36.04 0.0001 
Mannitol 0.01 0.11 0.7486 
 
In general, all low-dose formulations at this stage of development could be classed as a 
potential marketable product; disintegration time is below 30 seconds, and hardness and 
friability data is within usable limits in order to withstand the stress of further unit 
processing, such as film coating and packaging. For the high-dose tablets, the decision was 
made to stop development after the second round of screening and pursue the low-dose 
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formulations for rotary press production. At the most advanced level of development, the 
lead formulation high-dose tablets, F13 had a disintegration time of 36 s and a hardness 
value of 10.7 kp (Figure 5.11b). 
 
 Scale-up Manufacture using the Rotary Tablet Press 5.6.
Scale-up is an essential part of the transformation of a formula to a viable commercial 
product in the pharmaceutical industry. This phase can identify problems in the process 
such as unreproducible compressibility and lack of uniformity that may be problematic in 
the larger production cycle. In order to test the scale-up capability of the tablets, three 
formulations were selected for rotary trial using a Picolla multi-station press. The previous 
formulation F9, the theoretical centre point of the DoE design in which all excipients were 
at the same content, was modified according to Table 5.10. Formulation 1 is identical to the 
previous Formulation 9 from the second round of DoE (Table 5.6). This is accompanied by 
Formulation 2 containing 50 % more StarCap 1500 as a multipurpose binder and 
Formulation 3 containing 50 % more mannitol. The modified Formulation 2 (F2) and 
Formulation 3 (F3) were chosen to assess the impact of the multipurpose binder on the 
automated tableting press and to boost the concentration of mannitol to increase the 
potential palatability of the dosage formulation, respectively. 
 
Table 5.10. The composition of the final formulations chosen for production of the Picolla rotary tablet press 
indicating the key variables (red). 
Excipient 
Composition, % (w/w) 
F1 F2 F3 
Mannitol 26.83 26.83 33.54 
MCC 26.83 13.42 33.54 
StarCap 1500 26.84 40.26 13.42 
Poloxamer 407 2.00 2.00 2.00 
Crospovidone 5.00 5.00 5.00 
Glycerol Behenate 1.50 1.50 1.50 
APAP 11.00 11.00 11.00 
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 Physical Characterisation 5.6.1.
The formations shown in Table 5.10 were first produced via manual compression on the 
Atlas A5 in order to compare single and rotary press data. The results are presented in 
Figure 5.14. Compared to F1, which has a hardness value of 7.9 kp, F2 and F3 have 
significantly (p > 0.0001) different hardness values of 5.4 kp and 9.4 kp, respectively. 
Interestingly, disintegration times have the opposite effect, F1 showed a disintegration time 
of 19s, which increased to 23s for F2, and decreased to 16s for F3.  
 
Figure 5.14. The formulations shown in Table 5.10 made by direct compression, showing tablet hardness (clear 
bars) and disintegration time (blue bars). Data presented as mean ± SD from n = 10 tablets for hardness and 6 
tablets for disintegration time ± SD. Statistical significance was calculated using one-way ANOVA with Dunnett’s 
post hoc test, annotated as follows: **** (p < 0.0001).  
 
The 10-station rotary press was equipped with 5 convex 10 mm die, with the remaining 
stations fitted with a blank die to reduce overall production rates. Of the die fitted, 4 were 
of normal convex curvature and one was equipped with an embossed Colorcon brand. The 
latter die was noticed to be of a different diameter during the first run, and was unable to 
correctly press embossed tablets. This impacted the main compression force of all of the 
stations since the computer interface takes an average reading over all 5 stations. Due to 
the limited availability of the equipment and the large amount of time it would take to 
replace the defective station, the remaining tablets were intentionally produced at 6, 12, 18 
and 22 kN compression force, rather than the intended 5, 10, 15 and 20 kN. As such, the 
compression force was approximately 25 % higher accounting for the ineffective station. 
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The hardness and disintegration times for the tablets produced by the rotary press are 
presented in Figure 5.15. Over the compression range tested, the differences in hardness 
are statistically well defined. At each level of compression, F3 is statistically (p < 0.001) 
harder than F1 at each compression level. For disintegration, F3 was significantly (p < 
0.0001) faster at disintegrating at 6 kN and 12 kN than F2 except at 18 kN (p > 0.05), and 
significantly (p < 0.001) slower at 23 kN. Compared to F1, F3 was significantly faster at 
disintegrating at 12 kN and 18 kN, but statistically similar at the remaining compression 
forces (p > 0.05). In general, F3 had the fastest disintegration times at 6-18 kN with 
disintegration times of 9 s, 15 s and 28 s, respectively, but at the highest compression (23 
kN), F2 disintegrated the quickest at 31 s. 
 
Figure 5.15. The results of the physical characterisation of tablets produced by the rotary tablet press, showing 
tablet hardness (clear bars) and disintegration time (blue bars). Data presented as the mean of n = 10 tablets for 
hardness and n = 6 tablets for disintegration time ± SD. 
 
For friability, all tablets were well within the 1 % limit recommended by the United States 
Pharmacopeia (USP, 2013) with values of 0.05-0.59 % loss, and substantial damage was only 
observed under accelerated friability stress conditions of 500 rotations (Table 5.11), 
although most tablet formulations still conformed at or close to the 1 % recommended limit 
under these conditions. 
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Table 5.11. The percentage weight loss of tablets produced by the rotary press, showing normal friability (100 
rotations) and accelerated friability (500 rotations). 
Formulation Compression (kN) 
Friability (%) 
100 rotations 500 rotations 
Formulation 1 
6 0.29 1.79 
12 0.13 0.67 
18 0.13 0.65 
23 0.05 0.46 
      
 
Formulation 2 
6 0.59 4.58 
12 0.48 1.03 
18 0.14 0.83 
23 0.05 0.66 
      
 
Formulation 3 
6 0.13 1.06 
12 0.04 0.49 
18 0.10 0.49 
23 0.05 0.41 
 
The rotary software has the added advantage of providing a plethora of information for the 
compression and ejection forces on each of the turret-fitted die, giving a greater 
interpretation of data than is possible on a single manual compression press. The impact of 
compression force on the physical characteristics of the tablets is presented in Figure 5.16. 
The relationship between compression and ejection force is shown in Figure 5.16a. High 
ejection forces can result in tablet defects such as capping and lamination. The data shows 
that F3 has the highest ejection force of the formulation tested, followed by F1 and then F2, 
following the rank order of StarCap 1500 composition (F2>F1>F3), indicating that StarCap 
1500 has superior lubricating properties to both mannitol and MCC. Starches have long 
been known to have lubricating properties (Jarosz and Parrott, 1984), and StarCap 1500 has 
been shown to increase sensitivity of the presence of the lubricant (Mužíková and 
Eimerová, 2011). The high lubricant sensitivity of starches is due to the compaction 
mechanism of plastic deformation (Jarosz and Parrott, 1984). In a study on a range of 
compressible powders, Starch 1500 and StarCap 1500 were shown to be highly plastic 
deforming (Li et al., 2013b).  
The compactibility curves of the formulations are presented in Figure 5.16b. Hardness 
increases as a function of compression, however it can also be seen that hardness decreases 
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in the order F3>F1>F2. This rank order corresponds to the increasing concentrations of 
MCC in the formulations, and/or the decreasing StarCap 1500 content in agreement with 
the results of the second round of DoE screening (Figure 5.12).  
Disintegration times as a function of compressibility are presented in Figure 5.16c. 
Disintegration time increases with increased compression, although interestingly F2 
appears linear over the compression range tested suggesting that StarCap 1500, the main 
constituent material of F2, is able to maintain a wicking effect even after increased 
compression, whereas F2 had the lowest compression at 23 kN, both F1 and F3 had the 
fastest disintegration times at the remaining compression forces. 
The effects of compression on friability are presented in Figure 5.16d. Friability decreases 
with increased compression force, and all formulations converged to almost 0 % friability 
at 23 kN. At low compression (5 kN), F3 shows the lowest percentage friability followed by 
F1 and F2, corresponding to a decrease in MCC content and/or an increase in StarCap 1500 
content  
 
 
     
 
 
Figure 5.16. The results of the impact of compression force on range of physical tablet attributes, showing A) ejection force, B) hardness, C) disintegration time and D) friability. 
Data presented as the mean of n = 10 tablets for hardness and friability and n = 6 tablets for disintegration time ± SD. 
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 Weight Variation 5.6.2.
Weight variation for tablets must conform to the following specifications according to the 
United States Pharmacopeia (USP, 2011): 
 All 10 tablets tested must fall within ± 15 % of the mean. 
 RSD must be below 6 % of the mean. 
Weight variation for all formulations is presented in Table 5.12. All formulations over a 
range of compressions, and the RSD did not exceed 1.8 % for all formulation. 
 
Table 5.12. The weight variation data of tablets produced using the rotary press. Data presented from 10 tablets 
per formulation. 
Formulation Compression (kN) Average Weight (mg) Standard Deviation RSD (%) 
Formulation 1 
6 296.48 2.78 0.94 
12 298.64 2.25 0.76 
18 300.72 3.77 1.25 
23 303.87 4.62 1.52 
    
 
Formulation 2 
6 301.13 2.77 0.92 
12 296.74 5.20 1.75 
18 303.24 2.83 0.93 
23 303.01 2.41 0.80 
    
 
Formulation 3 
6 293.24 2.60 0.89 
12 298.56 2.43 0.81 
18 301.16 3.34 1.11 
23 302.91 4.97 1.64 
 
 Evaluation of Over the Counter Orally Disintegrating Tablets 5.7.
In order to compare the ODTs of APAP to known established products, three marketed 
formulations were tested in parallel to both the high and low-dose tablets. These were 
Nurofen® Meltlets, Calpol® SixPlus and Imodium instants® (Figure 5.17).  
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Figure 5.17. Marketed products used for comparative study, showing the biconcave shape of A) Calpol SixPlus and 
B) Nurofen Meltlets produced via direct compression and C) the flat faced, lyophilised Imodium Instants, and 
their respective unbroken blister packs. 
 
Nurofen® Meltlets and Calpol® SixPlus tablets were both biconcave with rounded edges, 
whereas Imodium Instants® were small and flat faced (Figure 5.17). Both the Nurofen® 
Meltlets and Calpol® SixPlus tablets appear to be made by direct compression owing to the 
presence of magnesium stearate in the formulations. Imodium Instants are made via 
lyophilisation by pouring the mixture directly into blister packs. The OTC hardness and 
disintegration data is presented in Figure 5.18. The Nurofen® Meltlets and Calpol® SixPlus 
had hardness values of 6.1 kp and 5.3 kp, respectively, whereas the Instants were thin and 
fragile, and produced no detectable hardness value. The Meltlets had a disintegration time 
of 17.7s, and the Fastmelts has a disintegration time of 9.8s. For the Imodium Instants®, no 
disintegration time was recorded as the tablet dissolved instantly upon contact with water.  
When compared to the lead low-dose and high-dose APAP formulations produced during 
the second round of DoE screening (low-dose F15 and high-dose F13 shown in Figure 
5.11b), the marketed products display lower hardness values (Figure 5.18). For all three 
OTC products, the patient instructions state to break the foil lining of the blister pack prior 
to pushing the tablets out of the packet to prevent the tablet breaking. Therefore, the OTC 
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products demonstrate the feasibility of producing an ODT with excellent disintegration 
properties at the expense of poor hardness as this can be addressed with appropriate 
packaging. The current high-dose tablets developed in the present study are harder than 
the marketed OTCs for a similar drug loading – 250 mg paracetamol for Calpol® SixPlus 
(5.3 kp) and 325 mg paracetamol for the APAP high-dose formulations (10.7 kp). 
 
Figure 5.18 The hardness and disintegration times of OTC formulations. Data shown as the mean of n = 3 tablets 
for disintegration and n = 3 tablets for hardness, ± SD. For Imodium® Instants, disintegration time was 
instantaneous upon contact with water. Likewise hardness was too low to be detected. OTC data is shown in 
comparison to the fastest disintegrating low-dose and high-dose tablets, F15 and F13 respectively, from the second 
round of DoE screening (shown in Figure 5.11) where data is presented as the mean of n = 6 tablets for 
disintegration time n = 10 tablets for hardness, ± SD. 
 
The lead formulation of the final development of the high-dose APAP after the second 
round of DoE screening, F13, had a disintegration time of 36 s and a hardness of 10.7 kp 
(Figure 5.18). The OTC Calpol® SixPlus, an ODT of identical weight to our high-dose tablets 
at 795 mg, and with comparable drug loading (325 mg for F13 and 250 mg for the Calpol® 
SixPlus), had a hardness of 5.3 kp with a disintegration time of 10 s (Figure 5.18), much 
faster than those which we were able to achieve. However, for the low-dose tablets, the 
rotary press provided a number of formulations with disintegration times less than 30 s. 
The rotary press Formulation 3 was able to disintegrate in 15 s when compressed at 12 kN, 
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with a hardness of 9.4 kp (Figure 5.15). Moreover, this same formulation provided tablets 
with disintegration times of 9 s when compressed at 5 kN, with a hardness of 4.9 kp similar 
in strength to that of Calpol® SixPlus. 
 Conclusions of Tablet Design and Manufacture 5.8.
The work in this chapter describes the development of two ODT formulations 
incorporating 2 % (w/w) poloxamer 407 as ABCB1 efflux transporter modulating excipient. 
At the end phase of development, tablets manufactured using a rotary tablet press had 
disintegration times below 30 seconds, conforming to United States Pharmacopeia 
specification. Any of these formulations, taken with a 250 mL glass of water on an empty 
stomach, are capable of delivering 5.9 mg of poloxamer 407 to give a final concentration of 
2.36 x 10 -3 % (w/v), or 2.7 times higher than the IC50. All three of the final formulations 
made by rotary press conform to the United States Pharmacopeia specifications for 
disintegration in under 30 seconds at 12 kN compression, F2 and F3 also conform at 18 kN 
with F1 falling just outside this limit with a disintegration time of 31 seconds. 
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 6. An Investigation into the Incorporation of Biologically-Active Surfactants into 
Ibuprofen Granule Coatings for the use in Directly Compressed  
 Introduction 6.1.
In the previous chapter, ODT tablets were produced by direct compression containing 2 % 
(w/w) poloxamer 407, which was selected due to the high efficacy against the ABCB1 efflux 
transporter system. In order to widen the application of the excipients with inhibition 
properties found during screening in Chapter 4, a number of excipients were chosen for 
evaluation as constituents of granule coatings. Direct processing of drug particles by coatings 
have been used to improve the properties of the powders, such as improving flowability 
(Ehlers et al., 2009, Genina et al., 2010), or taste masking (Hamashita et al., 2007). Ibuprofen is 
known for its high degree of cohesion, resulting in poor flow properties as well as bad 
compaction (Rasenack and Müller, 2002), in addition to having a bitter taste (Gryczke et al., 
2011). Therefore, ibuprofen is an excellent candidate for coating trials. 
The aim of the work presented in this chapter was to evaluate the suitability of incorporating 
biologically active surfactants found to have kinetic activity against efflux transporters as 
coating agents alongside Kollicoat IR, and to study the impact of these coatings on the 
powder flow and the physical characteristics of the ODTs produced using the coated 
granules. The surfactants of interest were PEG 2000, poloxamer 407 (ABCB1 IC50 = 8.85 x 10-
4), and Cremophor EL (PEG 40 Castor Oil) similar to the Etocas excipients that showed 
efficacy for both ABCB1 and ABCC2 (ABCB1 IC50 = 3.80 x 10-3, ABCC2 IC50 = 3.49 x 10-3). 
Cremophor EL offered the additional challenge of being the only liquid used for formulation 
studies. 
Kollicoat IR® is a polyvinyl alcohol-polyethylene glycol graft copolymer which has been 
specifically formulated for the purpose of tablet coating (Figure 6.1). As a non-ionic 
hydrophilic polymer, Kollicoat IR has the advantage of being equally soluble throughout the 
gastro-intestinal tract. This polymer has also been shown to reduce surface tension of water 
(Kolter et al., 2002). 
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Figure 6.1. The chemical structure of the polyvinyl alcohol-polyethylene glycol copolymer Kollicoat IR. 
 
In order to evaluate the additional impact of surfactants in granule coatings, particles were 
made by wet granulation according to the composition of Table 6.1, and the resulting 
granules were then coated using Kollicoat IR or Kollicoat IR with 2 % (w/w) surfactant as 
outlined in Table 6.2. 
 
Table 6.1. Formulation composition of ODTs used in coating trials. 
 
 
 
 
 
Table 6.2. Nomenclature of Kollicoat IR dispersions. 
Coating dispersions Name 
Uncoated C0 
10 % (w/v) Kollicoat IR C1 
10 % (w/v) Kollicoat IR + 2 % (w/v) PEG 2000 C2 
10 % (w/v) Kollicoat IR + 2 % (w/v) Poloxamer 407 C3 
10 % (w/v) Kollicoat IR + 2 % (w/v) Cremophor EL C4 
 
Excipient Percentage Content (%) Mass (g) 
Starch 1500 8.68 10.42 
MCC 17.37 20.84 
Mannitol 28.95 34.74 
Crospovidone 4.50 5.40 
Magnesium stearate 0.50 0.60 
Ibuprofen 40.00 48.00 
Total 100.00 120 
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 Evaluation of Flow Properties of Surfactant-Coated Granules 6.2.
The flow properties of a powder during manufacturing can impact the quality of the finished 
product during pharmaceutical processing. Powder must flow easily and in a uniform 
manner to fill the die and to ensure uniformity of content and reproducibility within the 
tablet production cycle, as poor flow properties are associated with difficulties with filling 
and compression (Räsänen et al., 2003). Powder flow can be regarded as a multi-faceted 
process, influenced by particle size and size distribution, shape and moisture content, 
amongst others (Li et al., 2004). Due to this complexity, multiple methods of determining and 
classifying powder flowability have been developed as outlined in Table 6.3. As such, the 
coated granules were subjected a number of flowability tests, presented in Table 6.4.  
Powder bulk density, defined as the ratio of mass of untapped powder over volume, and 
tapped density, the increase in bulk density after mechanical tapping, are simplistic 
measures of powder flow based on the intrinsic density of the powders (USP, 2012a). All 
coated granules showed significantly (p > 0.01) higher bulk density measurements than that 
of the uncoated granules (C1), in addition, all coated granules showed a significantly (p > 
0.001) higher tapped density than that of the uncoated granules (Table 6.4). In contrast, the 
angle of repose showed no significant (p < 0.05) difference between coated and uncoated 
granules (Table 6.4). However, these granules are categorically different according to this 
measure, with the granules made from formulation C2 showing ‘excellent’ flow properties, 
C3 and C1 showing ‘good’ flow properties, and C4 demonstrating ‘fair’ flow properties. 
According the Carr’s Index data, only coating C3 containing 2 % poloxamer 407 showed any 
significant (p > 0.05) difference compared to that of the uncoated granules. As a Carr’s index 
value below 25 indicates excellent flow properties (Carr, 1965), all granules fall into the 
‘good’ to ‘excellent’ category with the exception of C3 (Table 6.4). Likewise, C3 also showed a 
significant (p > 0.05) increase according to the Hausner ratio, defined as the ratio between 
tapped and bulk density of powders, in relation to the other surfactant-coated granules. A 
Hausner ratio value below 1.25 indicates good powder flow characteristics (Abdullah and 
Geldart, 1999). As such, all granules demonstrated ‘good’ flowability with the exception of 
C3 which was characterised as ‘fair’ (Table 6.4). Granules coated with Cremophor EL (C4) 
showed the lowest values for both indicators out of all of the coatings tested. 
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As powder flow is a complicated process, many of the methods of determining the flow 
properties are subjective. In reflection of this, multiple methods were used to determine the 
flow properties of the coated and surfactant-coated granules. The angle of repose measures 
the internal friction or cohesion of the particles (Fahmy and Kassem, 2008), and according to 
this measure, formulation C4, containing Cremophor EL, showed the poorest flow properties 
of all the formulations tested, whereas Carr’s index and the Hausner ratio determined C4 to 
have the best flow properties (Table 6.4). These latter two forms of measurement are based 
on the compressibility of the materials, whereby a higher coefficient of internal friction is 
associated with higher values (Chan and Page, 1997), whereas the angle of repose is based on 
the internal friction or cohesion of the particles (Fahmy and Kassem, 2008). The differences 
between the rank order of the granule flowability obtained from the angle of repose measure 
(C2 > C3 > C0 > C4) versus Carr’s Index and the Hausner ratio (C4 > C0 > C2 > C3) are likely 
attributed to the subjective nature of the former. Despite its ease of use, the angle of repose is 
often considered as only a guide to powder flow characteristics, since it is subjective to the 
user and the initial experimental conditions, and is not an intrinsic property of the powder 
(Nagel and Peck, 2003). The angle of repose can vary depending upon the nature of the 
powder base which can influence cone morphology, and falling powder can add distortions 
in the cone peak (Taylor et al., 2000). As such, Carr’s Index and the Hausner ratio are more 
widely considered as acceptable methods of measuring powder flowability. According to 
these two measures, granules coated with formulation C4 (Cremophor EL) showed the 
greatest flow properties. As the only liquid excipient tested amongst the three surfactants, 
Cremophor EL formed a visibly more viscous coating solution. In relation to the less viscous 
solutions of PEG 2000 and poloxamer 407, the coating containing Cremophor EL may have 
led to an increase in granule size. This could have led to a corresponding increase in 
flowability by overcoming the Van der Waals forces which restrict the flowability of smaller 
particles (Heim et al., 1999). In addition to particle size, the flowability of the granules is 
similar to the rank order of the moisture content for the surfactant-coated granules. 
Therefore, the poorer flowability of C2 and C3 compared to C4 and the uncoated powder is 
most likely attributed to the higher moisture content, which has been implicated in 
decreasing the flow properties by increasing interparticle interactions (Sun, 2016) and/or 
increasing the number of interactions by shortening the distance between particles (Coelho 
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and Harnby, 1978). Despite this, all powders showed appropriate flow properties and would 
perform well during pharmaceutical unit processing without arching in the hopper.  
 
Table 6.3. The classification of powder flow based on angle of repose, Carr’s Index and Hausner Ratio. 
  Angle of Repose (θ) Carr's Index (%) Hausner Ratio 
Excellent 25-30 5-12 1.00-1.11 
Good 31-35 12-16 1.12-1.18 
Fair - aid not needed 36-40 18-21 1.19-1.25 
Passable - may hang up 41-45 23-35 1.26-1.34 
Poor - must agitate 46-66 
 
1.35-1.45 
Very Poor 56-65 33-38 1.46-1.59 
Very, very poor > 66 > 40 > 1.60 
 
 
Table 6.4. The powder flow properties of the ODT formulations. Results are presented as mean ± SD from n = 3, 
except moisture content. 
Coating solutions 
Bulk 
density 
Tapped 
density 
Angle of 
repose (θ) 
Carr’s index 
(%) 
Hausner 
ratio 
Moisture 
content 
(%) 
C0 – Uncoated 0.43 ± 0.01 0.49 ± 0.01 33.04 ± 1.50 12.24 ± 4.90 1.14 ± 0.06 7.20 
C2 – 2 % (w/v) PEG 2000 0.49 ± 0.01 0.58 ± 0.02 30.62 ± 2.36 15.52 ± 5.00 1.18 ± 0.07 9.40 
C3 – 2 % (w/v) Poloxamer 407 0.46 ± 0.01 0.60 ± 0.02 31.35 ± 0.44 23.33 ± 4.12 1.30 ± 0.07 10.50 
C4 – 2 % (w/v) Cremophor EL 0.53 ± 0.00 0.58 ± 0.02 35.17 ± 0.61 8.62 ± 3.07 1.09 ± 0.04 8.10 
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 Evaluation ODTs Produced using of Surfactant-Coated Granules 6.3.
In order to evaluate the impact of the surfactant-coated granules on the ODT physical 
characteristics, the powders C2-C4 were compressed to form 500 mg tablets using 1 ton 
compression, and the tablet characteristics data is presented in Table 6.5. All surfactant-
containing formulations showed a significantly (p < 0.05) lower disintegration and 
hardness value compared to C1 (Kollicoat IR-only coating), alongside lower friability. Of 
the tablets made from the surfactant-coated granules, formulation C4 containing 2 % 
Cremophor EL showed the lowest friability at 2.19 %, followed by C3 (2 % poloxamer 407) 
and C2 (2 % PEG 2000) at 2.53 % and 3.62 %, respectively (Table 6.5). Between the 
surfactant-coated formulations, C4 produced the hardest tablets at 28.1 N, although 
hardness for all of these tablets was statistically similar (p > 0.05). All formulations 
displayed disintegration times conforming to the United States Pharmacopeia limit of 30 
seconds (McLaughlin et al., 2009, USP, 2013) (Table 6.5), with no significant (p > 0.05) 
difference between all disintegration times. 
The significantly lower disintegration times and hardness of the surfactant-containing 
formulations compared to the C1 (Kollicoat IR-only coated) formulations is most likely 
attributed to the higher compression forces used for C1 formulations (2 ton instead of 1 ton 
for C2-C4). This was used to address the poor hardness of a previous batch (data not 
shown) and likely contributed to an increase in tablet strength due to an increase in 
intramolecular bonds. Disintegration times for the surfactant-coated tablets were 
significantly (p < 0.05) decreased under decreased compression attributed to the increase in 
the tablet porosity (Kitazawa et al., 1975), and partially due to the addition to the 
hydrophilic nature of the surfactants which increases wettability of the coating in 
comparison C1, which only contains Kollicoat IR. The acceptable levels of hardness for all 
tablet formulations is most likely attributed to the good compressibility of MCC, which is 
known to undergo a unique plastic deformation during compression that occurs through 
enhanced hydrogen bonding to adjacent MCC particles (Al-Khattawi and Mohammed, 
2013). The formulation containing Cremophor EL (C4) showed lower friability and higher 
strength than the tablets made using the other formulations, which may be associated with 
the higher viscosity of this surfactant which aids the binding of the granules under 
compression (Gumaste et al., 2013).  
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Table 6.5. The physical properties of tablets produced from the coated powders C1 (compressed at 2 metric tons) 
and C2-C4 (compressed at 1 metric ton). Data presented ± SD from n = 3 tablets (aside from friability). 
Coating solutions Friability (%) Hardness (N) Disintegration time (s) 
C1 – 10 % Kollicoat 0.807 81.76 ± 2.22 79.00 ± 6.56 
C2 – 10 % Kollicoat + 2 % PEG 2000 3.624 24.13 ± 0.49 13.30 ± 1.53 
C3 – 10 % Kollicoat + 2 % Poloxamer 407 2.525 27.30 ± 3.03 14.00 ± 1.73 
C4 – 10 % Kollicoat + 2 % Cremophor EL 2.188 28.10 ± 3.92 13.67 ± 0.58 
 
The application of surfactants in coatings has been the focus of a number of previous 
investigations. These studies are almost always directed towards the properties of the 
coating itself, rather than the holistic physical properties of the resulting tablets. Initial 
studies focused on the role of surfactants as plasticisers for tablet coatings, with one of the 
earliest studies focusing on the Tweens, where Tween 20 was shown to increase the 
hydrophilicity of the ethylcellulose coatings, with up to 60 % of this surfactant able to act as 
a plasticiser (Lindholm et al., 1986). Likewise, up to 20 % PEG 400 has been shown to 
decrease the glass transition temperature (Tg) of HPMC free film coatings (Johnson et al., 
1991). The same concentration of this polymer was shown to lower the Tg of Surelease® 
from 34.9 oC to 29 oC (Rohera and Parikh, 2002). In another study, up to 10% (w/w) Tween 
80 and Span 80 were incorporated into the film-coating formulations. These surfactants 
increased the wettability of the tablets, shown by a decrease in the contact angle between 
the polymeric dispersion and the tablet surface. In addition, these surfactants decreased the 
Tg of the coatings shown by differential scanning calorimetry (DSC), indicating the polymer 
was able to emulsify the hydrophobic plasticiser tributyl citrate (TBC) (Felton et al., 2000). 
In a study looking at microporous membrane coatings for a water-soluble drug, PEG 4000 
and Tween 80 were evaluated for their role in pore formation (Mishra and Mishra, 2010). In 
this study, PEG 4000 was found to be the most effective pore former followed by Tween 80, 
with PEG also acting as an effective plasticiser (Mishra and Mishra, 2010). In a more recent 
study examining the effects of the surfactant PEG 6000 added to HPMC as a coating for 
ibuprofen particles, PEG effectively reduced the agglomeration of the particles during 
coating when compared to HPMC alone (Miyadai et al., 2012). The results of the tablet 
studies herein demonstrate the addition of biologically active surfactants to granule 
coatings that can produce tablets with acceptable levels of hardness with disintegration 
times below 30 seconds.  
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 Uniformity of Content 6.4.
Weight variation for tablets must conform to the following specifications according to the 
United States Pharmacopeia (USP, 2011). All 10 tablets tested must contain 85% - 115% of the 
drug content in comparison to the mean amount of Ibuprofen with an RSD below 6 % of 
the mean. The weight variation and content uniformity for all formulations is presented in 
Table 6.6. The highest weight variation was seen for uncoated tablets, although all 
conformed to the USP specifications. In addition, all tablets conformed to the content of 
uniformity. 
 
Table 6.6. Content uniformity of tablets (n = 3) produced from uncoated granules and granules coated with 
various dispersions (C1-C4). 
Tablet batch Content uniformity (%) % RSD 
C1 – Uncoated 98.80 2.78 
C2 – 2 % (w/v) PEG 2000 99.39 2.21 
C3 – 2 % (w/v) Poloxamer 407 99.12 2.21 
C4 – 2 % (w/v) Cremophor EL 99.03 2.21 
 
 Conclusion of the Investigation into Surfactant –Coated ODTs 6.5.
This work demonstrated the feasibility of incorporating surfactants into granule coatings as 
an additional method of increasing the content of excipients with efflux inhibition 
properties within an ODT. The formulations containing these surfactants had flow 
properties ranging from ‘good’ to ‘excellent’ on the Carr’s Index and Hausner ratio scale, 
with the exception of coatings containing poloxamer 407, which was categorised as ‘fair’, 
most likely due to the higher water content of this coating. Cremophor EL demonstrated 
superior flow properties to that of uncoated granules, and produced tablets with lower 
friability and increased hardness compared to formulations containing PEG 2000 and 
poloxamer 407. All tablets made from the surfactant-coated granules showed 
disintegration times conforming to the USP, with disintegration times below 30 seconds 
with acceptable levels of hardness. The results of this study demonstrate the feasibility of 
incorporating biologically active surfactants into granule coatings for the use in making 
ODTs via direct compression, offering an additional supplementary method for potentially 
enhancing the delivery of drugs which are efflux substrates.  
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 7. Overall Conclusions 
Collectively, efflux transporters expressed on the apical membranes of intestinal epithelial 
cells are of interest from the pharmacodynamic and pharmacokinetic perspectives in 
anticipating the behaviour of a drug in vivo. The existing literature on the subject revealed 
an extensive yet disparate list of excipients that elicit an effect against the ABC efflux 
transporters, chiefly ABCB1. Such information is rarely quantified in the pharmacokinetic 
terms that could be of use to a formulation scientist wishing to increase the bioavailability 
drugs that fall victim to efflux.  
The aim of this thesis was to develop and validate a high-throughput screening assay to 
detect and quantify the effects of commonly used excipients against the ABCB1 and 
ABCC2 efflux transporter systems, and to utilise this knowledge to design and 
manufacture an oral dosage formulation with the capability to achieve enhanced delivery 
of drugs with poor oral bioavailability. In order to achieve this, a number of objectives 
were met: 
 A novel HTS screening assay was developed and validated using the Caco-2 
platform for the detection of commonly used excipients with a biological effect 
against ABCB1 and ABCC2. This assay had a turnaround time of less than 7 days. 
 
 Unique modelling techniques were used in order to display the inhibition data 
synonymous with drug-drug interactions (DDIs). For the first time a number of IC50 
values are presented which quantifies this data on par with established inhibitors of 
efflux. 
 
 Finally, having identified poloxamer 407 as one of the most efficacious excipients at 
inhibiting ABCB1-mediated efflux using the HTS assay, a DoE approach was 
applied to the design and manufacture of ODTs incorporating quantities of this 
excipient that could exceed the calculated IC50 value if the tablet was taken with a 
250 mL glass of water. 
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Initially IND was evaluated as an efflux probe substrate using the Caco-2 platform grown 
in Transwell® inserts. This examination of the transport of IND indicated that the apparent 
permeability was higher in the BL-AP direction, indicating that the travel in the absorptive 
direction is influenced by the action of efflux transporters. Despite this, the efflux ratio 
between these directions of travel did not exceed 2, suggesting that this efflux is not a 
major barrier to the transport of IND. As such, the efflux ratios that we obtained leave the 
transport of IND in a state of contention. Over the course of the experiments examining the 
transport of IND through Caco-2 monolayers, Papp values between 2.18-2.59 x 10 -5 cm s-1 
were recorded, suggesting this compound is highly permeable and therefore a poor 
candidate for an efflux probe. 
Despite this, PEG 8000, POLYOX N-10 and poloxamer 407 were able to increase the 
permeability of IND, potentially by the inhibition of the efflux transporter ABCB1. The 
efficacy of PEG 400 requires further investigation since the increase in uptake did not 
appear to be concentration dependent and aside from P407, statistically significant 
increases in IND transport was only observed for the highest concentration of the other 
excipients, and only after 60 minutes. 
Although a powerful screening tool, the Transwell® model suffers from slow growth rates 
that limit throughput. As such, a novel assay was developed using the Caco-2 platform 
grown in 96-well plates to achieve high-throughput screening (HTS) using the fluorescent 
dye rhodamine 123 (R-123) as a high-affinity ABCB1-mediated dye and 5(6)-carboxy-2′,7′-
dichlorofluorescein as the high affinity ABCC2 probe. This latter probe is unable to cross 
membranes of cells, so is added to transport media in diacetate form that is able to freely 
diffuse to the cytoplasm where it gets converted to the fluorescent species. The fluorescent 
nature of these probes allowed for rapid detection and quantification of the in vitro data. 
This HTS assay was optimised to a 5-7 day cellular growth time, resulting in a net saving of 
time and growth media when compared to the Transwell® model. Using this optimised 
protocol, the non-ionic excipients Tween 20 and Tween 80 were tested for their biological 
effect against the ABCB1 transporter below their cytotoxic concentrations. The results of 
this study validated the HTS platform against existing literature examining the biological 
effects of surfactants.  
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The data from the HTS assay was modelled using the kinetic approach by examining the 
amount of excipients required to reduce transporter activity by 50 % - the IC50 value. This 
allowed the efficacy of excipients to be compared to that of the other excipients to achieve a 
rank order, particularly against established inhibitors, whilst also providing a theoretical 
excipient content that must come from the tablet dosage form.  
In order to establish the functional activity of the transporters in the cell line, established 
inhibitors of the efflux transporters were tested in conjunction with the fluorescent probes 
in order to obtain their IC50 values. Both ABCB1 and ABCC2 follow a dose-dependent 
response allowing the GraphPad Prism software to plot non-linear regression curves 
through the data points in order to obtain IC50 to 95 % confidence. The inhibitors of ABCB1, 
verapamil (VER) and ciclosporin (CsA), give IC50 values of 4.08 and 1.16 μM ,respectively, 
with the ABCC2 inhibitors indometacin (IND) and probenecid (PBD) giving IC50 values of 
38.08 and 68.08 μM respectively. This confirmed the functional activity of both ABCB1 and 
ABCC2 on the Caco-2 cell line. 
Having shown some efficacy during the previous Transwell® screening, PEGs of various 
molecular weights were re-examined using the HTS assy. Over the concentration range 
tested, none of the PEGs had a significant impact upon the intracellular accumulation of 
either fluorescent probes, suggesting no inhibition properties of these excipients. In 
contrast, poloxamers and Tweens were found to be highly efficacious against ABCB1-
mediated efflux. Both of the Tweens (Tween 20 and 80) and 4 out of the 5 poloxamers 
tested yielded data from which IC50 values could be determined for ABCB1 inhibition with 
over 95 % confidence. In order to expand on the study of poloxamers and Tweens, 
additional surfactants were obtained, incorporating a wider range of HLB values from 
lipophilic molecules of 4.5 to hydrophilic molecules at 29. These excipients were 
specifically chosen for variations in structure and molecular weights. These materials were 
evaluated for inhibitory effects against ABCB1 and ABCC2 transport using the HTS assay. 
Of the 24 surfactants tested, IC50 values could be determined for ABCB1 inhibition (with 
over 95 % confidence) for 12 surfactants. However, only Etocas 29 and 40 gave confident 
inhibition against ABCC2 (16.2 µM and 12.9 µM). Against ABCB1, the excipients gave the 
rank order poloxamer 335, poloxamer 407, Crovol A-70, Myrj S-40, poloxamer 184, 
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poloxamer 182, Etocas 40, Tween 20, Etocas 29, Tween 80, Acconon C-44 and Span 20. The 
excipients with the lowest value (greatest efficacy), poloxamer 335 and poloxamer 407, 
showed IC50 values of 0.63 and 0.71 μM, which exceeded that of VER (4.08 μM) and CsA 
(1.16 μM). The highest efficacy was seen for short linear or larger branched molecules, both 
with intermediate HLB values. 
The high-throughput screening assay produced two clear lead candidate excipients, 
poloxamer 335 and poloxamer 407, with IC50 values of 4.12 x 10-4 % (w/v) and 8.85 x 10 -4 % 
(w/v), respectively. Poloxamer 407 was chosen as the material for the development of the 
ODT formulations using the Colorcon micronised version of the same polymer. This 
excipient was incorporated within the low-dose (295 mg) and high-dose (795 mg) APAP 
ODT formulations at 10 % (w/w). 
In order to explore the response of the different combinations of the excipients MCC, 
mannitol and Starch 1500, a design of experiments approach was taken to design a set of 
experiments with varying concentrations of each material for both high and low-dose 
materials, with 40 % and 70 % excipient content, respectively. Using bivariate analysis, 
Starch 1500 decreased tablet strength, mannitol had little impact and MCC was able to 
improve tablet strength. Of these, Starch 1500 and MCC correlated well, with r2 values of 
0.60 and 0.80, respectively; moreover both of these excipients had a significant (p < 0.01) 
impact upon tablet strength. For disintegration, Starch 1500 and MCC increased 
disintegration time, whereas mannitol was able to decrease it. The impact of mannitol had 
good correlation with the model (r2 = 0.85); furthermore mannitol was the only material to 
have a significant (p < 0.001) impact upon disintegration for the low-dose formulations. For 
the high-dose tablet formulations, Starch 1500 and MCC correlated well with tablet 
hardness, with r2 values of 0.75 and 0.71 respectively, and both had a significant (p < 0.01) 
impact upon tablet strength. Starch 1500 increased disintegration time, MCC had little 
impact, whereas mannitol was able to decrease it. Both Starch 1500 and mannitol correlated 
well in this model (r2 = 0.77 and 0.79 respectively), and the impact of both was significant (p 
< 0.001). 
Both ODT formulations were then refined by the removal of ethylcellulose completely, the 
poloxamer content lowered to 2 % (w/w) and the modified starch, Starch 1500, was 
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exchanged for StarCap 1500, which has better disintegration properties. The net result was 
ODTs with disintegration times of 16 s and 45 s for the lead low-dose and high-dose 
tablets, respectively. A second round of DoE screening was used to examine the interplay 
between mannitol, MCC and StarCap 1500 on tablet hardness and disintegration.  
For the low-dose formulations, StarCap 1500 and mannitol decreased tablet strength, 
whilst MCC was able to improve it. Additionally, MCC had almost perfect correlation with 
tablet strength (r2 = 0.98), and both MCC and StarCap 1500 had a significant (p < 0.05) 
impact upon the response. For disintegration, higher StarCap 1500 content increased 
disintegration time, whereas MCC decreased it. These effects were both significant (p < 
0.05), but the impact of mannitol was insignificant (p > 0.05) on tablet disintegration. For 
the high-dose formulations, StarCap 1500 and MCC led to a significant (p < 0.05) decrease 
and increase respectively in tablet strength, with MCC showing a particularly good fit to 
the model with r2 = 0.98. Mannitol had an insignificant (p > 0.05) impact on high-dose 
hardness. For high-dose disintegration, higher StarCap 1500 content increased 
disintegration time, whereas MCC decreased it, with r2 values of 0.55 and 0.75, 
respectively. Mannitol correlated extremely poorly with disintegration time (r2 = 0.01), and 
neither was the impact significant (p > 0.05). 
From the second round of DoE screening, the low-dose formulation F9 was chosen for 
rotary press trial on the Picolla multi-station rotary tablet press in order to test the 
feasibility of the high-throughput manufacture of the designed dosage formulation. This 
formulation was chosen as the theoretical centre point of the DoE study e.g. equal 
composition of each excipient. Two additional variations were produced of this 
formulation: one contained 50 % more StarCap 1500 as a multipurpose binder and the 
second contained 50 % more mannitol.  
Tablets produced using a rotary tablet press had disintegration times between 9-43 s over a 
range of compressions (6-23 kN), providing tablets that conformed to both the European 
Pharmacopeia and United States Pharmacopeia. Any of these formulations, taken with a 250 
mL glass of water on an empty stomach, are capable of delivering 5.9 mg of poloxamer 407 
to give a final concentration of 2.36 x 10 -3 % (w/v), or 2.7 times higher than the IC50. 
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In addition to incorporating poloxamer 407 directly into the formulation used to make 
ODTs by direct compression, the impact of surfactants upon granule coatings was also 
investigated. Coated ibuprofen granules were prepared using 10 % (w/v) Kollicoat IR 
solution alone or with the addition of 2 % (w/v) PEG 2000, poloxamer 407 or Cremophor 
EL. The Carr’s index and Hausner ratio values indicated that granules coated with the 
solution containing 2 % (w/v) Cremophor EL had ‘excellent’ flow properties, with the flow 
properties of the uncoated granules and the granules coated with the additional 2 % (w/v) 
PEG 2000 being classified as ‘good’, and those coated in 2 % (w/v) poloxamer 407 being 
considered ‘passable’. The ODTs made from these granules by direct compression showed 
disintegration times below 30 seconds, conforming the United States Pharmacopeia. 
As such, the work of this thesis describes the development of a novel HTS assay for the 
detection of excipients with inhibitory properties against ABCB1 and ABCC2 that was 
harnessed to provide a shortlist of materials that could be incorporated into ODTs. This 
was then coupled with a DoE approach for producing ODT formulations with potentially 
enhanced delivery capability. Efflux transporters such as ABCB1 and ABCC2 expressed on 
the apical membranes of intestinal epithelial cells represent a formidable barrier to the 
efficient oral delivery of a plethora of drugs. Therefore, the integrated approach 
undertaken in this thesis provides a novel tablet design process that could provide 
formulation scientists with a method to improve the oral bioavailability of drugs that are 
efflux substrates. 
Whilst investigating the biological effects of commonly used excipients, this thesis 
generated a series of IC50 values in order to demonstrate how much of each material would 
be required to reduce transporter activity by 50 %. Whilst excipient IC50 values remain 
elusive in literature, one parameter remains absent from the literature entirely: the 
inhibition constant (Ki). This value indicates the potency of the inhibitor. By generating a 
series of Michaelis-Menten saturation curves (the initial rate of reaction, v, against the 
substrate concentration) in the presence of increasing inhibitor concentrations, double 
reciprocal Lineweaver-Burk plots can then be produced. From these, the change in Km and 
Vmax values at each inhibitor concentration (indicated by the x-axis and y-axis intercept 
respectively) compared to the non-treated control could then be used to elucidate if the 
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mode of inhibition is competitive, non-competitive or uncompetitive. Furthermore, 
plotting 1/v against the inhibitor concentration at each concentration of substrate (a Dixon 
plot) gives a series of intersecting lines, and where they intercept gives the negative Ki 
value. 
During the tablet development phase, paracetamol (APAP) was used as the model drug 
due to the safety concerns regarding the use of atorvastatin (ATV) in a commercial lab. 
Future work should focus on the conversion of these APAP tablets to ATV, and 
subsequently the reassessment of those tablets in terms of hardness, disintegration and 
friability which may have been altered by the presence of a different drug. Finally, the 
tablets were designed and manufactured to contain a surplus quantity of the biologically-
active poloxamer 407 for the purpose of potentially inhibiting ABCB1-mediated transport 
of ATV in vivo. It would be of great value to demonstrate the efficacy of these tablets using 
the in vitro Transwell model in order to establish the statistically significant increase in 
ATV apical to basolateral transport across these monolayers when compared to tablets 
containing ATV without the poloxamer. This would provide the proof of concept of 
incorporating biologically-active excipients into oral dosage formulations to inhibit efflux-
mediated drug transport, and validating the concept of the work behind this thesis. 
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Figure A.1. The effects of the surfactants on cellular viability using the MTT toxicology assay, showing A) Capmul 
PG-8, B) Capmul MCM, C) Capmul MCM C8, D) Capmul PG-12, E) Poloxamer 182, F) Span 20, G) Arlatone 
TV, H) Crovol A-70, I) Etocas 29, J) Brij S-10, K) Poloxamer 184, L) Etocas 40, M) Brij CS-12, N) Acconon C-44, 
O) NatraGem S140, P) Acconon MC8-2, Q) Tween 80, R) Cetomacrogol 1000, S) Tween 20, T) Myrj S-40, W) 
Poloxamer 335, X) Myrj S-100, Y) Poloxamer 407, Z) Poloxamer 188. Caco-2 cells were grown for 5-7 days on 96-
well plates prior to experimentation. Data presented as the mean value of at least 6 replicates ± SD. Statistical 
significance was analysed using one-way ANOVA followed by Dunnett’s post hoc test with variance as follows: * (p 
< 0.05); ** (p < 0.01); *** (p < 0.001); **** (p < 0.0001). 
 
 
